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ABSTRACT
Orf virus is a 139 kb double-stranded DNA parapoxvirus that has a world wide distribution
and infects sheep, goats and man. The virus infects broken or scarified skin and replicates in
regenerating epidermal keratinocytes. Infections are acute, contained locally and give rise to
pustular lesions that turn to scabs. Virus is shed with the scab. The immune response to orf
virus is characterised by a local accumulation of CD^T and CD8^ T cells, B cells, neutrophils
and a dense network of dermal dendritic cells. Evasion of the host immune system by orf
virus is implicated since the virus can repeatedly infect previously exposed sheep in spite of
an apparently normal host antiviral immune and inflammatory response.
The orf virus genome has been sequenced but only 31 gene sequences have been recorded
in the public databases. Several putative immunomodulatory genes have been discovered: a
viral homologue ofmammalian vascular endothelial growth factor, a viral homologue of IL-
10 and a homologue of the vaccinia virus E3L gene which encodes for an interferon resistance
protein.
A granulocyte-macrophage colony stimulating factor (GM-CSF) inhibitory activity
associated with virus-infected cells was first detected in a previous study of cytokine
production by sheep keratinocytes infected with orf virus. Although IL-8, TNF-a and GM-
CSF mRNAs and IL-8 and TNF-a protein were detected in infected keratinocyte cultures,
GM-CSF protein was not. In this study, the gene encoding the GM-CSF- inhibitory factor
(GIF) was isolated and mapped to the right terminal quarter of the orf virus genome. The orf
virus GIF cDNA was expressed as a secreted protein in Chinese hamster ovarian cells as
detected by GM-CSF inhibition ELISA. Recombinant GIF was purified by ovine GM-CSF
affinity chromatography and gel filtration. Sequence analysis of the 20 N-terminal amino
acids was performed on the purified GIF. The GIF gene encodes a 28 kD protein that exhibits
32% amino acid sequence similarity to the predicted sequence of the A41L gene product
encoded by vaccinia virus. Although the vaccinia virus A41F protein has sequence similarity
to the T1 secreted chemokine-binding proteins of leporipoxviruses, its function is not known.
GIF did not share any homology with any cytokine receptor molecule identified to date. In
contrast to other parapovxirus immunomodulatory proteins that are products of early viral
genes, GIF was found to be the product of an intermediate /late viral gene in orf virus-infected
cells. GIF formed homodimers and homotetramers in solution and bound ovine GM-CSF with
a Kd of 369 pM. In addition GIF bound ovine IF-2 with a Kd of 1.04 nM. Although orf virus
infects humans, GIF did not bind human GM-CSF or IL-2.
GIF was shown to inhibit the binding of ovine '"I-GM-CSF to its receptor on isolated
sheep neutrophils and to inhibit the haematopoietic activity of ovine GM-CSF in a soft agar
bone marrow colony assay. GIF also inhibited the binding of ovine 12" I-IF-2 to CD4+T cells
and inhibited the stimulatory activity of ovine IF-2 in a T cell proliferation assay. This
inhibitory activity was neutralised by a rabbit antiserum raised against purified GIF.
GIF was produced in vivo during orf virus reinfection. GIF was detected in skin, localised
to the area of orf virus infected cells and in afferent lymph draining the skin site of infection.
The presence ofGIF, 3-7 days after virus infection was associated with reduced levels ofGM-
CSF in the lymph plasma and the period of maximum viral replication in the skin.
Thus the GM-CSF and IF-2 inhibitory factor represents a growing number of
immunomodulatory proteins encoded by poxviruses and other large DNA viruses that inhibit
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Orf is an acute and highly contagious skin condition in sheep and goats (Glover,
1928; Abdulassam and Cosslet, 1957; Moore et al, 1983; Haig and Mercer 1998).
Also known as contagious pustular dermatitis, contagious ecthyma and scabbymouth,
orf constitutes a serious welfare problem in sheep and goats world-wide. In the
United Kingdom the number of cases of orf has not been documented but annual
sales of anti-orf vaccine were estimated in 1996 at 2.5 million doses.
The disease has no systemic phase and is characterised by pustular lesions from
which scabs develop. Normally lesions are resolved within six to eight weeks
without scarring. Outbreaks of the disease arise all year round but are most common
in the spring and summer (Aynaud, 1923; Schmidt and Hardy, 1932). Orf outbreaks
typically occur in the more vulnerable young and elderly animals and spread of the
disease is often rapid, particularly in animals that have been previously unaffected.
Transmission of the disease from the udders of nursing ewes to susceptible lambs can
result in severe pustular lesions around the mouth and nares (Fig. 1.1) that may
interfere with feeding and an inability to suckle.
Whilst mortality is rare, orf can be fatal in stressed or immunosuppressed animals.
Fatalities from orf amongst animals in over-crowded conditions or animals being
transported over long distances have been reported (Gumbrell and McGregor, 1997).
Orf occurs wherever sheep and goats are raised and can be transmitted to other
susceptible animals either in the wild, in captivity or as farmed domesticated species
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Fig. 1.1 Orf in a young lamb.
Lesions around the mouth and
nares are indicated.
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(Robinson, 1983; Robinson and Balassu, 1981). Other animal species that can
contract orf include bighorn sheep, chamois, thar ibex, camels and alpaca (Azwai et
al, 1995; Dashtseren et al, 1984; Hedger et al, 1980; Mercer et al, 1997a).
Kummeneje and Krogrsrud (1979) have reported outbreaks of orf in herds of
musk ox and more recently, Palatsi et al (1993) have reported an orf epidemic that
affected reindeer in Norway. In reindeer the disease is generally mild. However in
musk ox a high mortality rate has been recorded particularly in calves and adult
males, with females apparently being more resistant (Mathiesen et al. 1985, Moens et
al. 1990). There is no clear evidence that cattle can contract orf although the
condition bovine papular stomatitis is clinically similar (Nagington et al, 1967;
Czerny et al. 1994; Mercer et al. 1997a). When kept together with infected sheep,
cattle do not become affected (Aynaud, 1923; Darbyshire and Huck, 1966). Horses,
pigs, dogs and those laboratory animals in common use (e.g. rabbits, rats, mice)
appear to be resistant to the disease (Abdulassam, 1957; Darbyshire, 1961; Buttner et
al, 1990).
As a zoonotic disease, orf is recognised as an occupational hazard amongst those
whose livelihood is associated with sheep and goats, such as veterinary surgeons,
farm workers, slaughtermen, butchers and meat process workers (Purdy, 1955;
Moore, 1973; Arnaud et al, 1986; Groves et al, 1991; Yirrell and Vestey, 1994;
Buchan, 1996; Mourtada et al, 2000).
1.1.2. Epidemiology
Orf virus enters its animal host via broken, or scarified skin, probably caused by
grazing in rough pastures or by abrasions from fencing material contaminated with
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virus. Thus natural infections are normally localised around the mouth and nares or
around the lower limbs. Orf virus-infected animals are also susceptible to secondary
infections with bacteria, fungi or blow- fly larvae (Reid, 1991). Complications such
as mastitis and 'strawberry footrot' can arise as a result of opportunistic
Staphylococcus aureus and Dermatophilus congolensis infections respectively. In
addition, the development of venereal disease with subsequent disruption of breeding
and prolonged lambing has also been reported as a consequence of orf virus infection
(Reid, 1991; Reid, 1999).
Orf virus is shed (with scabs) into the environment as infectious scab material. It
is hardy and will persist in dust and wool that can act as the source of new infections
(Glover, 1928; Boughton and Hardy, 1935). Once pasture becomes contaminated, it
is difficult to eradicate since the shed scabs from infected animals contribute to the
environmental reservoir of infection. However, it is unlikely that the outbreaks
observed in the spring in the U.K. are due to over-wintered virus since wet weather
conditions found in Northern Europe are not favourable for virus survival and
infectivity (McKeever and Reid, 1986a). Orf virus infectivity is also reduced by
exposure to ultraviolet radiation (Sawhney and Toschkov, 1972).
Orf virus has been found to persist in previously clean animal accommodation and
to survive between outbreaks. It is suggested that this persistence in infected
premises is due to the long-term survival of the virus particularly in dry scab form
(Glover, 1928; Livingston and Hardy, 1960; Leavell et al, 1968). The route by
which orf virus is introduced into clean premises is not clear although Gumbrell and
McGregor (1997), Greig et al (1984) and McKeever (1986) suggest that animals
suffering from sub-clinical orf virus infections may act as carriers. This mechanism
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of orf virus spread was further established at the Moredun Research Institute when a
group of ewes with no clinical orf lesions were housed with lambs that had been kept
in isolation. The lambs experienced a severe outbreak of orf resulting from exposure
to the ewes (Nettleton et al, 1996a).
1.1.3. Clinical course and pathology
The clinical manifestations of orf are variable; in many cases the infection is
probably subclinical and goes undetected and at the other end of the spectrum, it may
be severe with mortality approaching 80% (Darbyshire, 1961). In natural orf virus
infections, the orf lesions produced are restricted to epithelium and oral mucosa,
although some cases have been reported of orf virus affecting other tissues of the
body e.g. the ocular conjunctiva (Freeman et al, 1984). Fever is not normally
associated with orf virus infection (McKeever and Reid, 1986b; McKeever et al,
1988).
In spite of a vigorous cutaneous immune and inflammatory response,
characteristic of an anti-viral response (Haig et al, 1997), the virus can repeatedly re¬
infect sheep. The protection against re-infections is incomplete and of short duration,
and vaccination with live attenuated virus is of limited use (Chand et al, 1994;
Mercer et al, 1997b). The route of orf virus infection is via damaged or abraded skin
where the virus replicates in the regenerating epidermal layer underlying the
damaged epidermis. This freshly regenerated epidermis derives from the basal
epidermal cells of the wool follicles (McKeever et al, 1988).
In lambs experimentally infected with virus, orf is normally induced by
application of virus to scarified skin (Wheeler and Cawley, 1956; Kluge et al, 1972).
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Generally, in both primary infections and reinfections, the disease progresses from
erythema around the sites of scarification, to lesions that develop in four stages from
papule, vesicle, pustule and finally to scab. The area of lesion can often encompass
2-4 cm of skin that surrounds the initial site of infection due to the development of
secondary papules, vesicles and pustules.
The duration of orf virus infection appears to be self-limiting. In a primary
infection of experimental animals, the progression to scab formation occurs within 7-
10 days with resolution within 4-6 weeks. Secondary infections are normally less
severe and of shorter duration. Scabs are formed within 3-4 days and shed by 14 days
(Robinson, 1983; McKeever et al, 1988).
Cutaneous lesions of naturally-occurring orf in 7-10 day old lambs were observed
to develop through four clinically progressive stages (McKeever et al, 1988;
Bassioukas et al, 1993; Lober et al, 1983; McElroy, 1997). The initial papular stage
(Stage 1, duration 5-7 days,) gave rise to a stage where the papule became covered
with a thin newly-formed scab (Stage 2, duration 4-5 days). The papules
subsequently developed a thick scab that was firmly attached and interdigitated with
the proliferating epidermis (Stage3, duration 5-7 days). Finally the regressing lesions
were covered with a desquamating scab (Stage 4, duration 5-13 days) and healing
was completed by the formation of a third epidermis derived from the deeper portion
of the wool follicles. Scabs were shed without scarring. Reinfections with orf virus
exhibited accelerated healing times (Stage 1 duration: 1-2 days; Stage 2 duration 2-3
days; Stage 3 duration: 2-4 days; Stage 4 duration 3-8 days.) (Jenkinson et al, 1990b;
Haig et al, 1997; Haig and Mercer, 1998; McElroy, 1997).
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1.1.4. Persistent orf
Persistent orf is a condition affecting individual sheep in a flock that often results
in death of the animal. Affected sheep have extensive and proliferative orf lesions
that are often located around the genitalia and ears, and show no evidence of
regression at least two months after orf lesions in their companions in the same flock
have resolved (Darbyshire, 1961: McKeever, 1984). Persistent orf lesions exhibit the
histopathological characteristics of Stage 2 lesions (papules with a thin scab) in
normally responding animals with orf but there is a dramatic increase in the degree
of epidermal proliferation and an extensive congestion and neo-vascularisation of the
superficial dermis.
Highly proliferative lesions have only been observed in natural infections. These
lesions form dense papillomatous outgrowths that, together with secondary
complications, become ulcerative and necrotic without scab formation (Glover, 1928;
Selbie, 1944; Darbyshire 1961).
1.1.5. Vaccination
Vaccines for orf virus are available that consist of live unattenuated virus
passaged in sheep or in tissue culture (Pye, 1990; Nettleton et al, 1996b). Currently
two vaccines are licensed for use in the United Kingdom. These are Scabivax
produced by Schering-Plough Animal Health (Uxbridge, U.K.) and Vaxall Orf
produced by Ford Dodge Animal Health (Kansas City, USA). Since even natural
infection does not induce lasting protection against reinfection, these vaccines are of
limited use. After vaccination, a typical orf lesion develops at the site of inoculation
but subsequent reinfections that occur tend to be milder with faster resolution times.
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Vaccines can therefore be useful (in the face of an outbreak) as a means of artificially
infecting all animals and ensuring that they experience only mild disease.
Vaccination also reduces the severity of the disease at the crucial early stage of lamb
development and helps prevent infection of the udder of the nursing ewe, thus
reducing production losses that are associated with natural orf virus infections around
the mouth of suckling lambs.
However, the virus in scab material that is produced by vaccination can
contaminate the environment in the same way as a natural infection and can
contribute to the perpetuation of the disease. A mutant strain of orf virus, D1701,
has been identified that has undergone gene loss and translocation particularly at the
left hand terminus of the genome (Cottone et al, 1998). Experimental infection with
D1701 virus results in very mild lesions with little or no scab formation (Buttner et
tf/,1995). In Germany, D1701 has been approved and licensed for use as a live
vaccine. D1701, as with other tissue culture adapted strains of orf virus such as orfl 1
does not offer the same level of protection against re-infection that is produced by
vaccination with more virulent strains (Mclnnes et al, in press).
1.1.6. Human orf
Around 50 cases of human orf a year were reported in the United Kingdom during
the period 1991 to 1993 (Health and Safety Executive, 1993). These are likely to be
the most serious cases and under-reporting is probable. Paiba et al (1999) estimated,
from a random serological survey of farmworkers in three areas of England, that the
incidence of orf virus infection for the year 1991/92 was 2.8 per cent. Human
infection rates have also been estimated at up to 34% in at-risk farming communities
9
in Wales (Buchan, 1996).
Orf virus is transmitted to man from infected animals, animal products or fomites.
Transmission of orf virus from person to person has also been reported (Lang 1962).
The risk of orf virus infection is increased ifwounds or abrasions are present on the
hands and arms (Pask et al, 1951). Most commonly, orf affects the skin of the fingers
and thumbs and sometimes the arms and face. The lesion(s) produced are clinically
similar to those resulting from exposure to milker's nodule virus (pseudocowpox
virus), the parapoxvirus of cattle (Nagington et al, 1965; Bowman et al, 1981) and a
distinction is usually made on the grounds of the likely animal source.
Although several lesions may be present, single lesions are more common (Fig.
1.2). These are raised, circular or oval and 0.5-1.5 cm in diameter with a depressed
yellow centre, a raised white edge and a surrounding red inflammed zone. Often this
is accompanied by swelling of the regional lymph nodes and pyrexia due usually to
secondary bacterial infection. In general lesions resolve within 4-8 weeks (Nagington
et al, 1965; Leavell et al, 1968; Arnaud et al, 1986; Johannessen et al, 1975; Gill et
al, 1990).
Orf virus infection ofman produces lesions that are not as well characterised as
those observed in sheep but some clinical and histological differences have been
suggested (Yirrell and Vestey, 1994). The central umbilication and vascular
proliferation characteristic of the human lesion is less obvious in the ovine lesion
whilst in sheep the most significant feature is a massive accumulation ofMFIC class
Il-positive dendritic cells (see Section 1.3.3.). However this accumulation of
dendritic cells has not been assayed for in man. In addition, in sheep the incubation
period is considerably shorter (2-4 days) than that for man (3-14 days). Yirrell et al
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Fig 1.2 Human orf.
Raised pustular lesion on a hand.
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(1994a) suggest that this difference in incubation times may significantly affect the
nature of the host immune response.
Although orf virus infection of sheep fails to provide lasting protection, in
humans the situation is less clear. Immunity to orf virus has been reported to be
lifelong (Buchan, 1996; Chahidi et al, 1993; Hall, 1976; Lo and Mathisen, 1996; Pask
et al, 1951). Nevertheless there is some evidence from surveys of farmers and
farmworkers in England that re-infections and subsequent lesion development do re¬
occur (Tan et al, 1991; Gourreau et al, 1986; Paiba et al, 1999)
1.2. Orf virus
1.2.1. Classification
The causative agent of orf is orf virus, the prototypical member of the
parapoxviruses that belong to the Poxvirus family (Table 1.1). Other members of the
genus Parapoxvirus include the closely related bovine papular stomatitis virus,
pseudocowpox virus and a parapoxvirus that infects deer (Lance et al, 1983;
Robinson and Mercer, 1995). Candidate members of the genus include poxviruses
that infect camels (Dashtseren et al, 1984), seals (Munro et al, 1988) and red
squirrels (Sainsbury and Ward, 1996).
One feature of the parapoxviruses is that whereas as individuals they exhibit a
narrow host range, generally one or two related species, they all appear to be capable
of infecting man. There is one possible exception, the deer parapoxvirus, where
transmission to man has not been recorded (Mercer et al, 1997a).
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Chordopoxvirinae Molluscipoxvirus molluscum contagiosum
Orthopoxvirus vaccinia virus, cowpox virus
Parapoxvirus orf virus




Yatapoxvirus Yaba monkey tumour virus
Entomopoxvirus A Melolontha melolontha entomo¬
poxvirus
Entomopoxvirinae Entomopoxvirus B Amsacta moorei entomopoxvirus
Entomopoxvirus C Chironomus luridus entomopoxvirus
Table 1.1 Taxonomy of the Poxvirus Family.
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1.2.2. Structure
Orf virus exhibits morphological similarities with other poxviruses such as
vaccinia virus (Nagington and Home, 1962; Hiramatsu et al, 1999). Parapoxviruses
may be distinguished from other poxvirus genera by two major features: firstly, the
virus particles are more cylindrical and consequently have a higher axial ratio
(length:width) and secondly the outer tubular coat of the viral particles is arranged in
a regular basket-weave pattern that resembles a 'ball of yarn' and which is unlike the
random arrangement exhibited by the orthopoxviruses (Fig. 1.3) (Nagington and
Home, 1962; Kluge et al, 1972; Okada et al, 1984; Hiramatsu et al, 1999). The
enveloped virions of orf virus that are released from infected cells or in scabs are
ovoid in shape and on average 260 nm long by 160 nm wide ( Abdulassam and
Cosslet, 1957; Nagington and Home, 1962; Romero-Mercado et al, 1973). The virus
coat consists of an inner and outer envelope. An additional membrane is observed in
tissue culture isolates of orf virus that appears similar to the outer membrane of
vaccinia virus and is thought to be derived from the host cell Golgi apparatus.
(Dubochet et al, 1994; McElroy, 1997; Moore et al, 1977). Analysis of negatively
stained orf virus particles by electron microscopy reveals two forms; the mulberry
(M) form, in which the outer tubular filaments are highlighted or the clear (C ) form,
where the capsule of the virus is stained (Balassu and Robinson, 1987; Nagington et
al, 1964; Rosliakov, 1972; Seifert and Saito, 1977).
Orf virus exhibits a similar internal structure to other poxviruses with a tubular S-
shaped construction of nucleoprotein surrounded by a lipoprotein envelope
(Nagington et al, 1964; Nagington and Home, 1962; Harkness et al, 1977; Loubet.
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Fig. 1.3 Electronmicrograph of orf virus particles.
The 'ball of yarn' morphology of the virus coat with its
outer tubular filaments is characteristic of the 'M' form,
x 80,000.
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et al, 1980; Mitchner, 1969; Seifert and Saito, 1977). The viral core is biconcave
with two lateral bodies (that are lens-shaped) and contains a folded nucleoprotein
thread of linear double-stranded DNA of 140 kb in size (see infectious intracellular
virion in Fig. 1.5) (Onwuka et al, 1995)
1.2.3. Replication
Orf virus, like other poxviruses, undergoes the process of viral replication and
virion assembly exclusively in the cytoplasm of the host cell (Moss, 1996; Onwuka
et al, 1995; Moyer and Graves, 1981). The genome of these large DNA viruses
contains many genes essential for the intracellular phase of their life cycle and which
are expressed in a well ordered sequence. Early genes encode factors that regulate the
transcription of intermediate genes that in turn regulate the expression of late viral
genes (Moss 1996).
Unlike the orthopoxviruses which have been extensively studied, knowledge of
the replication cycle of the parapoxviruses is not so comprehensive. Study of the
viral replication cycle in in vivo infections is restricted by the difficulty of ensuring
synchronous infection of target cells. In vitro cell infection and virus ultrastructural
studies have been developed to overcome this difficulty of non-synchronous
infection on the growth cycle of orf virus (Balassu and Robinson, 1987; Hessami et
al, 1979; Onwuka et al, 1995; Pospischil and Bachmann, 1980). The cycle of
replication of orf virus in cultured cells can be divided into three phases, an entry
phase, an eclipse phase and a stage ofmorphogenesis and virus release (Fig. 1.4)
(Onwuka et al, 1995).
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Fig 1.4 Diagramatic representation of the orf virus replication cycle
vitro (adapted from Onwuka et al,1995).
1.) Entry ofvirion(s) possibly by phagocytosis/pinocytosis. 2.) Virus
particles retained within vesicles. 3.) Vesicle membranes are lost and the
virus particles uncoat. 4.) The eclipse phase when no virus is detected.
5.) The formation of electron dense zones or viroplasm where the
maturation ofprogeny virions takes place 6.) and 7.) Mature virions
migrate to the periphery of the viroplasm prior to release. 8.) Release of
mature virions either by budding, exocytosis or cell disruption.
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i). Entry of the virus
Orf virus infection of an in vitro cell population (e.g. fetal lamb skin fibroblasts or
fetal lamb kidney cells) originates with the entry of the virus into cells within 5 hours
after addition to cultures (Onwuka et al, 1995). Internalisation of the virus occurs
probably by phagocytosis/pinocytosis whereby the cell extends pseudopodia that
surround the virus particles and produce, within the cytoplasm, membrane-bound
vesicles enclosing the virions. There is no evidence that, in the entry of orf virus, the
viral membrane fuses with that of the cell via some as yet unidentified cell surface
receptor as reported for other poxviruses (Armstrong et al, 1973; Hsiao et al, 1999;
Janeczko et al, 1987; Payne and Norrby, 1978; Smith and Vanderplasschen, 1998).
As the cell vesicles move deeper into the cytoplasm, the vesicle membrane is lost and
the virions are released into the cytoplasm where they uncoat. Naked (uncoated)
virions have not been observed and the factors that control the uncoating process
have yet to be determined. It is suggested that the disintegration of the outer envelope
is followed by release of the viral core which subsequently disaggregates to free the
viral DNA (Onwuka et al 1995).
Evidence from vaccinia virus studies suggest that prior to the second uncoating
step, the early transcription system packaged within the virus core initiates the
synthesis ofmRNA (Kates and McAuslan, 1967). RNA/DNA hybridisation studies
have shown that approximately half of the vaccinia virus genome has been
transcribed prior to DNA replication (Beaud, 1995; Golini and Kates. 1984; Golini
and Kates, 1985). The early genes encode proteins involved in viral DNA replication,
intermediate gene expression and virus-host interactions (Moss 1996).
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ii). The eclipse phase
The eclipse phase is characterised by the total absence of visible virus within the
infected cells and lasts for 8-10 hours after completion of the entry phase. It is
suggested that the virus exists as strands ofDNA that may well be undergoing
replication during this phase (Onwuka et al 1995).
Hi). Viral morphogenesis and release
The third phase of the orf virus cycle begins between 10 h and 12 h after infection
with the appearance of viroplasm. This constitutes the site of new virus assembly and
corresponds to the B-type inclusion bodies that are observed in cells infected with
poxviruses (Hollos and Lovas, 1968; Kluge et al, 1972; Okada and Fujimoto, 1975;
Sawhney and Toschkov, 1972; Yeh and Soltani, 1974). Viroplasm occurs free in the
cytoplasm without an encircling membrane. Several foci of viroplasm have been
detected in infected cells and may reflect a multiple infection with orf virus as seen
in infected sheep epidermal cells (Kluge et al, 1972; Onwuka et al 1995).
In the developing stages of orf virus morphogenesis, the virus particles move
from the centre of the viroplasm to the periphery. The absence of rough endoplasmic
reticulum and polysomes within the viroplasm suggest that, as for vaccinia virus
(Morgan 1976), the late proteins are synthesised elsewhere in the cell and transported
to the viral assembly site. In later stages of virus infection, viral DNA and the RNA
complex responsible for the transcription of early genes, are packaged into viral
particles. The virus is then packaged in a double membrane and will be retained
within the cytoplasm until cytolysis is induced. This is the intracellular mature virion
(IMV). An alternative form of infectious virus, the extracellular enveloped virion



















Fig. 1.5 Release of infectious orf virus particles.
A diagrammatic representation of the structure of both EEV
and IMV forms of infectious orf virus particles and their release
as suggested by Onwuka et al (1995). The release of virions can
occur by exocytosis through the cell membrane or as a result of
cell disruption.
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additional membranes and can fuse with the plasma membrane. Following the loss of
the outermost membrane, EEVs can be released from the cell (Fig 1.5)
(Kluge et al, 1972; Rosenbusch and Reed, 1982; Onwuka et al, 1995). Mature
virions appear at the cell membrane either freely or contained within vesicles with a
bilaminar membrane. Microfibrils of the cytoskeleton, the Golgi apparatus and rough
endoplasmic reticulum are thought to be involved in transport of the virions within
the infected cell (Florkiewicz et al, 1983; Morgan, 1976; Ward and Moss, 2000;
Onwuka et al, 1995). Release of the virions appears to occur by three mechanisms.
Firstly by the ultimate disruption of the infected cell, secondly by the release of the
vesicles through exocytosis or finally, by the enclosure of individual virions within
microvilli which are pinched off from the cell. Although this latter process whereby
the virions bud from the infected cell is common to vaccinia virus release, it has not
been observed during the release of orf virus virions, which instead appear to
undergo virus-induced exocytosis (Ehramatsu et al, 1999).
The duration of the orf virus cycle is considered to be 15-16 hours in vivo
(Balassu and Robinson, 1987; Hessami et al, 1979; Martinez-Pomares et al, 1995).
1.2.4. The genome
Orf virions contain one molecule of linear double stranded DNA with a total
genome length of approximately 140 kb. In common with the DNA of the
orthopoxviruses, orf virus DNA is cross-linked at each terminus by 'hair-pin' loops
to form a covalently continuous polynucleotide chain (Baroudy et al, 1982a and b)
The termini consist of inverted terminal sequences which are tandemly repeated,
internally reiterated and repeated at the two ends of the genome (Fraser et al, 1990).
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The lengths of these inverted, terminal-repeat sequences (ITR) can vary within a
genus.
The genomes of the different poxviruses are organised in a similar fashion with
terminal regions of variable DNA sequence flanked by a conserved central region
(Fig. 1.6) (Archard, 1983; Mackett and Archard, 1979; Esposito and Knight, 1985;
Pickup et al, 1982). The genes contained in the central region are for the most part
essential for viral replication and the assembly of new viral particles while 'non¬
essential' genes in this respect are concentrated in the terminal regions. Some of
these genes appear to encode proteins associated with virulence and pathogenesis
(Moss, 1996; Alcami and Koszinowski, 2000; Smith. 1999; McFadden et al, 1998).
Parapoxviruses differ from other poxviruses in possessing DNA with a high G+C
content (Wittek et al, 1979). In comparing orf virus with vaccinia virus, Mercer et al
(1997a) reported guanine and cytosine (G+C) values of 65% and 35% respectively.
Accordingly the orf virus genome does not cross-hybridise with those of the
orthopoxviruses. However a number of genes mapped to the orf virus genome have
homologues in vaccinia virus (Fig. 1.6). Genomic alignment of both orf virus and
vaccinia virus reveals a conserved core of approximately 88 kb from 15 kb to 103 kb
in the orf virus genome. This region encodes homologues of vaccinia virus genes and
proteins as identified from DNA and predicted amino acid sequences and that map to
the same relative positions as their vaccinia virus counterparts. Some of these orf
virus DNA homologues of vaccinia virus DNA have been studied in some depth and
include;
1.) A 3.3 kb fragment mapped to the centre of the orf virus genome that contains 3
open reading frames (F2L, F3R and F4R) (Fig. 1.6) (Fleming et al, 1993) that are
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Fig. 1.6 Alignment of the orf virus and vaccinia virus genomes
(Fleming et al, 1993).
The two horizontal heavy lines represent the genomes of the NZ2 strain
of orf virus (upper) and the Copenhagen strain of vaccinia virus (lower).
Marked on each genome are the locations of restriction enzyme cleavage
sites BamWl ( solid vertical lines) and EcoKl (dotted vertical lines) for
orf virus and Hin&lll (solid vertical lines) for vaccinia virus and the
location of homologous genes as outlined in the text. The position of the
genes encoding the orf virus homologues of mammalian IL-10 and
vascular endothelial growth factor (VEGF) are also marked on the orf
virus genome (dashed lines).
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homologous to the vaccinia virus genes H4L (RNA polymerase-associated protein
RAP 94), HSR (35 kD virion envelope antigen) and H6R (topoisomerase)
respectively (Rosel and Moss, 1985; Goebel et al, 1990). The DNA
topoisomerase encoded for by H6R appears to be highly conserved among the
genera of the vertebrate poxviruses (Moss, 1996).
2.) Orf virus genes that encode structural proteins of 42 kD (Fleming et al, 1993,
Sullivan et al, 1994), 65 kD (Fig. 1.6) (Sullivan et al, 1995) and 10 kD (Fig. 1.6)
(Housawi et al, 1998) that are homologous to the vaccinia virus proteins encoded
by the genes F13L (Blasco and Moss, 1991), A3L (Rosel and Moss, 1985) and
A27L (Rodriguez and Esteban, 1987, Gong et al, 1990) respectively. ThelO kD
peptide has been shown to share a 31% amino acid identity with a 14 kD protein,
encoded by the A27L gene of vaccinia virus (Fleming et al, 1993; Mercer et al,
1997a). Whilst the 14 kD protein is associated with the fusion of the vaccinia
virus particle to its target cell (Gong et al, 1990: Vasquez and Esteban, 1999),
there is no evidence that the orf virus 10 kD protein has similar function.
3.) A homologue of the vaccinia virus interferon-resistance gene E3L, called
interferon resistance gene (IFNR) (Fig. 1.6) (Mclnnes et al, 1998).
4.) A dUTPase like gene, homologous to the F2L gene of vaccinia virus, 5 kb from
the left end of the genome (Fig. 1.6) (Fraser et al, 1990)
5.) A DNA polymerase-like gene at position 26.4 kb from the left hand end (Fig.
1.6) homologous to the E9L gene of vaccinia virus (Mercer et al, 1997a).
In contrast, the major genetic differences between vaccinia virus and orf virus lie
in the terminal regions of their genomes and are thought to contribute to the
differences seen in their respective pathologies. In particular, a 20 kb region ofDNA
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at the right hand end of the orf virus genome has no counterpart in the genome of
vaccinia virus (Mercer et al, 1997a). Two genes have been identified from this region
to date (2000). One gene encodes a polypeptide with homology to mammalian
vascular endothelial growth factor (VEGF) (Lyttle et al, 1994). The other,
neighbouring gene encodes a homologue of mammalian IL-10 (Fleming et al, 1997).
It is suggested that these genes may have been acquired from a mammalian host
during the co-evolution of host and virus.
In tissue culture, orf virus (NZ2) has been reported to undergo genetic changes
that involve the duplication and translocation of approximately 19.3 kb of DNA at
the right-hand terminus to the left terminus (Fleming et al, 1995). This translocation
results in the deletion of three orf virus genes from the left-hand terminus. The genes
lost are; a homologue of the vaccinia virus F2L (a dUTPase) gene, a homologue of
the vaccinia virus 5K gene and a gene encoding an ankyrin repeat protein (Fig. 1.7)
(Sullivan et al, 1994). The tissue culture adapted isolates D1701 and orf 11 are also
representative of orf virus variants with similar translocations and deletions, and like
the NZ2 variant are reported to induce smaller lesions when compared with wild-
type orf virus (Mcinnes et al, in press). Thus the deleted genes are considered to be
non-essential to viral replication but may be associated with virulence in vivo.
1.3. The immune response to orf virus infection
1.3.1. The ovine immune system
The structure and function of the mammalian immune system is generally
conserved in the sheep and other ruminants. There is apparent conservation of
leukocyte surface molecules, the structure and function of cytokines, MHC
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ITR E2L E3L GIL G2L
Orf virus wild type
ITR VEGF-E IL-10 E3L GIL G2L
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Fig 1.7 Non-essential gene loss and translocation at the left hand termini
of attenuated strains of orf virus.
Each segmented strand shown above represents the left hand terminus of
the genome for a different orf virus strain.
A 16.5 kb DNA fragment at the right hand terminus of the orf virus
genome is duplicated and translocated to the the left hand end with the
loss of one or more genes. This fragment (shaded) contains, among
others, the genes that encode the homologues of VEGF and IL-10.
The deleted sequences encode the early transcribed genes, E2L, E3L,
GIL and G2L. E2L encodes a peptide homologous to the 5 kD peptide
of unknown origin in vaccinia virus. E3L is homologous to dUTPase
encoded by the herpes viruses. GIL encodes a protein that contains 8
ankyrin-like repeat sequences and is of unknown function. G2L is
homologous to the F11L gene of vaccinia virus which is also of
unknown function (Fraser et al, 1990; Fleming et al, 1995).
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organisation (except for sheep lacking primate MHC class II DQ2 genes whilst
possessing MHC class II DY genes not found in rodents or man; Ballingal et al,
1992; Hopkins et al, 1986) and the complement cascade (Oswald et al, 1990).
However, there are differences in y5 T cell population dynamics and B
lymphogenesis between ruminants and rodents or man (Mackay et al, 1988; Griebel
and Hein, 1996).
i). T cells
As in other species, sheep y5 T cells differ from a(3 (CD4+ and CD8+) T cells by
the expression and utilisation of a different set of T cell antigen receptor genes (y and
5) and surface receptor molecules. Young ruminants differ from other mammals in
having an unusually large number of y§ T cells, particularly in blood. In young sheep
the y§ T cell population may account for up to 60% of peripheral blood mononuclear
cells and is thought to provide early cover of non-MHC-restricted cellular immunity
until a more mature ap T- cell system becomes established (Hein and Mackay,
1991). As proposed in other species, a major function of y5 T cells in sheep is the
immune surveillance of epithelial surfaces that include the intestinal epithelium and
lamina propria (Mackay et al, 1989; Janeway et al, 1988). In sheep, y5 T cells are the
predominant lymphoid population in skin surfaces that are not covered by wool
(Mackay and Hein, 1989; Haig et al, 1999).
ii) Immunoglobulin repertoire
Sheep express IgM, IgGl, IgG2, IgA and IgE either as membrane-anchored B cell
antigen receptors or as secreted antibodies (Beh et al, 1986). There is no evidence
that sheep express IgD. The generation of the sheep Ig repertoire is unusual, in so far
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as it occurs by a hypermutation process that appears to operate autonomously during
B cell development in the follicles of the ileal Peyer's patch (Reynaud et al, 1995).
The sheep has proved extremely useful in the investigation into the physiology of
the immune system (Hein, 1995). Lymphatic duct cannulation has provided direct
access to a number of lymphoid micro-environments and can be used to investigate
the interaction between viruses and the local host immune system in vivo (Yirrell et
al, 1991; Haig et al, 1999).
1.3.2. The skin response to orf virus infection
In ovine skin, the host response to experimental infection (described in Section
2.6.) has been characterised histologically. Within the first 48h after a primary orf
virus infection, an early influx of neutrophils into the region surrounding orf virus-
infected epidermal cells was followed by an accumulation ofMHC class II+ dendritic
cells, y5 TCR+ T cells, CD4+ T cells, CD8+ T cells and B cells. This cell influx was
observed to peak between 9-15 days post infection and had returned to preinfection
levels by day 30 (Jenkinson et al, 1990a; Jenkinson et al, 1992; Lear et al, 1996;
Haig and Mercer, 1998). Throughout all four clinical stages of virus infection, the
majority of infiltrating lymphocytes were T cells (Haig et al 1996a, McElroy 1997).
In Stage 1 lesions (the initial papular stage), CD4+ T cells predominated but as the
lesions aged and regressed (Stage 4), the number of CD8+ T cells recruited to the
lesion site during viral replication and in the afferent lymph draining the site of
infection increased. The proportion of activated CD8+T cells in lymph and skin was
determined by the expression of the tryptase serine protease, BLT esterase, that is
associated with cytotoxicity (Haig et al, 1996b; McElroy, 1997). The number of y§
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TCR' T cells did not change significantly as the lesions aged.
In reinfections with orf virus, there was a parallel increase and decrease in the
accumulation of T cells, B cells and dendritic cells with the time course of viral
replication (Jenkinson et al, 1990c; Jenkinson et al, 1990a; Jenkinson et al, 1991;
Jenkinson et al, 1992; McKeever et al, 1988; Lear, 1995; Lear et al, 1996).
Experimentally-induced lesions were also smaller than those associated with the
naturally-occurring disease. Virus antigen was not detectable 11 days post-challenge.
The predominant lymphocyte subset obseved in the resolving phase of reinfection *
lesions was the CD4+ T cell; these resolving lesions also contained significantly
greater numbers of y5 TCR+ T cells than lesions in primary infections (McElroy,
1997; Haig et al, 1996d; Haig et al, 1997). The systemic depletion of different T cell
subsets prior to infection using mouse monoclonal antibodies directed against
specific cell subsets revealed that in animals depleted of CD8+ T cells or y5 TCR^ T
cells, lesion size and resolution times did not differ from those in the untreated
infected control group, although there was some evidence that CD8+ T cells may be
involved in an early immune response to orf virus reinfection (Lloyd et al, 2000).
However, those sheep, depleted of CD4+ T cells, developed larger lesions that took
longer to resolve. Accelerated healing times in reinfections indicates the
development of a degree of immunity to orf virus. The greater numbers of CD4~ and
yd TCR+ T lymphocytes in the rechallenge lesions compared to the primary lesions
suggests that these cells may have a role in this resistance.
1.3.3. The dendritic cell response
MHC class II+ dendritic cells are widely distributed throughout normal skin in
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two locations, namely in the epidermis and in the dermis in the vicinity of the dermal
structures e.g hair follicles, sweat glands and blood vessels (Jenkinson et al, 1991;
Lear, 1995; Lear et al, 1996). They are considered to constitute a population of
specialised antigen processing and presenting cells responsible for the induction and
maintenance of the immune response and may be involved in epidermal repair
processes (Jenkinson et al, 1991). After orf virus infection a dense mass of closely
associated MHC class II+ dendritic cells develop in the dermis adjacent to the
infected hair follicles and under and adjacent to infected degenerating epidermis
(Fig. 1.8). These cells interconnect and appear to form a barrier around the site of
infection with a network of processes interdigitating with the overlying epidermis
(Jenkinson et al, 1990a; Jenkinson et al, 1991; Lear, 1995; Lear et al, 1996).
This dense accumulation ofMHC class II+ dendritic cells, a majority (>90%) of
which are CDL, CD1 lb", CD1 lc" is representative of a minor dendritic cell
population that is found in uninfected sheep skin (Lear, 1995; Lear et al; 1996). (The
majority in normal skin are CD1+). The origin and function of these cells which lack
both the CD1 antigen of the antigen-capturing Langerhans cells of the epidermis or
the CD 1 lb/CD 1 lc antigens of tissue macrophages, is not yet known. Although
possible roles in skin repair, antigen processing and presentation and/or in containing
the spread of the virus directly, have been put forward (Jenkinson et al, 1991; Haig et
al, 1995; Haig et al, 1999; Haig and Mercer, 1998).
The control of different dendritic cell subsets and their function in host immunity
appears to be regulated by different cytokines and cytokine combinations. Haig et al
(1995) have shown that the intradermal injection of Tumour Necrosis Factor-alpha
(TNF-a) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in
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Fig 1.8 Immunohistolological analysis of an ovine orf lesion
(Haig et al, 1997).
A paraffin-wax -embedded section (x 350) from a skin biopsy
sample taken on day 5 following orfvirus reinfection. Orf virus
antigen (brown immunoperoxidase staining) is located by specific
monoclonal antibody in the epidermal cells showing evidence of
vacuolation.
Approximately 50% of MHC class II+cells (deep purple
immunoperoxidase staining) accumulating under and adjacent to
the virus-infected cells, were of dendritic morphology (Lear et al, 1996).
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unchallenged sheep promoted the accumulation of MHC class II+ CDF and CD1~
dendritic cells at the site of injection, whereas the injection of GM-CSF alone
promoted the infiltration ofMHC class II+ CD 1" dendritic cells. Both GM-CSF and
TNF-a in concert are known to support the survival and proliferation ofmurine
dendritic or Langerhans cells in culture and their development into potent T cell
stimulators (Heufler et al, 1988a and b). Furthermore antigen-presenting sheep veiled
dendritic cells found in afferent lymph survive in vitro provided TNF-a is present
and will increase in number if GM-CSF and TNF-a are added together in cultures
(Haig et al, 1995).
1.3.4. Lymph components of the immune response
It is possible to study the in vivo dynamics of the cellular immune response in
terms of the production of antibodies and cytokines in afferent lymph draining the
site of experimental orf virus reinfection (the prefemoral or popliteal lymph node
drainage area) and efferent lymph exiting the draining node (reviewed by Haig et al,
1999). The measurements obtained can be compared with those from lymph
cannulated from unchallenged sheep (Fig. 1.9) (McKeever and Reid, 1987; Yirrell et
al, 1991; Bujdoso et al, 1989; Haig et al, 1999). Afferent lymph in unchallenged
sheep contains CD4+ T cells, CD8 +T cells, y5 TCR+ T cells, B cells and 5-15% of
potent antigen-presenting veiled dendritic cells (Bujdoso et al, 1989; Mackay et al,
1989; Flaig et al, 1999). Efferent lymph contains > 98% lymphocytes, the majority of
which are CD4+ T cells and B cells with fewer CD8+ T cells and y5 TCR+ T cells.
Over 90% of these are derived from the blood filtering into the lymph node via high










Input 2-5 x 106 cells/hour.
85% T-cells; 5% B cells;
10% dendritic cells.
Low levels of cytokines
Stimulated
Input 5-10 x 106 cells/hour.
Blast transformed T cells
» B cells.









Output 2-5 x 107 cells/hour.
75% T-cells; 25% B cells;
Cytokines undetectable
Stimulated
Output 1-5 x 108 cells/hour.
Blast transformed T and B
cells.
Detectable cytokines.
High levels of antibody
Fig. 1.9 Cellular composition and flow rates of afferent and efferent lymph
circulating around a single skin-draining lymph node (Haig et al, 1999).
Afferent lymph contains antigen presenting cells, T cells and a small
proportion ofB cells. Following orf virus challenge there is an increase in
the frequency of lymphoblasts, particularly CD4+ T cell blasts, antibodies
can be detected and there is an increase in cytokine levels, particularly IL-2,
IFNy and GM-CSF. Furthermore afferent lymph cell input can triple.
Efferent lymph contains >98% lymphocytes with a higher proportion ofB
cells and much higher flow and cell output rates than the input rates of
afferent lymph.
Following infection, in efferent lymph there is often an initial shutdown of
lymphocyte output, followed by a recruitment phase whereby lymphocyte
output increases along with increased blood flow to the node. Efferent T and
B lymphoblasts appear after this phase with B cell blasts and antibody
produced within the lymph node. Finally with resolution, lymph flow rate
and cellular composition return to pre-stimulation levels.
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et al, 1989; Harp et al, 1988). The remaining 10% of efferent lymph lymphocytes are
derived from within the lymph node or from afferent lymph (Hall and Morris, 1962).
Following control scarification of the skin there are no significant or only small
changes in total cell output, lymphoblast transformation or the proportions of
different cell types in afferent or efferent lymph (Haig et al, 1996a; Haig et al, 1999).
Following orf virus challenge, total cellular and lymphoblast output is biphasic in
afferent and efferent lymph. The first peak response in both compartments was
blM tr.
thought to reflect an immediate antigen specific immune memory reaction to orf
virus antigen and the second to viral replication in the skin which occurs between 3
and 9 days post reinfection (Haig et al, 1996a and b). However, Haig et al, (1999)
more recently have suggested that the delay between the observed lymphoblast
responses to orf virus reinfection may be due to the effect of viral
immunomodulators (see Section 1.4.). In contrast, challenge with UV-inactivated orf
virus stimulates a delayed type hypersensitivity reaction in the skin and a single peak
response in both lymph compartments (Haig et al, 1999)
In the infected animal, total and blast-transformed CD4+ Tcell output precedes
and exceeds that of CD8T T and B cells in both afferent and efferent lymph as was
observed in the skin. yS TCR+ T cells show only a slight increase early in the
infection, between days 1-4. Antibody titres to orf virus antigens increase in both
lymph compartments following challenge (Yirrell et al, 1989; Yirrell et al, 1991).
Afferent lymph contains antigen-specific memory T cells that are able to respond
rapidly to reinfection by blast transformation and cytokine production whilst efferent
lymph cell output is delayed slightly by comparison. Effector cells in efferent lymph
are recruited from the blood prior to activation within the node thus amplifying the
34
number of antigen specific T and B cells able to react with orf virus antigens in the
skin (Haig et al, 1996a and b).
1.3.5. Cytokine production
The activation status of the skin and lymph following orf virus reinfection can be
determined by analysis of skin and lymph samples for the presence of those
cytokines that are involved in anti-viral immune responses.
Messenger RNA transcripts for the cytokines, IL-1 (3, IL-2, IL-3, TNF-a, GM-
CSF and IFN-y are detected in lesion biopsies taken from the skin of orf virus re¬
infected sheep. These transcripts are not detected in control sheep that undergo a
mock scarification (Haig et al, 1996c). This spectrum of cytokines produced
following orf virus challenge is indicative of a typical anti-viral immune and
inflammatory response. (Haig et al, 1997; Seow et al, 1994).
Similarly, cytokine mRNA and/or cytokine expression can be analysed in both
afferent and efferent lymph. Lymph plasma contains cytokine activity generated in
the skin as well as from the cells contained in the lymph. Cytokines, namely IL-1 p,
IL-2. IL-8, TNF-a, GM-CSF, IFN-a and IFN-y, are detected in afferent lymph
during the course of orf virus infection (Haig et al, 1996c; Haig and Fleming, 1999;
Haig and Mercer, 1998). IL-ip and IL-8 appear rapidly in both afferent and efferent
lymph and in cell-free supernatants from cultures of afferent and efferent lymph cells
within the first 24h following orf virus reinfection. This is consistent with the
involvement of these cytokines in the early stages of both innate and specific
immune responses (Haig et al, 1997; Seow et al, 1994). GM-CSF appears in afferent
lymph also in the early stages of infection but after IL-lp and IL-8. GM-CSF and
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IFN-y peak in parallel with the lymphoblast output that peaks on days 4-6 and 8-12
in afferent lymph and days 5-8 and 10-14 in efferent lymph (Haig et al, 1997). In
efferent lymph, Haig et al ( 1996a) suggest that those T cells subsets activated as a
result of orf virus reinfection and expressing the CD45RA" phenotype ofmemory T
cells, are the principal cellular sources of IL-2, IFN-y and GM-CSF.
The importance of T cell and cytokine function in immunity to orf virus infection
was highlighted in an experiment where 6 month old lambs were given a course of
the immuno-suppressive drug cyclosporin-A (CSA) for a period of 9 days prior to
and during re-infection. These animals developed severe lesions that were typical of
a primary infection (Haig et al, 1996d). CSA is reported to inhibit the transcription of
the genes for IL-2 and IFN-y via a calcineurin-dependent mechanism (Schreiber and
Crabtree, 1992). At the site of infection in the treated group, there was a marked
reduction in the recruitment of CD4+ T cells, CD8+ T cells, B cells and dendritic
cells. Futhermore the expression of IL-2 and IFN-y witnessed on days 3 and 9 post
challenge in the untreated group was not present in CSA-treated animals. However
on cessation of treatment, there was a rapid influx of immune cells (CD4+ T cells
followed by dendritic cells, then B cells, then finally CD8+ T cells) to the site of
infection (Haig et al, 1996d).
1.3.6. Humoral response
Sheep infected with orf virus produce detectable antibodies specific for a small
number (4 or 5) of immuno-dominant viral antigens (McKeever et al, 1987; Yirrell et
al, 1989; Housawi et al, 1998). However none of these antibodies appears to
neutralise virus or provide protection to virus challenge through passive transfer
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(Yirrell et al, 1989; Mercer et al, 1997b). In spite of high antibody titres in the sera
of infected sheep, the humoral response to orf virus infection is short lived (up to a
few months post infection) (McKeever et al, 1987; Mercer et al, 1994). Passive
antibody transfer studies imply a minor role if any for antibody in orf immunity
(Buddie and Pulford, 1984; Mercer et al, 1997b). In contrast, Lloyd et al (2000)
observed that in sheep with high orf virus-specific antibody titres at the time of
infection, orf lesions healed faster than in sheep with low antibody levels. In
persistent orf virus infections, McElroy (1997) suggests that in spite of a
considerable antibody response characterised by high antibody titres against orf virus
antigen, it is a defective T cell response marked by a local absence of T cells,
particularly CD4+ and y5TCR+ T cells, that prevents resolution of the infection.
Whilst it is still unclear whether antibodies play a minor role, CD4+ T cells, CD8+
T cells, and IFN-y fulfil major roles in the protective immune response to orf virus
infection (Haig and Mercer 1998). In spite of this, orf virus along with other
parapoxviruses can repeatedly infect their hosts; a phenomenon that suggested a role
for orf virus-encoded immuno-modulatory proteins.
1.4. Interference with host immunity
1.4.1. Poxvirus immuno-modulatory genes
Poxviruses, like other large DNA viruses, have evolved a number of mechanisms
by which they are able to survive and replicate in a wide range of species in spite of
an active host immune response. Orthopoxviruses, as represented by vaccinia virus
and cowpox virus and the leporipoxviruses, as represented by myxoma virus, have
been extensively investigated as models of poxvirus infections and of immune
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evasion of the host response. (Reviewed by: Palumbo et al, 1994; Smith, 1993;
Smith, 1999; Haig, 1998; McFadden et al, 1995; Alcami and Koszinowski, 2000).
Through the co-evolution of poxvirus and host, host immuno-modulatory genes have
been acquired and modified by the poxviruses in order to counteract many of the key
components of the host immune response (Table 1.2).
1.4.2. Orf virus interaction with host immune responses
Unlike either the orthopoxviruses or leporipoxviruses, the parapoxviruses fail to
develop a systemic infection and seldom give rise to fatal infections. However, an
intriguing characteristic of parapoxviruses is the ability to reinfect their host despite
an apparently typical anti-viral host immune response (Haig and Mercer, 1998). The
orthopoxviruses (represented by vaccinia virus) have evolved multiple mechanisms
that interfere with host anti-viral defences and although the parapoxviruses have not
been analysed to the same degree, there are several possible reasons why orf virus
may be able to survive host anti-viral mechanisms, particularly on reinfection.
Haig and Mercer (1998) suggest that since orf virus infects epidermal cells, the
period before anti-viral cellular and molecular components reach the infected site
may be sufficient time for limited viral replication. Furthermore, by infecting
regenerating epidermal cells, the virus may not stimulate apoptosis to the same
degree as in those cells not committed to proliferation. Lastly, the dense network of
accumulating MHC class II+ dendritic cells underlying the site of infection may act
as a barrier to further spread of orf virus infection.
Finally, several immuno-modulatory genes have recently been identified in the













































































































































































































































































































































































































































































































































































































































































































































































































endothelial growth factor (VEGF), a viral IL-10, and a viral interferon-resistance
factor (IFNR) (Haig and Mercer, 1998).
i). Orf virus vascular endothelial growth factor (VEGF)
The first orf virus virulence gene to be identified was a homologue of the
mammalian VEGF gene (Lyttle et al, 1994). VEGF is a secreted homodimeric
glycoprotein that stimulates the proliferation of vascular and lymphatic endothelial
cells and has a key role in normal and abnormal angiogenesis (Fava et al, 1994).
A feature of orf virus infection, in sheep and man, is the extensive capillary
proliferation and dilation found in the area of the lesion and it seems likely that orf
virus VEGF, an early expressed gene, is involved in the promotion of this condition
(Meyer et al, 1999). VEGF also promotes the expression of the integrins, VCAM-1
and ICAM-1 in endothelial cells (Melder et al, 1996) and may interfere with the
maturation of dendritic cells (Gabrilovich et al, 1998). Futhermore Flaig and Mercer
(1998) suggest that the accumulation ofMHC class II+ dendritic cells adjacent to the
site of infection and characteristic of orfmay be a result of viral VEGF released by
infected cells. Meyer et al, (1999) report that in contrast to mammalian VEGF, orf
virus VEGF binds to only one of 2 VEGF receptors, namely VEGF receptor-2
(VEGFR-2). VEGFR-2 is thought to dominate the angiogenic response
(Waltenberger et al, 1996).
Interestingly, there are 2 major forms of the orf virus VEGF gene as expressed by
the different orf virus strains NZ2 and NZ7 and which differ from one another in
DNA sequence to a degree whereby they share a predicted amino acid identity of
only 41%. Flowever orf virus isolates appear to contain only a single gene copy
encoding one of the VEGF isoforms, but not both (Lyttle et al, 1994). As to why
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different orf viruses should acquire one or other of 2 different VEGF genes is not
known. Haig and Mercer (1998) suggest that since multiple VEGF forms exist in
mammals (potentially 4-6 in man and sheep), it is possible that whilst different
strains of orf virus can acquire a single copy of several VEGF genes available in
infected tissue, they have not the capability of capturing another. The acquisition, by
individual orf viruses, of different VEGF genes with possible subtle differences in
biological activity may confer a specific advantage to that particular virus (Ferrara
and Davis-Smyth, 1997).
A recombinant orf virus in which the orf virus VEGF gene has been removed has
been tested for virulence and although no significant difference in virus growth in
tissue culture was observed, in sheep, lesion development was significantly reduced
in the 'knocked ouf virus (Wise et al, 1999).
From the evidence accumulated so far, Flaig and Mercer (1998) propose that orf
virus VEGF, either directly or indirectly, provides proliferating epithelial cells as
targets for virus replication and may prevent viral induced cell apoptosis in a similar
way to vaccinia virus epidermal growth factor (Reisner, 1985).
ii). Orfvirus IL-10
An orf virus homologue of the ovine IL-10 gene has been identified (Fleming et
al, 1997). IL-10 is a pleiotropic cytokine that is involved in the general down-
regulation of the Thl cell mediated immune response in favour of the promotion of
Th2 and B cell responses (Fig. 1.10) (Itoh et al, 1994; Perrin et al, 1999).
Thl and Th2 responses represent two different types of immunity mediated by
two distinct types of helper T cells (Th) (reviewed by Mosmann and Moore, 1991;


















Fig. 1.10 Mediation of effector mechanisms by Thl and
Th2 cells.
Activation of either Th subset by antigen presenting cells
(APC) leads to the output of cytokines which drive different
effector pathways. However the activation of Thl cells will
tend to switch off the activation of Th2 cells and vice versa.
Th2 cells release IL-10 which inhibits the Thl-driven response.
Viral IL-10 (vIL-10) is considered to act in a similar fashion.
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cellular immunity but only weak and transient antibody responses. In contrast, Th2
cells produce an array of cytokines that evoke strong antibody responses but weak
cellular immunity. In general, the immune response to most individual pathogens
involves both, with one or other predominating to most effectively combat the
invasion. By occurring together, Thl and Th2 responses, through the cytokines
produced, can suppress or moderate the activity of the other. However the action of
certain cytokines can sometimes alter the balance of the Thl/Th2 immune response
and bring about inappropriate reactions.
The inhibitory effects of IL-10 on Thl responses were found to be indirect and
due to the inhibition of accessory function and antigen presenting capacity of
monocytes and macrophages (Fiorentino et al, 1991). IL-10 blocks the production of
the Thl cytokines, IL-2 and IFN-y (Moore et al, 1993) and also the production of
pro-inflammatory cytokines that include TNF-a, IL-1 (3, IL-6 and IL-8 (de Waal et al,
1991; Wang et al, 1994; Mosmann, 1994). Finally, IL-10 has been reported to
suppress nitric oxide synthesis in both activated macrophages and keratinocytes in
culture (Corradi et al, 1993; Becherel et al, 1995).
Viral homologues of IL-10 have also been identified in Epstein Barr virus (EBV)
(Hsu et al, 1990; Moore et al, 1990) and equine herpes virus-2 (Telford et al, 1995)
but not in poxviruses other than orf virus so far.
Orf virus IL-10 is an early gene and the predicted protein sequence has 80%
amino acid identity with ovine IL-10, with major differences occurring at the N-
terminus. Orf virus IL-10 and ovine IL-10 have been shown to have similar activities
in a thymocyte proliferation assay (Fleming et al, 1997) but whether or not orf virus
IL-10 has both the inhibitory and stimulatory activities of host IL-10 is as yet
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unclear.
It is thought that orf virus IL-10 acts in the vicinity of virus infection to suppress
the inflammatory response via down-regulation of pro-inflammatory cytokines and
the cell mediated response via inhibition of Thl cytokines (Haig and Mercer 1998).
iii) Orf virus interferon-resistancefactor
Tissue culture-adapted strains of orf virus have been shown to be resistant to the
antiviral effects of IFN a,|3 and y (Haig et al, 1998). A homologue of the vaccinia
virus E3L interferon-resistance (IFNR) gene has been found in the left hand terminal
region of the genome of orf virus strain NZ2 (Mercer et al, 1997a). The orf virus
INFR gene is transcribed early and has a predicted 30% amino acid sequence
homology to vaccinia virus E3L gene product (Mclnnes et al, 1998). Vaccinia virus
E3L product binds double stranded (ds) RNA and inhibits the ds RNA-dependent
activation of both an IFN-inducible protein kinase (PKR) and the IFN-inducible 2-5
polyadenosine synthetase (Chang et al, 1992). Activation of PKR kinase would
normally result in the phosphorylation of the translation initiation factor eIF2 and
inhibition of the initiation of protein translation. On the other hand, activation of the
2-5 polyadenosine synthetase inhibits protein synthesis by activating RNAse L which
cleaves both mRNA and ribosomal RNA (Chang et al, 1992; Beattie et al, 1995).
Similarly, the orf virus INFR protein has been shown to bind dsRNA and inhibit
ovine PKR phosphorylation thus effectively suppressing the anti-viral state induced
by both type 1 and type 2 IFN (Mclnnes et al, 1998; Haig et al, 1998). The transient
expression of orf virus IFNR in ovine fibroblasts infected with the unrelated Semliki
forest virus suppressed the anti-viral effects of type 1 and 2 IFN that would normally
restrict the growth of the virus (Haig et al, 1998).
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Thus orf virus is one of several poxviruses that contain a gene or genes, the
products of which interact with one or more of the host components involved in the
IFN-induced and dsRNA-dependent shutdown of viral and host protein synthesis. By
targeting IFN, those viruses indicate the importance of the interferons in host anti¬
viral defence.
1.4.3. A GM-CSF-inhibitory factor (GIF) associated with orf virus infection
As a result of a previous study (Lear, 1995), a factor was discovered which was
expressed by orf virus-infected ovine keratinocytes in culture that cleared both
constitutively produced GM-CSF and exogenous recombinant ovine GM-CSF as
measured by a GM-CSF ELISA (described by Entrican et al, 1996). This activity
was a consequence of orf virus infection and was not due to proteolysis of the GM-
CSF, since addition of protease inhibitors failed to prevent GM-CSF clearance (Lear,
1995).
In the skin, GM-CSF is up-regulated in a number of skin inflammatory diseases.
Introduction ofGM-CSF intradermally either as soluble protein (Haig et al, 1994) or
by the expression of transgene protein (Xing et al, 1997) promotes the influx and
accumulation in the dermis of neutrophils, eosinophils, macrophages, MF1C class IIr
CDL dendritic cells and lymphocytes, particularly T cells. An increase in the number
of epidermal Langerhans cells, endothelial cells and keratinocytes was also observed
(Ruef and Coleman, 1990; Xing et al, 1997). From studies with transgenic mice, Sato
et al, (1999) suggest that GM-CSF is involved in the maturation of a specific sub-
population of natural killer cells.
Whilst GM-CSF in the context of local immune responses stimulates
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macrophages and granulocytes, and enhances healing and repair by its action on
fibroblasts and epidermal cells, a more pivotal role may be as a mediator of the
maturation and function of dendritic cells and their induction of the primary T cell
immune response (Baldwin, 1992; Tarr, 1996; Wada et al, 1997). An orf virus-
induced protein that binds GM-CSF and so inhibits normal GM-CSF function may
contribute significantly to the suppression of anti-viral defences to the advantage of
orf virus.
1.5. Objectives of this study
GM-CSF inhibitory activity (GIF) has not been associated with other viruses or
pathogens and so the GIF activity found in orf virus infection represented an
important focus of study. This thesis was designed to further our understanding of
the mechanisms by which viruses block host anti-viral immune responses by
characterising in detail this novel immuno-modulatory protein.
The initial aim of the project was to determine whether the GIF protein was the
product of an orf virus gene or a host cell gene under virus control (see Chapter 3). A
vaccinia virus-orf virus library comprising restriction fragments of orf virus DNA
inserted into a vaccinia virus vector was used to screen cells infected with the
vaccinia-virus-orf virus recombinants for the expression of GIF by ETISA. In this
way the orf virus gene associated with GIF activity was isolated. This gene was then
expressed in a suitable expression vector and the protein isolated. N-terminal amino
acid sequence analysis was carried out on the GIF protein to determine whether or
not it was the product of the isolated orf virus gene. Protein sequences recorded in
protein databases were examined for any similarity with the sequence of the GIF
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protein. In addition, ovine fibroblast cultures were infected with orf virus in vitro to
determine the kinetics ofGIF gene expression. Antibodies to the isolated GIF protein
were raised for this and other purposes.
The interaction of the GIF protein with GM-CSF was examined by ELISA and
Western blotting to determine the physio-chemical properties of the GIF (Chapter 4).
Since a number of poxvirus immuno-modulatory proteins have been reported as
possessing multiple reactivities with host cytokines, the specificity ofGIF for
cytokines other than ovine GM-CSF was tested by ELISA and ligand blotting
(Chapter 5).
A soft agar clonogenic assay that measured GM-CSF-driven proliferation of bone
marrow myeloid progenitor cells was used to determine the effect ofGIF on GM-
CSF function (Chapter 6).
Finally skin biopsy tissue and samples of afferent and efferent lymph taken from
sheep experimentally infected with orf virus were examined for the presence ofGIF





2.1. General Materials and Methods
2.1.1. Reagents
Unless stated otherwise, the chemicals used in this study were obtained from Sigma
Chemicals (Poole, U.K).
2.1.2. Animals
Female Suffolk-cross sheep were used in experiments involving sheep.
Antiserum was raised against GIF in female New Zealand strain rabbits and female
BALB/c strain mice.
2.1.3. Viruses
The orf virus strains used in this study were orfl 1 (generated at the Moredun
Research Institute, Mclnnes et al, in press), scabbymouth (Pye, 1990), D1701
(Czerny et al, 1997), NZ2 (Mercer et al, 1987; Lyttle et al, 1994) and the field isolate
MRI Scab (McKeever and Reid 1987).
The orfl 1, scabbymouth, D1701 and NZ2 orf virus strains were originally isolated
from sheep scab material and subsequently propagated in primary bovine testes cells
or primary fetal lamb muscle or kidney cells. The field isolate, MRI Scab virus, is
propagated in sheep and has not been adapted to grow in cell culture.
German isolates of bovine papular stomatitis virus (V660) and pseudocowpox
virus (B074) were kindly provided by Dr. M. Buttner, Federal Virus Laboratory,
Tubingen. Both isolates had been adapted to cell culture by passage in bovine lung
epithelial cells followed by passage in fetal lamb muscle cells (Mayr et al, 1974).
The vaccinia virus strain Lister was used in this study (Robinson and Mercer,
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1988). This strain was originally isolated in the Lister Institute of Preventive
Medicine, U.K. for use as a smallpox vaccine.
Semliki Forest virus (SFV) was used in this study as an unrelated virus control.
SFV is a positive stranded RNA virus of the genus, Alphavirus, that is transmitted by
mosquitoes and has been isolated in central, eastern and southern Africa. Infection of
sheep fibroblast cell cultures with SFV resulted in a cytopathic effect similar to that
observed after infection with orf virus. It was propagated by passage in ST-6 ovine
fibroblasts (Entrican et al, 1989).
2.1.4. Cells
i). Cell maintenance
Orf virus, bovine papular stomatitis virus and pseudocowpox virus were grown in
fetal lamb muscle (FLM) fibroblast cells maintained at Moredun Research Institute
as a primary cell line in Medium 199. Vaccinia virus was grown in CV-1 cells, a
monkey kidney fibroblast cell line (European Collection of Cell Cultures [ECACC],
CAMR, Salisbury U.K.), maintained in Eagles minimal essential medium (MEM).
The mouse hybridoma lines 3C2 and 8D8 that secrete monoclonal antibodies to
ovine GM-CSF (Entrican et al, 1996), were maintained in RPMI-1640 medium.
Chinese hamster ovarian epithelial (CFIO) cells (ECACC) were maintained in
Glasgow's modified Eagle medium (GMEM) supplemented with 7.5% heat -
inactivated dialysed fetal bovine serum (PAA Laboratories, Kingston upon Thames,
U.K). CHO cells transfected with orf virus DNA or ovine DNA were maintained in
glutamine-free GMEM supplemented with 7.5% heat -inactivated dialysed fetal
bovine serum and methionine sulphoxamine (see Section 2.2.3 .ii).
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Media were obtained from Life Technologies Ltd (Paisley, U.K.) and with the
exception ofGMEM, supplemented with 10% fetal bovine serum, ImM glutamine
and 100 units/ml penicillin and streptomycin. Cell cultures were propagated in
plastic tissue culture plates and flasks supplied by Corning Costar Ltd (High
Wycombe, U.K.).
ii). Cryopreservation
Cells (2-5 x 106) were harvested (see Section 2.2.3.i) and washed once in
medium containing serum before gentle resuspension in 1 ml of fetal calf serum
containing 10% dimethyl sulfoxide (DMSO) and transferred into a cryotube (Nunc
Inc., Naperville, Illinois ) The tubes were placed in a Cryo freezing container (Nalge
Nunc International, Hereford, U.K.) and stored at -75°C for 24 hours. The tubes
were then transferred to a liquid nitrogen tank for storage until required.
Cells removed from frozen storage were thawed rapidly in a 37°C waterbath and
the suspension diluted in 5 ml ofwarm culture medium. The cells were then washed
and inoculated into 25 cm2 and 75 cm2 flasks at 5 x lO5 cells/ml.
2.1.5. Chromatography
i). Equipment
All chromatography described in this study was carried out using the Fast Protein
Liquid Chromatography (FPLC) system (Amersham Pharmacia Biotech Ltd (APB),
Little Chalfont, U.K.). Column buffer flow rates were controlled by an integrated
Liquid Chromatography Controller LCC-550 and the protein concentrations in




Proteins were separated by adsorption to specific ligands immobilised on
Sepharose 4B (APB) as outlined in Section 2.1.7.
Hi). Gel Filtration Chromatography
Recombinant proteins were separated on the basis of size by gel filtration
chromatography on Sephacryl S200HR (APB). Prior to separation protein mixtures
were concentrated at least 10-fold by ultrafiltration in a Centricon YM-10 (molecular
weight cut-off 10,000) microconcentrator cell (Amicon, Stonehouse, UK) at 6000 x g
for 3 hours.
Volumes of 0.2-0.5 ml were generally loaded onto a 16 x 600 mm Sephacryl
S200HR column equilibrated with PBS containing 0.02% sodium azide or PBS
containing 0.5 M NaCl and 0.1 % CHAPS (3-[(3-cholamidopropyl)-
dimethylammonio]-l-propanesulfonate) if protein concentrations were < lOOpg/ml
and adsorption of protein to the gel matrix was suspected. Column flow rate was 0.5
ml/min and 1ml fractions were collected. Fractions were analysed by ELISA
(Section 2.1.7.) and/or sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) run under reducing conditions (Section 2.1.6.).
The apparent molecular weights of separated proteins were estimated by
comparison with the retention times for a range of gel filtration protein standards





Proteins were separated by gel electrophoresis as outlined by Laemmli (1970),
using the Mini-Protean gel system (Bio-Rad, Hemel Hempstead, U.K.). Samples (10-
15 pi) were reduced in an equal volume of SDS-PAGE sample buffer (0.0625 M
Tris-HCL [pH 6.8], 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.002%
bromophenol blue) and immersed in boiling water for 2 min. Samples, run under
non-reducing conditions, were mixed with sample buffer without 2-mercaptoethanol
and were not heated. Electrophoresis buffer consisted of 25mM Tris, 0.19M glycine,
0.1% SDS (pH 8.3). Samples were loaded into the wells of discontinuous SDS-
PAGE minigels comprising a 4% stacking gel and a separating gel of either 7.5%,
12% or 15% and electrophoresed at 200 V until the dye had reached the bottom of
the gel. Generally, gels were produced from a 30% stock acrylamide solution
containing 0.8% bis acrylamide (Severn Biotech Ltd. Kidderminster, U.K). However
the use of ProSieve 50 acrylamide gel solution (FMC, Rockland, USA.) to generate
the 12 % separating gel was found to improve the separation of reduced proteins
(with molecular masses in the range 25-60 kD) when compared with conventional
acrylamide solutions.
ii). Silver staining ofseparated proteins
In general, separated proteins were visualised by silver staining. Gels were fixed
in 50% methanol, 10% acetic acid in distilled water for 15 min, rehydrated twice in
5% methanol, 7% acetic acid in distilled water for 10 min then washed twice in
distilled water. Proteins were reduced in 5 pg/ml dithiothreitol in distilled water for
15 min, washed again, immersed in 0.1% silver nitrate in distilled water for 20 min,
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washed briefly and finally developed for stained protein by immersion in 3% sodium
carbonate containing 0.05% formaldehyde. Development was terminated by the
addition of citric acid to 1% w/v.
Molecular weight markers (SDS-PAGE standards, Bio-Rad.) that consisted of
phosphorylase b (97,400 Daltons), bovine serum albumin, (66,200), ovalbumin,
(45,000), carbonic anhydrase (31,000), trypsin inhibitor (21,500) and lysozyme
(14,400) were included in all gels.
iii). Estimation ofmolecular mass ofseparatedproteins
All molecular mass estimations were carried out using the standard curve
generating tool provided with Microcal Origin Data Analysis software version
4.0/5.0 (Plikaytis et al, 1986). Standard curves were generated from either retention
times (gel filtration) or mobilities (SDS-PAGE) of protein standards run either in
parallel or under identical conditions.
2.1.7. Detection of GIF by ELISA
i). Introduction
The binding of recombinant GIF to recombinant ovine GM-CSF (rovGM-CSF)
was measured by the decrease in unbound rovGM-CSF as detected by GM-CSF
sandwich ELISA (Entrican et al, 1996). This exploits the fact that GM-CSF bound to
GIF is no longer detected in the GM-CSF ELISA. The ELISA uses two affinity-
purified monoclonal antibodies 8D8 and 3C2 that recognise mutually exclusive
epitopes ofGM-CSF (Entrican et al, 1996).
ii). Antibodies and rovGM-CSF
The generation of rovGM-CSF and the anti-GM-CSF Mabs 3C2 and 8D8 has
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been described (Entrican et al, 1996). An IgG fraction of 3C2 was prepared from
three 300-400 ml volumes of 3C2 hybridoma conditioned medium by separation over
2.5 mis of Protein A-Sepharose 4 fast flow (APB) equilibrated with PBS containing
0.02% sodium azide.
Bound material was eluted by the addition of 0.5 M NaCl in 0.1 M glycine pH
2.9. The collected fractions (1ml) were immediately neutralised by the addition of
(38pl) 1M Tris-HCl pH 11, then concentrated at least 10-fold by ultrafiltration. The
pooled IgG fractions (10 mg) were dialysed against 0.1 M NaHCCfi buffer, pH 8.2.
overnight then coupled to 1 g (dry weight) of CNBr-Sepharose (APB) to prepare an
affinity column according to the manufacturer's instructions.
Cell free supernatants (supernatant, 50 to 100 ml; containing a total of 0.5-3 mg
rovGM-CSF) from the stable rovGM-CSF transfectant CFIO cell line 1G10 ,
maintained in serumless- GMEM (Gibco BRL, Paisley, UK) for 4 days, were applied
to the 3C2-affinity column equilibrated with PBS and the eluants monitored for
protein content at OD 280nm. Bound material was treated as described above and
'J? C-L4, C, *]
aliquots taken for analysis by SDS-PAGE.
In a similar manner, purified rovGM-CSF (5-10 mg) was bound to CNBr-
Sepharose. The rovGM-CSF-Sepharose affinity column was then used to purify the
anti-GM-CSF Mab 8D8 from hybridoma conditioned medium as described for the
Mab 3C2.
The Mab 8D8 was used to coat the ELISA plate and so capture any GM-CSF
present in the samples and the second Mab 3C2 conjugated to horse radish
peroxidase (HRP) then bound to the second epitope on the captured GM-CSF. The
captured GM-CSF was quantified by comparison with a standard curve using
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rovGM-CSF (Mclnnes and Haig, 1991; Mclnnes et al, 1993).
Hi). Conjugation ofHorse Radish Peroxidase (HRP) to 3C2 antibody
A HRP-aldehyde was formed by the addition of 50 pi NaKAj (38.5 mg/ml) to 4
mg HRP (Boehringer Mannheim, Lewes, UK) in 1 ml of distilled water for 20 min
with stirring at room temperature (RT). The HRP-aldehyde solution was dialysed
against ImM acetate buffer pH 4.5 overnight before the pH was raised by the
addition of 20 pi of 0.2 M sodium carbonate pH 9.5 to >9.0 and 5-8 mg of purified
3C2 in 1 ml of 0.01M sodium carbonate pH 9.5 added immediately. The reaction
mixture was stirred for 2 h at RT. The reaction was terminated by the addition of 100
pi of freshly prepared sodium borohydride solution (4 mg/ml in water) at 4°C for 2
hours. The conjugate mixture was then fractionated by gel filtration on Sephacryl S-
200HR (APB) equilibrated with PBS. From the measured absorbances at 280 nm, the
first peak fractions were pooled and tested for function in the GM-CSF clearance
ELISA.
iv). The modified GM-CSFELISA for the detection ofGIF
M129B 96 well ELISA plates (Greiner Laborotechnik, Dursley, UK) were coated
with 50 pi per well purified anti-GM-CSF Mab 8D8 at a concentration of 2 pg/ml in
0.1 M carbonate buffer pH 9.6, at 4°C overnight. Plates were washed twice with PBS
containing 0.05% Tween 20 (PBST), then blocked for 30 min at RT with 100 pi per
well PBST containing 4% BSA. At this stage 20 pi of affinity purified recombinant
ovine GM-CSF at 40 ng/ml or 80 ng/ml in wash buffer was added to 180 pi of
sample to be tested for the presence ofGIF and the mixture incubated for 1 hour at
37°C.
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A range of GM-CSF standards were prepared from a stock of rovGM-CSF at a
concentration of 20 pg/ml which was diluted to 8000, 4000, 2000, 1000, 500, 400,
200 and 100 pg/ml in wash buffer. After blocking with 100 pi of 4% BSA in PBS,
the plates were washed twice with wash buffer and 50 pl/well of standards, samples,
controls or buffer alone were added to the plate in duplicate. The plate was left at RT
for lh, washed 3 times in wash buffer, then 50 pi of affinity-purified anti-GM-CSF
Mab 3C2 (1 pg/ml) conjugated to HRP were added to each well. The plate was
incubated for a further 1 hour, washed as before, then 50 pi of substrate solution
produced from orthophenylene diamine tablet sets (OPD) following the
manufacturer's recommendations, were added to each well. Colour was allowed to
develop for approximately 15 min. The reaction was terminated by the addition of 25
pi per well 2.5 M FB SO4.
The optical density (OD) of the reaction mixture was measured using a MRX
Microplate reader (Dynex Tecnologies Ltd. Billingshurst, U.K.) equipped with a 492
nm filter. The level of GM-CSF bound to GIF was estimated by comparison of
measured unbound cytokine with a standard curve generated from the range of GM-
CSF concentrations using dedicated EndPoint software (Dynex).
2.1.8. Western blot analysis
Ligand or immuno-blot analysis was performed on proteins separated by SDS-
PAGE under reducing and non-reducing conditions and electrotransferred to BA 83
nitrocellulose membranes (Schleicher and Schull. Anderman, Kingston upon
Thames, U.K.) for 3 hours at 70mA/gel (2 mA/cm" of gel). The membranes were
then blocked in PBS containing 4 % non-fat milk powder (Marvel; Chivers, Dublin,
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then blocked in PBS containing 4 % non-fat milk powder (Marvel; Chivers, Dublin,
Ireland ) for 1 h at RT before probing with antibody or radioiodinated ligand diluted
in blot wash buffer; PBS containing 0.35M NaCl and 0.5% (v/v) Tween 80 (Sigma)
for lh at RT. After extensive washing of the blot, bound 12?I-ligand was visualised by
autoradiography whereby the dried blot was exposed to Hyperfilm MP x-ray film
(APB ) overnight.
Bound antibody was visualised by a further 1 hour incubation with a 1:1000
dilution of goat anti-rabbit IgG conjugated to horse-radish peroxidase (HRP)
(DAKO, Ely, UK) in wash buffer, followed by treatment with the enhanced
chemiluminescence (ECL) reagent (APB), according to the manufacturer's
instructions, and exposure to Hyperfilm ECL (APB) for 30 sees to 5 min before
development.
2.1.9. Radioiodination of proteins
Purified proteins were radioiodinated by the chloramine-T method as described by
McConahey and Dixon (1980). Protein (20-30 pg) in 20-50 pi of PBS was added to
20 pi of 0.5 M sodium phosphate buffer pH 7.5 and 0.5 mCi (18.7 MBq) ofNai2:l
(free of carrier, 3.7 GBq/ml, APB) in a 1.8 ml microfuge tube. The reaction was
initiated with the addition of 60pl of chloramine T (1 mg/ml) in distilled water to the
mixture which was vigorously shaken and left for 2 min at RT. The reaction was
terminated by addition of 60 pi of stop buffer containing 1 mg/ml L-tyrosine
(Sigma), 1 mg/ml potassium iodide in water and the volume made up to 1 ml with
PBS. 12:,I-labelled protein was separated from free Na12?I by gel filtration on a 10 ml
column of Sephadex G-25 (APB) equilibrated with PBS. Aliquots (10 pi) were taken
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counter, Packard, Pangbourne, U.K.) to identify radiolabeled protein fractions and
to determine the efficiency of labelling and the specific activity of the recovered
protein.
2.1.10. Statistical analysis of data
Throughout this project statistical tests were applied to data obtained where
appropriate. Tests were based on within-sample variation and were performed using
a standard error of differences established from an analysis of variance (ANOVA)
applied to data normalised by logio (x + 1) transformation. In this study, the values
given in tables and figures are the mean of 3 or 4 samples +/- standard error of the
mean unless stated otherwise.
2.2. Isolation and characterisation of the orf virus gene encoding the GM-CSF
inhibitory factor
2.2.1. Expression of the VVOV recombinant library
CV-1 and FLM cells were grown to confluence in 25 cm2 flasks. After washing
with 5 ml of PBS, the cells were inoculated with one of 16 VVOV recombinants in
2ml ofDMEM and at a multiplicity of infection (MOI) of 0.1. [The multiplicity of
infection is the average number of infectious virus particles per host cell. Virus titre
was calculated by the Spearman-Karber formula for the determination of 50%
endpoints as outlined by Klement and Nicolson (1977)]. Other cells were inoculated
with vaccinia virus (strain Lister) or orf virus (strain NZ2) at a MOI of 0.1. After 2
hours the inoculum was removed, the cells washed and 5 ml ofDMEM
supplemented with 10% FCS added. Uninfected cell cultures were used as a control.
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After 18-20 hours cell free supernatants were collected from each culture and tested
for GIF activity.
2.2.2. Expression of subclones of VVOV85
Eight overlapping orf virus DNA fragments that together corresponded to the orf
virus insert ofVVOV85 plus 1 kb of DNA on either side were cloned into the pUC8
expression vector by A. Mercer (Mercer et al, 1987). (This vector requires the
presence of the transcriptional machinery of vaccinia virus for expression).
Recombinant plasmids were designated pVU followed by the clone number. Plasmid
DNAs were transfected with the cationic lipid carrier, lipofectin (GIBCO BRL), into
FLM cells infected with vaccinia virus (Mercer et al, 1997b). After 20 hours cell-free
supernatant from each culture were collected for GIF analysis.
2.2.3. Expression of recombinant GIF
i). Transfection of the GIF cDNA into Chinese hamster ovary cells
Stable expression of recombinant GIF was achieved in CHO cells using the
Celltech pEE14 vector (Fig. 2.1) and recommended procedures (Cockett et al, 1990).
The plasmid pEE14 allows the expression ofDNA under the control of human
cytomegalovirus major immediate early promoter. The cloning of orf viral GIF DNA
followed methods described previously (Mclnnes et al, 1993). The pEE14 vector
contains a glutamine synthetase (GS) gene as an amplifiable marker in CFIO cells.
Transfectants expressing GS were selected by cloning the transfected cells, by
limiting dilution, in glutamine deficient medium containing dialysed fetal calf serum
and 25 pM methionine sulphoxamine (MSX; an inhibitor of glutamine synthetase).
The lipid-mediated transfection of plasmid DNA into CHO cells was optimised
61
Fig. 2.1 Restriction map of the pEE14 mammalian expression vector.
The plasmid pEE14 allows the expression of cDNA under the control
ofhuman cytomegalovirus major immediate early promoter
(huCMV-MIE). It contains the glutamine synthetase selectable marker
gene (GS MINIGENE) that is transcribed from the SV40 late promoter
(SVL). Restriction endonucleases which cut once in the plasmid are
shown. PL = polylinker. Poly A = SV40 early polyadenylation signal.
The rest of the vector sequences in pEE14 are from plasmid pEE6hCMV
and contain an ampicillin-resistance gene and an origin of replication for
propagation in E. coli (Stephens and Cocket, 1989).
The cDNA incorporating the gene(s) of interest are ligated into the
polylinker region between the Hindlll and EcoRI cleavage sites
(underlined).
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using the Superfect® DNA-transfection kit (Quiagen, Crawley, UK). In addition to a
range of different lipid transfection reagents (Pfxl-8) this kit contained a control
plasmid pcDNA3.1/His/lacZ that encoded the gene for (3-galactosidase. The
efficiency of different lipid reagents and optimum exposure times were then
determined by staining those cells transfected with the control plasmid for p-
galactosidase activity.
CHO cells were grown at 37°C in a humid 5% CO2 in air atmosphere to log phase
(50-60% confluent, 1-2.5 X 106 cells/flask) in 25 cm2 flasks in GMEM buffered with
(7.5%) sodium bicarbonate and containing 7.5 % heat-inactivated, dialysed fetal
bovine serum (FBS), 1% non-essential amino acids, 0.6% glutamate and 0.6%
aparagine, ImM sodium pyruvate and nucleosides (0.7% each of adenosine,
guanosine, cytidine, and uridine; 0.24% thymidine), lOOU/ml penicillin. 0.01%
streptomycin, and 0.03% glutamine.
The medium was removed and cells washed twice with 5 mis of PBS. To
duplicate flasks was added 30 pi of a different lipid reagent (Pfx 1-8) and 10 pi of
control plasmid pcDNA3.1/His/lacZ at 1 pg/ml in 5 ml ofGMEM without serum or
glutamine. The flasks were left for 2, 4,6 8 and 20 hours at 37°C then the medium
was replaced with 5 mis glutamine-free GMEM containing 7.5 % dialysed FBS and
incubated for a further 24 hours. After 24 hours, cells were stained for P-galacosidase
activity. Flasks were rinsed twice with 5 ml PBS and cells fixed with 2.5 ml 2 %
formaldehyde, 0.2 % glutaraldehyde in PBS, pH 7.3 for 10 min at RT. Flasks were
again rinsed twice with PBS before addition of 2.5 ml X-gal reagent (Quiagen) and
left at RT overnight. The percentage of cells that were successfully transfected with


















































































































































































































each flask (Table 2.1). From this experiment it was deduced that for the transfection
of the plasmids pEE14GMl and pEE14GM2 into CHO cells, a high transfection
efficiency could be achieved with the transfection lipid reagent Pfx 7 and an
incubation time of 8 hours. This medium was then replaced with 5 ml glutamine-free
GMEM containing 7.5% dialysed FBS and the flasks incubated for a further 24
hours. Cells were detached from the flasks by first rinsing with PBS then by
incubating with 1 ml/flask of 0.25% trypsin/EDTA at 37°C for 10-15 min. Further
unwanted digestion of detached cells was prevented by the addition of 2 ml of
culture medium without growth factors. Clumps of detached cells were broken up by
pipetting vigorously and the suspension was then centrifuged at 400 x g for 5 min to
pellet the cells. The cells were washed twice with PBS and harvested. After counting
cells were resuspended in medium containing 25 pM MSX to 100 cells/ml and set up
at 1, 2, 5 and 10 cells/well in multiples of 6 wells in 96 well culture plates. Plates
were incubated until cell growth was visible and viable cell aggregates could be
identified. When viable cells covered approximately 50% of the area of the wells,
medium was removed for testing for GIF production in the GM-CSFclearance
ELISA. Positive cells were removed by trypsinisation and transferred to 24 well
tissue culture plates. GIF production was monitored as cultures were expanded from
24 well plates to 25 cm flasks and cell bank stocks of only the best producing cells
were established in liquid nitrogen.
ii). Maintenance of transfectecl cell cultures
A higher level of recombinant GIF (rGIF) expression was obtained by further
cloning of transfectants in increasing concentrations ofMSX (Fig. 3.5B). The rGIF
CHO cell line, GM1-CHO, used for all experiments was grown in the presence of
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0.25mM MSX.
For bulk production of rGIF, the cells were propagated in 175 cm" flasks (Life
Technologies, Paisley, UK). When the cells became confluent, the culture medium
was removed and the mono-layer washed four times in warm phosphate-buffered
saline (PBS). The cells were then incubated for 4 days in GMEM without serum or
MSX. The serum-free supemate was harvested, clarified by centrifugation at 1000 x
g for 20 min at 8°C, aliquoted and stored at -20°C.
2.2.3. Isolation of recombinant GIF
Cell-free supernatant (20-100 ml) from GM1-CFIO was applied to the rovGM-
CSF-Sepharose affinity column (Section 2.1.7.) and fractions collected throughout
the process. After extensive column washing, bound protein was eluted. The
collected fractions were tested for the presence ofGIF by GM-CSF clearance
ELISA. To minimise interference by rovGM-CSF leaking from the column during
elution, the column was washed between runs with 2 cycles each of 0.5 M NaCl in
0.1 M NaHC03, pH 4.5 and 0.5 M NaCl in 0.1M Tris-HCl pH 8.5. The eluted GIF
fractions as determined by ELISA (approximately 5-7 ml) were pooled and
concentrated in a Centricon YM-10 microconcentrator cell (Amicon) by
centrifugation at 6000 x g for 3 hours or until the total volume of the retentate was
reduced to 200-400 pi. Aliquots (10 pi) were then analysed by 12 % SDS-PAGE.
2.2.4. The identification ofGIF protein
i). N-terminal sequence analysis
Affinity-purified rGIF, separated by SDS-PAGE mini-gel, was transferred by the
semi-dry method, as described by Khyse-Anderson (1984) and Matsudaira (1987), to
66
an inert support material, Immobilon-P (Millipore, Watford, UK). The Immobilon-P
was first soaked in methanol then washed in water and finally immersed in 10 mM of
3-[cyclohexylamino]-propane-sulfonic acid (CAPS; Sigma) transfer buffer. Electro-
transfer was for 3 h at 70 mA/minigel in a semi-dry blotting apparatus (Sigma).
Transferred protein was stained with 0.02% Coomassie brilliant blue in 50%
ethanol for 15 min before rinsing the sheets briefly in 50% ethanol to remove
background staining and then allowed to air dry. Stained protein bands were excised
and sent for analysis to the Microchemistry Department at the AFRC Institute of
Animal Physiology and Genetics Research, Cambridge Research Station, Babraham,
Cambridgeshire, UK.
N-terminal protein sequencing of the soluble proteins was performed using liquid
phase Edman degradation chemistry (Hunkapillar et al, 1983) on a Model 492,
Procise Protein Sequencer (PE- Applied Biosystems, Warrington,Cheshire,UK). The
purified protein was applied to a polybrene-treated glass fibre filter prior to
sequencing. The N-terminal 20 amino acids of each protein were analysed.
ii). Comparative sequence analysis
The amino acid sequence ofGIF and the 43 kD protein were compared with
sequences recorded in the Swiss-Prot (release 37.0) and TREMBL (release 10.0)
databases. The search for a sequence match with the query sequences was carried out
using the Basic Local Alignment Search Tool (BLAST) provided by the United
States National Center for Biotechnology Information (NCBI). Blast is designed to
search all of the available sequence databases using a heuristic algorithm (Altschul et
al, 1990) which seeks local rather than global alignments and therefore is able to
detect relationships among sequences which share only isolated regions of similarity.
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Further investigation of protein sequences was carried out using the ExPASy
(Expert Protein Analysis System) proteomics server of the Swiss Institute of
Bioinformatics (SIB). This server is dedicated to the analysis of protein sequences
and structures.
2.2.5. Analysis of GIF expression by virus infected fetal lamb muscle cell cultures
i). Characterisation ofrabbit anti-GIF
GIF antiserum was prepared by injecting rabbits intra-muscularly with affinity-
purified GIF (10 pg/injection) in 0.5 ml PBS containing 20 jag Quill-A saponin
A /
adjuvant (Sperfos Biosector, Kvistgaard, Denmark). Eight days after a third monthly
injection, the rabbits were bled from a peripheral ear vein and 5 ml of blood
collected. An IgG fraction (400 pg) from 1ml of immune serum (ralOl) was isolated
on Protein A-Sepharose (APB) as described for the preparation ofmAb 3C2. Eluted
material was tested for inhibition ofGIF clearance of exogenous rovGM-CSF as
measured by GM-CSF clearance ELISA. Briefly, 90 pi ofGM1-CHO supernatant
(rovGM-CSF clearance of approximately 500 ng/ml) was incubated with 90 pi of a
range of dilutions of the polyclonal IgG (1:100-1:5000 of a 200 pg/ml protein
solution as determined by BCA reagent, Pierce) in PBST for 1 hour at RT before
addition of the 20 pi rovGM-CSF 'spike' (100 ng/ml). An IgG fraction from pre-
immune rabbit serum was run in parallel as a control.
ii). Virus infection offetal lamb muscle cell cultures
Fetal lamb muscle (FLM) cells were grown to confluency in 75 cm" flasks
(Costar) containing 10% FBS in DMEM. The cultures were washed three times with
PBS then an inoculum of 2 ml ofDMEM containing either NZ2, orfl 1,
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scabbymouth. D1701 strains of orf virus, bovine papular stomatitis virus,
pseudocowpox virus or Semliki forest virus at a MOI of 0.1-1 was added for 2 h at
37°C. The inoculum was then removed and replaced with 10 ml of serum-free
DMEM. FLM cultures that had not been exposed to virus were taken as uninfected
controls. After 24 h, the level of cytopathic effect was noted and cell free
supernatants were collected and analysed for GIF activity by GM-CSF clearance
ELISA.
A number ofFLM cultures were treated before and after orf virus infection with
cytosine arabinoside (CA) (40pg/ml) as described by Haig et al (1998). At an
appropriate dose, CA inhibits viral DNA replication but not the expression of early
viral genes (Schreiber and Crabtree, 1992).
Samples of supernatant from cultures were taken prior to and at 1, 2, 4, 6, 8, 10,
12, 18, 20 and 24h intervals after infection. At the same time, cells were harvested by
trypsinisation, washed 3 times in PBS then counted. Cell pellets were lysed by
resuspension in ice- cold PBS containing 1% NP-40 (Sigma) at 107 cells/ml lysis
buffer. After 15 min on ice, the lysate was centrifuged at 9200 x g for 10 min and
both soluble and insoluble material taken for analysis ofGIF activity by GM-CSF
clearance ELISA and Western blotting. Insoluble material was assayed as a
suspension in ELISA wash buffer (the volume of wash buffer taken was 'A volume of
the lysis buffer used).
Hi). Western blot analysis ofGIF with rabbit anti-GIF
Serumless conditioned media from GM1-CHO, GM2-CHO, untransfected CHO
cells and virus-infected and uninfected FLM cell cultures were concentrated ten-fold
by ultrafiltration in Centricon YM-10 microconcentrator cells before separation of 10
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jliI aliquots by 12% SDS-PAGE run under non-reducing conditions and
electrotransfer to nitrocellulose as described in Section 2.1.8. After blocking,
immobilised proteins were probed with either a 1:500 dilution of the polyclonal IgG
fraction or a 1:500 dilution of control IgG (from pre-immune rabbit serum) in blot
wash buffer. Bound antibody was visualised by treatment of the blots with HRP-
conjugated anti-rabbit IgG followed by ECL reagent as described in Section 2.1.8.
2.3. Analysis of GIF physico-chemical properties
2.3.1. Analysis of affinity-purified GIF activity by gel filtration
To determine whether GIF functions as a monomer, dimer or higher order
structure, approximately 500 ml of serum-less GM1-CHO supernatant was partially
purified in 60-100 ml volumes over rovGM-CSF-Sepharose. Fractions containing
GIF activity as determined by GM-CSF clearance ELISA were pooled and
concentrated 50-fold by ultrafiltration at 3000 x g in Centricon YM-10 devices. The
concentrated GIF mixture (1.5 ml) was applied to a 16 x 600 mm column of
Sephacryl-200HR (APB) equilibrated with PBS containing 0.5 M NaCl, 0.01%
CHAPS, 0.02% sodium azide and adjusted to pH 7.2. The mixture was separated
over the column at a flow rate of 0.75 ml/min and 1 min fractions collected. The
protein content of each fraction was measured by an in-line UV spectrophotometer
(APB) at 280 nm. Fractions were tested for GIF activity in the GM-CSF clearance
ELISA and analysed by 12% SDS-PAGE. The molecular mass of each protein peak
was estimated by comparing the retention times of each peak with a calibration curve
generated from the retention times of a mixture of proteins (that ranged from 25 kD-
116 kD and were supplied as components of a gel filtration calibration kit (APB).
70
This standard protein mixture comprised 0.5 mg of each protein and was separated
prior to the purification ofGIF under identical conditions. Those fractions containing
GIF activity were pooled and concentrated to 0.5 ml by ultrafiltration.
The protein content of the GIF isolate (115 kD) was determined by the bichinoic
acid (BCA) protein estimation kit (Pierce) using a range ofBSA concentrations (50
pg/ml -2 mg/ml) to generate a standard curve as detailed in the manufacturer's
instructions. This colourimetric assay was performed in a 96 well ELISA plate
(Dynex) and the plate read in a MRX Microplate reader (Dynex). From the BSA
standard curve, the concentration ofGIF was estimated using dedicated EndPoint
software (Dynex).
2.3.2. Dissociation of the GIF complex
In order to test whether the 28 kD GIF bound rovGM-CSF, an aliquot (0.5ml) of
the GIF isolate (115 kD) at 20pg/ml was reduced to its 28 kD subunit by boiling in
the presence of 1, 2 or 5 mM dithiothreitol. Once the mixture had cooled, aliquots
(50 p.1) were tested for GM-CSF clearance in the GM-CSF ELISA. The remaining
volumes were dialysed overnight against 2000 ml of PBS to remove the dithiothreitol
and further aliquots tested for GIF activity by GM-CSF clearance ELISA.
2.3.3. Analysis of l2?I-GIF structure and GM-CSF binding activity
i). Radioiodination ofGIF
Further investigation into GIF monomer/higher order structural forms was carried
out on purified GIF (115 kD) that was radio-iodinated by the chloramine T method
as described in Section 2.1.9.
After desalting over a 10 ml Sephadex G-25 gel filtration column equilibrated
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1 T<j
with PBS to remove free Na "I, a 10 jj.1 sample was taken from 1 ml of radio-
labelled, protein collected and counted. From this value (2.2 x 106 dpm/min) the
specific activity of 123I-GIF was calculated as follows;
'"I-GIF count = 220 x 106 dpm/ml
Counting efficiency = 86% (from calibration carried out using the Instrument
Performance Assessment feature of the Cobra II Auto-Gamma counter and a 125I
source).
Concentration 123I-GIF = 20 pg/ml (assumed 100% recovery of protein from
desalting column)
Specific activity ( kBq/mg) = [(count dpm/ml/0.86)/6 x 104 dpm/ kBq ]/20 pg
= 211 kBq/pg = 211 MBq/mg
Molecular mass of isolated GIF = 115 kD
Specific activity (TBq/mM) = (specific activity MBqi/mg x molecular mass mg/mM)
= 24.2 TBq/mM
ii). Gelfiltration of125I--GIF
To determine whether the 125I-GIF was affected by the oxidation reaction of the
radiolabelling procedure, 0.5 ml of l2:,I-GIF was analysed by S-200HR gel filtration
as described above. Aliquots (lOpl) were taken from each fraction for y-scintillation
counting. Fractions from each peak of radioactivity were then sampled (5 pi) and
analysed by 12 % SDS-PAGE under reducing conditions. Separated radiolabeled
protein was visualised by autoradiography overnight.
iii). '' I-GIF ligand blotting
In order to test whether different 12" I-GIF forms separated by S200F1R were capable
of binding GM-CSF, column fractions were tested in a ligand blot assay.
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Affinity purified rovGM-CSF (25 pg) was separated under reducing conditions on
a 15% SDS-PAGE gel. All sample wells were loaded with rovGM-CSF save for a
single end well retained for molecular mass protein standards. Separated proteins
were electrotransferred to nitrocellulose membrane as described previously. After
removal of the portion of membrane containing the protein standards for staining
[see Section 2.2.4.(i)], the remainder was blocked with 4% powdered milk in PBS.
The nitrocellulose membrane was then cut into strips and each strip incubated in a
sealed tube containing 60 pi from a pool of 2/3 consecutive column fractions in 1 ml
of blot wash buffer. The strips were incubated for 1 hour at RT with continual
agitation then washed extensively over a period of 2 hours. The strips were allowed
to air dry, realigned on card and autoradiographed overnight.
iv). Gel mobility shift cross-linking assay
The reactive form of GIF was investigated using a chemical cross-linking assay as
described by Upton et al, (1992). Briefly l2"I- GIF (0.6 pg/ml) was incubated with
affinity purified rovGM-CSF (5-10 pg/ml protein) for 2 h at RT.
Cell-free supernatant from an IL3-transfectant CHO cell line was concentrated by
ultrafiltration in a YM-10 Centricon. An aliquot of IL-3-CFIO concentrate that
contained 5-10 pg/ml rovIL-3 (as determined by microdensitometry of SDS-PAGE
separated IL3-CHO concentrate and a range of concentrations of chymotrypsinogen
[2-50 pg/ml] see Section 2.4.3.) was incubated with 12ft-GIF in a parallel control
experiment.
After incubation, purified 12T-GIF and the l2:>I-GIF-protein complexes were cross-
linked by the addition of l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to a
final concentration of 40 mM for 30 min at RT and the reaction was quenched by the
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addition of 1/10 volume of 1M Tris pH 7.5. SDS-PAGE sample buffer without
mercaptoethanol was added to the mixtures before separation on 5%, 7.5% SDS-
PAGE gels. Cross-linked complexes were analysed by autoradiography as described
in Section 2.1.8.
2.3.4. Analysis of N-linked carbohydrate associated with the GIF molecule
Aliquots of purified GIF (1-2 pg) or rovGM-CSF (5-10 pg) in 200 pi of 20 mM
sodium phosphate buffer pH 7.2 containing 10 mM EDTA, 1% (v/v) 2-
mercaptoethanol, 0.1% (w/v) SDS and 1% (v/v) Triton XI00 (Sigma) were boiled
for 5 min. The mixtures were then allowed to cool before the addition of 1U of endo-
glycopeptidase F (PNGase F; Roche) and incubation for 24 hours at 37°C. At the end
of this period, a further 1 U of enzyme was added and the incubation repeated.
Samples (10 pi) were analysed either by Western blot analysis (GIF) or SDS-PAGE
followed by silver staining (rovGM-CSF) for a shift in relative mobilities after
separation.
2.3.5. Determination of the isoelectric point of GIF
Purified GIF (2pg) was added to 1 ml aliquots of Q-Sepharose (APB) anion
exchange resin (O.lg) that had been equilibrated to different pHs (range pFI 5-9.5) by
washing 10 times with 10 ml of 0.2M Tris-HCl adjusted to a particular pFI. After
mixing for 10 min, the gel was allowed to settle and the supernatant assayed for the
presence of GIF by GM-CSF clearance ELISA.
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2.3.6. Analysis ofGIF-rovGM-CSF binding kinetics
i). Reactivity with time
Affinity purified GIF (1 pg/ml) was spiked with increasing amounts of rovGM-CSF
(4-50 ng/ml) and incubated for 1 h and 20 h at 37°C. At the end of each incubation
time, unbound rovGM-CSF was measured by GM-CSF ELISA.
ii). The effect of temperature
Aliquots of supernatant, from GM1CHO cultures, were spiked with increasing
amounts of rovGM-CSF and incubated at different temperatures ( 4°C- 56°C) for 1
hour. Samples were then immediately assayed for rovGM-CSF.
Hi). The effect ofhigh salt concentration
The binding of affinity purified GIF (1 pg/ml) to 8 ng/ml rovGM-CSF in the
presence of increasing salt concentration (0.1 M-l M NaCl) was analysed by GM-
CSF clearance ELISA. The effect of high salt concentration on the detection ofGM-
CSF was evaluated in the absence ofGIF.
iv). The effect ofextremes ofpH
Prior to addition of rovGM-CSF, affinity purified GIF was diluted to 5 pg/ml in
either 0.1 M citrate buffer adjusted to pH 3.0 or pH 4.0 or 0.1M carbonate buffer
adjusted to pFI 10 or pFl 11 for lh at 37°C. After this period, the pEl of the solutions
were adjusted to pFl 7.5 with the addition of either 0.1 M carbonate buffer pH 11 or
0.1M citrate buffer pH 2.5. The GIF was further diluted to 1 pg/ml in wash buffer
before analysis by GM-CSF clearance ELISA.
In a similar manner, samples of a mixture of affinity purified GIF (2 pg/ml ) and
rovGM-CSF (16 ng/ml) were adjusted to either pH 3.0, 4.0, 10, or 11 and after
incubation for lh at 37°C neutralised and analysed. The effect of extremes of pH on
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the GM-CSF clearance ELISA was investigated in the absence ofGIF.
2.4. Analysis of the binding specificity ofGIF
2.4.1. Recombinant cytokines/chemokines
The recombinant ovine cytokines IL-ip, IL-2, IL-3, IL-4, IL-5, GM-CSF, MCP-1,
MlP-la, RANTES, TNF-a and IFN-y were prepared from serumless supernatant
from CHO cells transfected with the respective cytokine or chemokine cDNAs (from
Ian Colditz, T. Yoshimura, Heng-Fong Seow, Paul Wood, J-P Scheerlink and Paul
Chaplin, CSIRO, Melbourne Australia and Gary Entrican, Moredun Research
Institute). The transfected CHO cells were propagated as described in Section
2.2.3 .ii.
In order to identify and quantify individual cytokines, supernatant from each
transfectant CHO culture was analysed by SDS-PAGE followed by
microdensitometry. Supernatant was first concentrated ten-fold by ultrafiltration in a
Centricon YM-10 filtration device and the protein content determined by the BCA
reagent assay. Aliquots (20 pi) were run on 15% SDS-PAGE and separated proteins
visualised by silver staining. Individual gel tracks were analysed by
microdensitometry on a GS-670 Imaging Densitometer (BioRad) using the
Molecular Analyst Program (BioRad). Recombinant cytokines were identified by
comparison with material from untransfected CHO cultures and molecular mass
protein standards run simultaneously (Figs. 2.2-2.6 and Table 2.2). The proportion of
cytokine present in each supernatant was determined by measuring the area(s) of
cytokine peak(s) and those of the other proteins present in the optical density profiles
for each sample. Since the protein content of each sample had been determined, an
76
estimate of the level of expression of each cytokine was obtained (Table 2.2).
Purified human (hu) and murine (mu) GM-CSF and huIL-2 and huIL-4
recombinant cytokines were purchased from R&D Systems (Abington, U.K.).
Recombinant ovine IL-8 was a gift from Heng-Fong Seow and Paul Wood, CSIRO,
Australia. Recombinant bovine GM-CSF and IL-2 were gifted by Sarah Duggan,
BBSRC, Institute of Animal Health, Compton, U.K. The other putative ligands used
in this study, heparin and a.2-macroglobulin, were purchased from Sigma.
For soluble ligand binding assays, purified rovGM-CSF was prepared by
affinity chromatography as described in Section 2.1.7.ii whilst rovIL-2 was isolated
from 1 ml aliquots of a 80 fold concentrate of rovIL-2 cDNA-transfectant CHO
supernatant by S200HR gel filtration as described in Section 2.1.5.ii. The
concentration of purified rovGM-CSF and rovIL-2 were determined by the BCA
reagent assay.
2.4.2. GIF binding assays
GIF reactivity with ligands, other than rovGM-CSF, was tested by a ligand
competition assay. A 90 pi aliquot of each recombinant cytokine (100-200 ng/ml),
heparin (1-2 pg/ml) or a2-macroglobulin (1-2 pg/ml) was incubated with 90 pi of
GM1-CHO supernatant for 1 h at 37°C before addition of the GM-CSF spike (8
ng/ml) and analysis by GM-CSF clearance ELISA. Ligands were tested in the
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Fig. 2.2 Expression of recombinant ovine cytokines; IL-ip, IL-2 and IL-3.
Supernatants from CHO cell cultures transfected with cDNA encoding the ovine
cytokines IL-lp (A), IL-2 (B) and IL-3 (C) were separated by 15 %
SDS-PAGE under reducing conditions and analysed by microdensitometry.
Analysis of individual profiles where protein band optical density
(Absorbance, y axis) and protein mobility in the gel (Mobility, x-axis) were
measured, allowed both the level of expression and molecular mass of the
recombinant protein(s) (given in Table 2.2) to be calculated using the BioRad
GS 790 Imaging densitometer and BioRad Molecular Analyst software.
Recombinant cytokines were identified by comparison with supernatants taken
from untransfected CHO cultures (D) and processed in parallel.
The molecular masses (kD) of individual cytokines are given above each peak
and were estimated by comparison with a standard curve generated from
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Fig. 2.3 Expression of recombinant ovine cytokines; IL-4, IL-5 and
GM-CSF.
Microdensitometry profiles of supernatants from CFIO cell cultures
transfected with cDNA encoding A) IL-4, B) IL-5 and C) GM-CSF.
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Fig. 2.4 Expression of recombinant ovine cytokines; IFN-y, SCF and
TNF-a.
Microdensitometry profiles of CFS from A) IFN-y , B) SCF and
C) TNF-a -cDNA transfected CHO cell cultures compared with
supernatant from untransfected CHO cell cultures (D).
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Fig. 2.5 Expression of recombinant ovine chemokines; MCP-1, MlP-la
and RANTES.
Microdensitometry profiles of CFS from A) MCP-1, B) MlP-la and
C) RANTES-cDNA transfected CHO cell cultures compared with CFS
from untransfected CHO cell cultures (D).
The molecular masses ascribed to individual chemokine peaks are
approximate since the mobilities of the chemokines fall outwith the
standard curve generated from the mobilities of the molecular mass











IL-ip 19.2 17.0-22.0 (Brazel et al, 1991) 2.4
IL-2 26.8 15.4 (human, Riske et al, 1991); 27.0
(bovine, Arunachalam, 1989)
8.4
IL-3 23.0, 20.4 15.0-17.0 (Zenke et al, 1991) 3.6
IL-4 22.3,21.3 20.0-22.0 (Boulay and Paul, 1992) 2.2
IL-5 22.6,21.6 45.0 (homodimer, Takatsu et al, 1988,
Takatsu, 1991)
3.1
GM-CSF 23.8, 19.8 14.0-35.0 (Okamoto et al, 1991) 28.5
IFN-y 23.0, 20.5 20.0, 25.0 (Curling et al, 1990) 1.8
SCF 21.5 20.0 (Arakawa et al, 1991) 2.4
TNF-a 19.2 51.0 (homotrimer, Eck and Sprang,
1989)
0.9
MCP-1 10.5-13.0# 7.0 (Yoshimura and Leonard. 1992);
30.0 (murine, Liu et al, 1996)
1.2
MlP-la 10.0-12.0# 8.0 (Graham et al, 1994) 0.9
RANTES 10.0-12.0# 8.0 (Schall, 1991) 1.4
Table 2.2 Expression of recombinant ovine cytokines
The molecular masses of ovine recombinant cytokines expressed by CHO cells and
analysed by SDS-PAGE and microdensitometry under reducing conditions are
compared with the molecular masses of cytokines of human origin.
(# = Approximate values since cytokine peaks were outwith the range of molecular
mass standards).
The concentration of cytokine (pg/ml) in cell free supernatant collected from
confluent CEIO transfectant cultures maintained in serum-free medium is also given.
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In order to test whether rovIL-2 and rovGM-CSF shared the same (or very
close proximity) binding site within the GIF complex, increasing amounts of purified
rovIL-2 (10-500 ng/ml) were tested for inhibition of GIF clearance of an 8ng/ml
spike of rovGM-CSF in the GM-CSF clearance ELISA.
1 9S ...
For GIF-cytokine ligand blots, I-GIF was prepared as described in Section
3.3.3.i. Two hundred to 350 ng of each cytokine was separated by 15% SDS-PAGE
under reducing and non-reducing conditions and then transferred to nitrocellulose
membranes. After blocking and washing, the membranes were incubated with l25I-
GIF (100 pM) for 2h at RT. After further washings, cytokine-GIF binding was
visualised by autoradiography. In order to demonstrate the specificity of 12I-GIF
binding, a 10 nM concentration of unlabelled GIF was used for competitive
inhibition of binding of 12G-GIF to the cytokines.
2.4.3. Scatchard Analysis of GIF reactivity
The affinity binding ofGIF to ovGM-CSF and ovIL-2 was determined by
Scatchard analysis of l2G-cytokine-GIF soluble binding assay as described by
Symons et al (1990).
RovIL-2 and rovGM-CSF (25 pg) were radio-iodinated by the chloramine T
method. The l2"I-rovIL-2 fraction was found to contain significant levels of
1 9 S
contaminating radio-labelled protein (presumed to be "I-BSA from trace amounts
of FCS in the supernatant from the rovIL-2 CHO transfected cultures) and was











Fig. 2.6 SDS-PAGE analysis of 125I-rovIL-2 and 125I-rovGM-CSF.
After radio-iodination and further purification of 125I-rovIL-2 by
S200 gel filtration to remove contaminating radio-labelled proteins
both 125I-rovIL-2 ( 27 kD; lane 1) and 125I-rovGM-CSF (20kD and
24 kD; lane 2) were analysed by SDS-PAGE followed by
autoradiography. (The 24 kD band of 125I-rovGM-CSF represents a
glycosylated form of the 20 kD band). The position of molecular
weight markers (14.5 kD-66 kD, dashed arrows) are indicated.
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S200HR gel filtration containing 12_T-rovIL-2 were pooled and concentrated ten-fold
by ultrafiltration in Centricon YM-10 devices. The concentration of each radio-
labelled cytokine was estimated by separation of 10 pi aliquots on 12 % SDS-PAGE
followed by silver-staining and comparison with a range of concentrations of
chymotrypsinogen analysed by micro-densitometry as described previously (Figs.
2.7 and 2.8).
The specific activity of each radio-ligand was calculated as follows;
1.) I2?I-GM-CSF count = 384 x 106 dpm/ml
Counting efficiency = 86%
1 9 S
Concentration I-GM-CSF = 14.2 pg/ml (estimated from microdensitometric
analysis)
Specific activity (MBq/mg) = [(count dpm/ml/0.86)/6 x 104 dpm/ kBq ]/l4.2 pg
= 524 kBq/pg = 524 MBq/mg
Molecular mass of rovGM-CSF = 20 kD
Specific activity (TBq/mM) = (specific activity MBq/mg x molecular mass mg/mM)
= 10.48 TBq/mM
2.) l2'I-IL-2 count = 119 x 106 dpm/ml
Concentration 12'I-IL-2 = 12.5 pg/ml (from microdensitometry)
Specific activity (MBq/mg) = 184.5 MBq/mg
Molecular mass of rovIL-2 = 26.8 kD
Specific activity (TBq/mM) = 4.94 TBq/mM
A soluble-ligand-binding assay was performed for each cytokine. Briefly, 50 pi
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Fig. 2.7 Estimation of rovGM-CSF concentration by microdensitometry.
A) The optical densities of protein bands separated by 15% SDS-PAGE
and silver stained were determined by microdensitometry. The optical
densities (1.982 and 2.396 O.D. x mm2) of both silver stained
125I-rov GM-CSF bands at 20kE) and 24 kD were compared with the
optical densities of different chymotrypsinogen concentrations
(20-250 fig/ml) from which a standard curve (B) was generated.
The standard curve (y-axis, O.D. x mm2 vs x-axis, pg/ml) was generated
in the Molecular Analyst Program (BioRad) using a quadratic non-linear
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Fig. 2.8 Estimation of IL-2 concentration by microdensitometry.
The optical densities of protein bands separated by 15% SDS-PAGE
and silver stained were determined by microdensitometry as described
for Fig. 2.8. The optical density (0.911 O.D. x mm2) of a silver stained
125I-rovIL-2 band at 27 kD was compared with a range of band optical
densities of different chymotrypsinogen concentrations (10-200 pg/ml)
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were incubated with 100 p.1 ofGIF (100 ng) containing 5% FBS for 2h at RT. Bound
proteins were precipitated by the addition of 300 pi of 20 % polyethylene glycol
(PEG 6000; Sigma) in PBS and incubation on ice for 30 min. The material
precipitated from each sample was collected onto GF/C fdter discs (Whatman,
Maidstone, U.K.) by filtration under vacuum and after washing with four 10 ml
volumes of ice cold PEG 6000 in PBS. Radio-labelled complex was measured by
counting the discs in the y-scintillation counter. The levels of non-specific binding of
l2:T- cytokines to the filters were obtained in the absence of GIF and the data
presented adjusted accordingly. Scatchard analysis as outlined by Segel (1976) was
performed on best-fit plots (bound 12"I-cytokine [pM, x-axis] versus bound /free
[cpm. y-axis]) performed on three separate sets of data for each cytokine using
Origin software (Microcal).
2.5. Analysis of GIF inhibition of cytokine binding to cell receptors
GIF was tested for inhibition of l2"T-rovGM-CSF binding to GM-CSF receptors
on sheep neutrophils and 12T-rovIL-2 binding to IL-2 receptors on sheep CD4+ T
cells.
2.5.1. Preparation of ovine neutrophils
In order to measure the binding of GM-CSF to its cellular receptor, neutrophils
were isolated from sheep peripheral blood (Nash et al, 1997). To minimise
contamination of the neutrophil fraction with eosinophils, animals were treated with
anti-helminthic for 1-2 weeks prior to blood collection. A 50 ml volume of blood was
collected by venipuncture of the jugular vein and immediately mixed with 10 ml of a
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solution (ACD) containing 2.2% trisodium citrate, 0.8% citric acid and 2.5% glucose
to minimise clotting. Thirty ml volumes of blood were centrifuged at 1500 x g for 30
min without braking and the buffy coat and plasma removed without disturbing the
red blood cell (RBC) pellet. The RJBC pellet was then resuspended in 15 ml warm
(37°C) pyrogen-free water and agitated for 1 min in a 37°C water bath before the
addition of 1.5 ml lOx Tyrode's solution consisting of 8% sodium chloride, 0.2%
potassium chloride, 0.05% sodium dihydrogen orthophosphate, 1% sodium
bicarbonate and 1% glucose. The suspension was then centrifuged at 800 x g for 10
min.
After discarding the supernatant, the cell pellet (between 0.75 - 1.5 xlO7 cells
total) was resuspended at 2 x 106 cells/ml in Hanks" balanced salt solution (HBSS/T,
Gibco-BRL) containing 0.1% gelatin and adjusted to pH 7.2 with 1 M Tris-HCl.
Approximately lO3 cells in 200 pi of HBSS were spun down at 6000rpm for 10 min
in a Cytospin3 (Shandon) cyto-centrifuge for cytosmears and stained with
Leishman's staining solution for a differential count. (Fig. 2.9)
2.5.2. Preparation of ovine CD4+ T cells
Mesenteric lymph nodes were collected post mortem into Hanks' balanced salt
solution containing 5 % heat inactivated FBS (Sigma) and 25 pg/ml penicillin and
streptomycin (Gibco-BRL) (HBSS). The nodes were then transferred to a 60 mm
petri dish, trimmed and finely chopped with a scalpel blade in 5 ml of HBSS. The
suspension was transferred to a stomacher bag and processed in a Stomacher 80
(Camlab Ltd. Cambridge, U.K.) for approximately 10 sees. The disrupted tissue was
filtered through a double layer of sterile lens tissue that was rinsed with 5 ml of
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Fig. 2.9 Preparation of neutrophils from ovine peripheral blood.
Light micrograph (x 400) of a cytocentrifuged cell suspension,
isolated from the cell pellet after hypo-osmotic lysis of red blood
cells.
Polymorphonuclear leucocytes (multi-lobed nuclei stained with
Leishman's solution) comprise approximately 84% of 500 cells
counted in the cytospot
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HBSS. The filtrate was collected, spun down at 1200 rpm for 5 min and resuspended
in 5 ml ofHBSS. Lymphocytes were isolated by centrifugation over Lymphoprep
(Nycomed, Oslo, Norway) and washed twice in HBSS.
A CD4+ T cell-enriched fraction was prepared from the lymphocyte population by
magnetic cell sorting (MACS). CD8+, y8T cells and B cells were labelled with
magnetic microbeads coated with specific antibody and then separated using a
magnetic separation column placed in a strong magnetic field. The magnetically
labeled cells were retained in the column while non-labelled cells (enriched for CD4"
T cells) passed through. Lymphocytes (107) were resuspended in 1ml of pre-chilled
HBSS containing 5 pg/ml each of an anti-CD8 (7C2; Mackay et al, 1986), anti-y5
TCR (86D; Hunig, 1985) and anti-B cell immunoglobulin (VPM8; Hopkins and
Dutia, 1990) mAb and incubated for 15 min at 6-12°C (in refrigerator). Cells were
washed carefully and resuspended in 80 pi of HBSS/ per 107 cells then 20 pi of
MACS rat anti-mouse IgG magnetic microbeads (Miltenyi Biotec, Bisley, U.K.)
added for a further 15 min at 6-12°C. The magnetically labelled suspension was then
loaded onto a MiniMACS (Miltenyi Biotec) separation column (10' cells/column) as
outlined in the manufacturer's instructions and unlabelled cells collected in the
effluent. Aliquots (106 cells) were taken from the unlabelled cell fraction to
determine the percentage of CD4+ T cells present (Fig 2.10). The cells were
resuspended in 100 pi of PBS 2% BSA, 0.02% sodium azide and 1 pg/ml of anti-
CD4 mAb (17D; Mackay et al, 1986) or 1 pg/ml of an isotype matched negative
control mAb VPM21 (specific for border disease viral epitope and obtained from
Gary Entrican, Moredun Research Institute) and left for lhour on ice. The cells were
washed twice in 5 ml of PBS/BSA then resuspended in 100 pi of a 1:50 dilution of
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Fig. 2.10 Immunofluorescent analysis of CD4+ T cells.
Lymphocytes from sheep mesenteric lymph node were analysed for CD4+
T cells by flow cytometry using specific mAb 17D before (A) and after
(B) depletion of CD8+, yS T+ and B cells. The percentages of CD4+ T cells
were as measured by fluorescence intensity within the gate, Ml (determined
by comparison with (C) the negative control mAb VPM 21) were A) 32%
and B) 89.8%.
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fluorescein (FITC)-conjugated rabbit anti-mouse IgG ( Dako, High Wycombe, U.K.)
and incubated for 1 hour on ice. After washing, cells were resuspended in 400 pi of
PBS before the addition of 100 pi of 4% paraformaldehyde in PBS. The fixed cell
suspensions were analysed by flow cytometry on a Facscan (Becton Dickinson,
Franklin Lakes, U.S.A.).
2.5.3. Binding assays of 12?I-cytokines to cells
The binding of l23I-rovGM-CSF or l2;T-rovIL-2 to neutrophil or CD4^ T cell
fractions respectively were carried out as suggested by Dr. Antonio Alcami
(Department of Pathology, University of Cambridge, U.K.) and based on a method
described by Dower et al, (1985). Cells were washed twice in binding buffer
comprising RPMI 1640 (Gibco-BRL) containing 1% FCS and 20 mM Hepes pH 7.5
then added at 2 xlO6 in 50 pi to 250 pi of binding buffer containing l2H-labelled
cytokine (0.1-InM) for 2h at 4°C. Pretreatment of cytokine with unlabelled cytokine
(lOOnM), GIF (lOnM), GIF and anti-GIF (ralOl, 2 pg/ml) was carried out at 4°C for
60 min, 60 min and 90 min respectively prior to the addition of the cells.
Cells were isolated from the reaction mix by centrifugation of the cell suspension
(300 pi) through 400 pi of a phthalate oil mix comprised of a 1.5 parts of dibutyl
phthalate (Sigma) and 1 part of bis(2ethylhexyl)phthalate (Sigma) at 13000 x g for 1
min in 1.5 ml eppendorf tubes. The supernatant was carefully removed and the tip of
the tube containing the cell pellet removed with a surgical blade and cell bound
radioactivity measured in a y-counter.
93
2.5.4. Investigation of GIF inhibition of cytokine stimulatory activity
GIF was tested for inhibition of rovGM-CSF stimulatory activity as measured by
a bone marrow soft agar clonogenic assay and rovIL-2 stimulatory activity as
measured by CD4+ T cell proliferation assay.
i). Bone marrow soft agar clonogenic assay
GM-CSF stimulation of neutrophil, macrophage, and eosinophil colony
development was measured using a soft agar haemopoietic cell clonogenic assay as
described by Haig (1997).
Sternal bone marrow cells were obtained from lambs (aged 4 months to 1 year
and bred at the Moredun Research Institute) at postmortem. Bone marrow was
collected into universals containing 15 ml of HBSS and allowed to settle for 5 min A
A
cell suspension was removed, by syringe from beneath a layer of fat that formed at
the top of the universal and filtered through a double layer of sterile lens tissue.
Light-density cells (<1.077 g/ml) were prepared from the filtered cell suspension by
centrifugation over Lymphoprep (Nycomed). The interphase cells were washed
several times in HBSS containing 5% heat-inactivated FBS (Sigma) then
resuspended in culture medium, Iscove's modified Dulbecco's modified Eagle's
medium (IMDM; Gibco-BRL), at 106 cells/ml.
Samples to be tested that included GIF (50 and 520 ng/ml), rovGM-CSF (46, 460
and 4600 pg/ml), rovIL-3 (50 ng/ml) and rabbit anti-GIF (ralOl; 2 pg/ml) in a final
volume of 200 pi were added to duplicate 35 mm Petri dishes. A 3 % solution of
Bacto agar (Difco Laboratories, Detroit, USA ) in PBS was prepared by boiling
gently, then for each set of 8 dishes, 1 ml of hot agar was transferred to 6.5 ml of
IMDM. To this was added 0.5 ml of the cell suspension and the mixture stirred
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slowly, avoiding air bubbles. The cells were then dispensed as 0.8 ml aliquots (5 x
104 cells/plate) to each dish, ensuring even distribution of the agar and cells.
The medium was allowed to gel for 15 min, then two 35 mm dishes were placed,
together with an open 35 mm dish containing distilled and de-ionised water in a 90
mm Petri dish. Lids were then placed on the 90 mm dishes which were incubated for
7-14 days, stacked in a tissue culture incubator at 37°C in a highly humidified
atmosphere containing 5% C02 in air. The analysis of live cell colonies (> 40 cells)
and clusters (3-40 cells) were performed on day 7 and again on day 14. The cell
count was carried out using an inverted microscope at low power and with the
culture dishes placed on a glass plate on which a grid of 2-3 mm" squares had been
scratched with a diamond pencil.
ii). CD4+ T cell proliferation assay
CD4+ T cells were set up at 2 x 106 cells /ml in IMDM containing 10 % FBS,
penicillin, streptomycin and 5 pg/ml Con A (Sigma) in 24 well culture plates
(Costar) for 3 days at 37°C in the presence of 5 % CO2 in air. The number of blast
cells was determined in Leishman-fixed and stained cytospots of the cell suspension
(Haig et al, 1996e). The cells were washed and set up in culture in 24 well plates at 5
x 10^ blasts/ml in IMDM with 10 % FBS and recombinant human IL-2 (Chiron Inc.
[formerly Eurocetus], Emeryville, USA) at 20 U/ml for a further 3 days. The cells
were washed with IMDM containing 2 % FBS to remove IL-2 and 100 pi of T cell
blasts at 5 x 1 0 /ml were added to each well of a 96 well plate (Costar). A further
100 pi containing a range of rovIL-2 dilutions (final concentration; lOpg-lOOng/ml)
in IMDM and either affinity purified GIF (final concentration; 520 ng/ml and 50
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ng/ml) or medium were added to quadruplicate wells. After 24 hours, the cultures
were pulsed with H -thymidine (APB, specific activity 185 GBq/mmol ), at 18.5
Mbq/well for a further 24 h before cell harvest onto glass fibre sheets in a Micromate
196 cell harvester (Packard). Incorporated H -thymidine in each sample was
measured by counting the dried sheets in a Matrix 96 direct beta counter (Packard).
2.6. Detection of GIF and GM-CSF in skin and lymph of sheep infected with orf virus
2.6.1. Immunohistochemistry
Conventionally reared female Suffolk-cross sheep aged between 12 and 14
months were used. All had previous experience of sub-clinical orf virus infection as
evidenced by serum ELISA tests for virus-specific antibody (Yirrell et al, 1989). The
inner thighs were clipped and two days later, scarified (Jenkinson et al, 1990a;
McKeever et al, 1988). Orf virus prepared from scab material and kept as a stock at
MRI (McKeever et al, 1988) was immediately applied to the scarified skin of half the
group of animals and diluent (PBS) to that of the remainder which were housed
separately. Skin samples, 6mm in diameter, were taken by biopsy punch from each
animal before scarification (day 0) and subsequently across the scar lines at two-
three day intervals for up to 21 days.
The skin samples were fixed for 2-3h at 4°C in a cacodylate/formalin solution
(4% formaldehyde, 6.8% sucrose in 0.1 M cacodylic acid) and processed to paraffin
wax by the St. Marie method (Pearse, 1980). Serial sections, each 10 pm thick, were
cut from each block and mounted on Vectabond-coated microscope slides that were
air-dried overnight at 38°C and stored at -20°C. Sections were de-waxed in 3
changes of xylene for 5 min each, followed by re-hydration for 20 min in 100%, 95%
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and 75% ethanol and finally distilled water. The slides were washed twice in PBS
buffer (pH 7.5) containing 0.05% Tween 80 (wash buffer). The sections were dried
and the area around the slide isolated by wax pen (PAP pen, Sigma) before 100 pi of
blocking solution comprising 25% horse serum in PBS with 0.5 M NaCl (high salt
buffer, pH 7.5) was added for 30 min at RT. Slides from every sample were
immunostained using a murine mAb for orf virus 39 kD envelope antigen (10E6;
Housawi et al, 1998), mAb 3C2 and IgG fractions of 1.) rabbit anti-GIF (ralOl) and
2.) a rabbit polyclonal antiserum for GIF (ral61) raised against GIF 28 kD-
thioredoxin fusion protein expressed in E. coli and isolated by electro-elution from a
12% Schagger gel system (Schagger et al, 1988) (by Ann Wood and Colin Mclnnes)
and 3.) a mouse polyclonal antiserum for purified GIF (muLTl). Ral61 was raised as
described for ralOl (Section 2.2.4.). MuLTl was raised by injecting Balb/c mice
intraperitoneally with firstly, 2-5 pg of purified GIF in 150 pi of a 1:1 mixture of
PBS and complete Freunds adjuvant, then at three, 30 day intervals with the same
inoculum but in the presence of incomplete Freunds adjuvant. Ten days after the
final injection, the mice were exsanguinated. Immunoglobulin-G fractions from pre-
immunised mouse serum and pre-immunised rabbit serum were used as controls.
Dilutions of primary antibodies at 0.1 -1 pg/ml were made in high salt buffer and
incubations were carried out overnight at 4°C in a humidified box. Sections were
washed as before and 100 pi of a 1:1000 dilution of biotinylated horse anti-mouse
IgG (Vectastain, Vector Laboratories, Peterborough, U.K.) in high salt buffer
containing 1% horse serum added to each section for 30 min at RT. After washing
endogenous peroxidase activity was blocked by incubating the slides in 1% hydrogen
peroxide (30% solution, Sigma) in methanol for 30 min.
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The Vectastain ABC reagent was prepared as per the manufacturer's instructions
at least 30 min prior to use. After washing 100 pi Vectastain ABC reagent was added
to each section for 30 min at RT. After a further washing stage, bound antibody was
visualised by addition ofDAB substrate solution provided with the Vectastain ABC
reagent. After incubation in the dark for 5 min, sections were washed in water
Sections were examined after counterstaining in hematoxylin using a Varistain
automated staining apparatus (Shandon, Runcorn, U.K.).
2.6.2. Analysis of lymph
The cannulation of lymph node ducts of orf virus-infected and control scarified
sheep was carried out in a previous study by Professor High Miller and the
techniques used have been described previously (Yirrell et al, 1991; Haig et al,
1996a and e). Briefly, at least eight weeks before cannulation for afferent lymph, the
prefemoral lymph node was removed and the various afferent lymphatics allowed to
anastomose (interconnect) with a single efferent duct. This was cannulated to provide
——-—
•.
pseudo-afferent lymph. Efferent lymph was obtained by cannulating an efferent
lymphatic of the prefemoral lymph node as described by Hall and Morris (1962). For
the duration of the experiment the animals were kept in metabolic crates. Lymph was
collected in plastic bottles that were changed at regular intervals and contained
heparin, penicillin and streptomycin.
Animals were rested for 2-4 days following surgery to allow lymph output to settle
before scarification of the epidermis and application of live virus or UV-inactivated
virus as described above.
For GIF and GM-CSF analysis, lymph samples were centrifuged at 250 x g for 10
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min and lymph plasma and cells collected separately. Lymph plasma was re-
centrifuged at 1000 x g for 15 min and then passed through a 0.45 pm filter
(Millipore, Cramlington, U.K.) to remove any remaining cellular debris before being
frozen at -20°C.
To determine whether cells in the lymph were producing cytokine or GIF as a
consequence of in vivo activation, cells were washed three times in Hanks balanced
salt solution containing penicillin/streptomycin and 2% fetal calf serum (FCS) (to
remove exogenous cytokines) and then cultured at 2-4 x 106 nucleated cells/ml of
IMDM + 10% FCS in wells of 24 well tissue culture plates (Costar) or 25 cm tissue
culture flasks (Costar) without exogenous stimulation. No GM-CSF was detected in
the FCS used in this experiment. Cultures were maintained at 37°C for 24h before




THE ISOLATION AND CHARACTERISATION OF THE ORF
VIRUS GENE ENCODING GM-CSF-INHIBITORY FACTOR
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3.1. Introduction
The first approach to the identification of the GM-CSF inhibitory/binding activity
was to test the hypothesis that an orf virus protein and not a host cell protein is
involved in GM-CSF inhibition. The precedence for this was the increasing number
of poxvirus and herpesvirus 'immuno-modulatory' proteins described in the literature
(reviewed by Davis Poynter et al, 1996; Smith, 1996; Alcami and Koszinowski, 2000
and Brander and Walker, 2000). Some of these viral proteins counteract the host
immune system by binding to host cytokines and chemokines.
A recombinant vaccinia virus library of recombinant viruses containing between
them more than 95% of the orf virus genome (a gift from Dr. Andy Mercer,
University of Otago, Dunedin, New Zealand) was employed to identify the putative
orf virus gene encoding the GM-CSF-inhibitory factor (GIF). In recent years,
vaccinia virus has been used as an expression vector for foreign genes (Moss. 1991;
Tartaglia et aU 1990). Fleming et al (1992) and Sullivan et al (1994) have shown
that, for a number of orf virus genes, early and late promoter sequences are
recognised by the vaccinia virus transcriptional machinery and, as a result, the orf
virus genes are transcribed from their own promoters. This has circumvented the
need to isolate each orf virus open reading frame (ORF) for fusion to a vaccinia virus
promoter. Instead large fragments of orf virus DNA that carry multiple undefined
genes can be recombined into vaccinia viruses and the recombinants screened for the
expression of orf virus protein. Mercer et al (1997b) have constructed in vaccinia
virus, an orf virus genomic DNA library consisting of 16 DNA restriction fragments
of 10-20 kilobase pairs (kb) that together cover 95% of the orf virus genome in
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overlaps. Each recombinant virus from the vaccinia virus-orf virus (VVOV)
recombinant library was used to infect foetal lamb muscle cells and CV-1 cells.
Supernatants from individual recombinant virus-infected cultures were then tested
for GIF activity. GIF activity was assayed by inhibition of ovGM-CSF detection in
an ovGM-CSF capture ELISA.
The next stage, if the first was successful, was to identify possible homologues of
the GIF gene by comparing the GIF nucleotide and amino acid sequences with those
sequences recorded in protein and nucleotide databases. Whilst it was possible that
GIF was a homologue of a cellular protein, a number of poxvirus proteins have been
identified that bind specific host cytokines and/or chemokines and show homology to
host receptors. These include viral receptors for IFN, IL-1 p and TNF (Smith and
Chan, 1991; Upton et al, 1991; Barry and McFadden, 1997; Haig, 1998; McFadden
et al, 1998).
To determine whether the GIF gene was transcribed early or late in the
replication cycle of orf virus, two parallel approaches were adopted, firstly, Northern
blot analysis of GIF mRNA isolated from orf virus infected FLM cell cultures treated
with cytosine arabinoside (an inhibitor of viral replication) and secondly, Western
blot analysis of supernatants from FLM cell cultures sampled at various times and
analysed for the presence of GIF by the binding of a rabbit antiserum that was raised
against affinity-purified GIF protein.
Finally, the question whether GIF activity was restricted to orf virus infections or
whether it is also present in cultures infected with other parapoxviruses such as
bovine papular stomatitis and pseudocowpoxvirus was also investigated by GM-CSF
clearance ELISA and Western blotting.
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In this chapter, all work that involved DNA/RNA manipulations was carried out
by Dr. Colin Mclnnes and Miss Ann Wood (Moredun Research Institute). The
results derived from this work are presented in order to give a clear overall picture.
The analyses of cultures for GIF activity by ELISA, the expression in CHO cells of
orf virus DNA containing the GIF gene and the subsequent isolation and
identification of the GIF protein were carried out by the author.
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3.2. Results
3.2.1. Mapping of the GIF gene to the OV genome
The VVOV recombinant library (Fig. 3.1) was expressed in CV-1 and FLM cells
and supernatants from individual recombinants tested for GIF activity in the GM-
CSF clearance ELISA (as outlined in Section 2.2.1.). The only regions of the orf
virus genome not included in the library were sections of 1.3kb at each terminus and
a 5kb gap between clones VVOV82 and VVOV85. The vaccinia-recombinants
containing fragments of orf virus DNA were given the prefix VVOV and a clone
number.
The results for the FTM cell cultures are given in Fig. 3.2. GIF activity, as
measured by a decrease in O.D. units representing GM-CSF clearance in the GM-
CSF ETISA, was detected in supernatant from the cultures infected with the
VVOV85 recombinant ( p < 0.001 when compared with either uninfected cells or
cells infected with vaccinia virus, Lister control). GIF was not detected in cells
infected with; VVOV330 (which overlaps the 5' end ofVVOV85 by approximately
1,4kb), the remaining members of the VVOV recombinant library or the vaccinia
virus control. A similar result (not shown) was achieved with the infection of CV-1
cells.
In order to map the gene encoding GIF activity to a locus within orf virus DNA
fragment 85 (rf 85), a number of plasmids that contained overlapping restriction
fragments covering the entire rf 85 plus approximately lkb of flanking DNA on
either side were transfected into vaccinia virus-infected FLM cells (Fig. 3.3).
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80 96 247 243 330 Okb
215 97 212 86 283 85 82
Fig. 3.1 Insertion library of orf virus genomic DNA (restriction fragments)
aligned with the Kpnlmap of the orf virus (NZ2) genome (Mercer et al,
1997).
To determine whether ovGM-CSF inhibition was produced by a viral
gene product, 16 vaccinia virus-orf virus recombinants containing orf
virus DNA fragments (numbered, fine lines), the majority of which
overlapped one another and together encompassed approximately 95%
of the orf virus genome (heavy line), were used to infect FLM cells and
the cell free supernatants tested for GIF activity.
The relative positions of the putative virulence genes; interferon
resistance gene (IFNR), interleukin-10-like gene (IL-10) and vascular
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Fig. 3.2 Analysis of vaccinia virus-orf virus recombinants (VVOV,
containing orf virus DNA) for expression of GIF activity.
The VVOV clones are numbered on the y axis. Cell-free supernate
samples from FLM cell cultures infected with each VVOV
recombinant virus were spiked with rovGM-CSF (4 ng/ml) and
tested by GM-CSF ELISA for the expression of GIF.
GIF activity was measured as the decrease in O.D. units (x-axis) representing
rovGM-CSF clearance in the ELISA. The presence ofGIF activity is clearly
seen in culture medium taken 24 hours after infection from FLM cells
infected with orf virus NZ2 (+ ve control § p < 0.001) and VVOV
recombinant 85 (§ § p < 0.001) when compared with control samples of
medium alone. No GIF activity was found in cells infected with vaccinia
virus alone. Values given represent the mean of 4 samples and standard

























Fig. 3.3 Restriction map of fragment 85 from the genome of orf virus
NZ2 and the alignment of subclones from that fragment.
In order to map the gene encoding GIF activity to a locus within
restriction fragment 85 a number of overlapping restriction fragments
(shown numbered and prefixed pVU) were cloned into the pUC8
expression vector. The resulting plasmids were transfected into FLM
cells where orf virus gene expression was initiated and regulated by
subsequent infection with vaccinia virus.
Supernatants from infected cell cultures were assayed for GIF activity.
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The analysis of cultures of the subclones of rf 85 for GIF activity is given in Fig.
3.4A. GIF activity is clearly seen in cultures transfected with the plasmid pVUl
which contains the entire lOkb ofDNA from rf 85 (p < 0.001 when compared with a
medium control sample or cultures infected with vaccinia virus Lister strain).
Of the other clones tested only FLM cells transfected with the plasmid pVU13 were
found to express detectable levels ofGIF activity (p < 0.01 when compared to the
control samples). Neither of the clones, pVU31 or pVU226 that overlapped pVU13
at its 5' end, expressed GIF. A major portion of the orf virus DNA insert of pVU 13
covering 2.3 kb at the 3' end of rf 85 was considered to contain the gene encoding
GIF.
In order to determine the direction of transcription of the GIF gene(s) contained in
pVU13, the 2.3kb fragment was ligated into the mammalian expression vector
pEE14 in both orientations. The plasmids were transfected into CHO cells and the
MSX-selected cultures tested for GIF activity (Fig. 3.4B). GIF was expressed by
cultures transfected with the orf virus DNA fragment in the 5'-3' orientation
(pEE13.1).
Sequence analysis of clone pVU13 identified 2 potential single ORFs as
candidates for the gene encoding the GIF protein. (A third ORF within pVU13 was
discounted since its nucleotide sequence matched that of a vaccinia virus gene and
was therefore considered unlikely to encode GIF activity).
PEE 14 constructs containing both candidate ORFs (designated GM1 and GM2)
isolated from DNA prepared from the NZ2 and Moredun Research Institute (prefix
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Fig. 3.4 Analysis of orf virus DNA restriction fragment 85 for expression
ofGIF activity.
A) Samples of supernatants from FLM cells transfected with restriction
fragment DNA subclones (pVU series, y-axis) were taken at 20 hours post
infection for GIF analysis by the GM-CSF ELISA. GIF activity is clearly
seen in cultures transfected with plasmid pVUl which contains the entire
lOkb restriction fragment 85 (§ p < 0.001 when compared with medium
control). The decrease in O.D. as observed with clone pVU13 indicates
that GIF activity is present (§§ p < 0.01 versus medium control).
B) Testing for GIF activity in supernatants from CHO cells transfected
with plasmid pEE14 that contained the 2.3 kb fragment of orf virus DNA
(pVU13) in either orientation (pEE 13.1 and pEE13.2). GIF activity was
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Fig. 3.5 Analysis of GM1 and GM2-transfected CHO cells for GIF
expression.
A) The two open reading frames contained within the 2.3 kb restriction fragment of pVU13
and designated GM1 and GM2 were cloned into the mammalian expression vector pEE14 for
transfection into CHO cells. Cell free supernatants from individual transfectant cell lines
(numbered on the y-axis) were selected by growth in methionine sulphoxamine (MSX, an
inhibitor of glutamine synthetase) then tested for GIF activity by GM-CSF ELISA.Plasmids
containing DNA from NZ2 (13) and Moredun Research Institute (MRI) orf virus strains were
compared for GIF expression.
B) Increasing concentrations ofMSX were used to select cultures for high levels ofGIF
production as measured by low absorbances (x-axis, O.D. 492nm) in the GM-CSF ELISA.
Subsequently GM1CHO cells were maintained in medium containing 0.25mM MSX.
Samples from supernatants from fetal lamb muscle cells infected with orf virus (NZ2, positive
control) with and without ImM MSX and supernatant from untransfected CHO cells
(CHOUTF, negative control) were included as controls.
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clones were selected and tested for GIF activity (Fig. 3.5). GIF activity was detected
in supernatant from GM1-CHO transfectants containing DNA from both NZ2 and
Moredun orf virus strains (p < 0.001 when compared with medium control). CHO
cells transfected with the GM2 plasmids did not express GIF. The GM1 ORF was
mapped to a locus 20.1kb from the right hand terminus of the viral genome.
3.2.2. Isolation and identification of recombinant GIF
Expression of the recombinant GIF protein was carried out using the CFIO cell
transfectant clone NZ2GM1-1E10 (hereafter referred to as GM1-CHO). Supernatant
from GM1 -CHO cell cultures maintained at confluency for 4 days in serumless
medium was separated over a GM-CSF-Sepharose affinity column (Fig. 3.6).
Fractions were collected and analysed for GIF activity. GIF activity was recovered
from the elution of bound material from GM-CSF Sepharose. In general, in order
minimise the number of column runs and subsequent regeneration cycles, saturating
volumes of supernatant (60-80ml) were applied to the column. Consequently
significant levels of GIF were detected in the collection of unbound material.
SDS-PAGE analysis of the eluted fraction run under reducing conditions revealed
2 major proteins of 28kD and 43kD (Fig. 3.7).
Sequence analysis of the 20 N-terminal amino acids was carried out on each
isolated protein band and is as follows;
28 kD: AQC7IGERDFFTAAAQVVFAR
43 kD: S?QLPVEAKTGNVYQTSN?AV?Y
(The ? after individual amino acid residues denotes some uncertainty with the





























Fig. 3.6 Affinity purification ofGIF activity from GM1-CHO transfectant
cell cultures.
A) The O.D. (280nm) profile of the column outflow from a GM-CSF
-Sepharose affinity column which was loaded with 60 ml of CFS from
GM1-CHO cell cultures. After washing (80-120ml column outflow),
bound protein was eluted with 0.1M glycine, 0.5M NaCl pH2.8 (Low pH)
then neutralised with 1M Tris.
(In order to monitor eluted protein, the sensitivity of the spectrophotometer
was set on a higher scale hence the fall-through peak is off-scale).
B) Column outflow fractions were analysed for GIF activity by GM-CSF
ELISA. Values given represent the mean of 4 samples and standard error
of the mean.
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Fig. 3.7 SDS-PAGE analysis of affinity-purified GIF
Aliquots from unbound peak (lane 1) and eluted peak (lane 2)
fractions that were collected from the chromatography ofGM1-CHO
supernatant on the GM-CSF-affinity column, were analysed by
12% SDS-PAGE run under reducing conditions.
Separated proteins were visualised by silver staining. The molecular
masses of the major protein bands in the eluted fraction (28kD and
43kD) were calculated from a standard curve ofmolecular mass vs
mobility for a range ofmolecular mass markers (lane 3) in Microcal
Origin 5.0 using a log linear fit.
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TCGGGTAAAAACGTACACCGTCGCCTTGTCGCGGCGGTGTACGCTTTTTTCACGCCCTTT 60
M A C L R V F
TTGCAAAATTTAAATTGTACCCGCGCCGGCTCTAGGAAAGATGGCGTGCCTCAGAGTGTT 120






























Fig. 3.8 The GIF gene sequence.
Alignment of the nucleotide sequence of open reading frame GM1
(plus 100 bases of flanking sequence 898-998) with the predicted
amino acid sequence (bold type) and the sequence of 20 amino
acids (italic type) as determined by the N-terminal analysis of the
28kD GIF protein. The first 19 amino acids (underlined) of the
predicted a.a. sequence constitute a putative signal peptide.
The region of nucleotide bases containing potential transcription
promoter and/or initiator sequences is also underlined
(figure and data courtesy ofColin Mclnnes).
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Comparison of the N-terminal sequence of the 28kD protein with the predicted
amino acid sequence computed from the nucleotide sequence of the GM1 ORF,
resulted in an almost perfect matched alignment of 20 amino acids (Fig. 3.8, courtesy
ofColin Mclnnes). The recombinant GIF sequence was shown to start at an alanine
residue at position 20 of the predicted amino acid sequence and from this alignment a
total GIF sequence of 246 amino acids with a putative signal peptide of 19 preceding
amino acids was predicted. This polypeptide length corresponds to the observed
28kD molecular mass of the GIF protein. The N-terminal sequence of the 43kD
protein did not align with the GIF predicted sequence.
The search for a sequence match for the 246 amino acid GIF sequence and the 20
amino acid sequence of the 43kD protein was carried out using the BLAST. The
BLAST failed to return any significant match for the 43kD protein. For the GIF
sequence, BLAST returned 4 protein matches with sequences that were similar.
These sequences were; 1.) protein A41 precursor of variola virus with 33% identity
over a sequence of 88 amino acid residues, 2.) protein A41 precursor of vaccinia
virus (Copenhagen and Lister strains) with 32% identity over the same 88 amino acid
sequence, 3.) chain 4 ofNADH dehydrogenase with 48% identity over 27 residues
and 4.) homologue 1 of the cell division protein FTSZ with 26% identity over 118
residues. The position of each protein sequence alignment relative to the GIF
sequence is outlined in Fig. 3.9A. The 88 amino acid alignment ofGIF with the A41
proteins occurred at the same position of the polypeptide chain in both GIF and A41
(the alignment ofGIF and A41 of vaccinia virus is shown in Fig. 3.9B). When the
alignments ofNADH dehydrogenase and FTSZ with GIF were compared they did
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Fig. 3.9 Comparison of GIF amino acid sequence with sequences registered
in the Swiss-Prot (37.0) and TREMBL (10.0) databases.
A) A BLAST search identified 4 protein entries that showed amino acid
identity with the GIF sequence. The portion ofmatching polypeptide from
each protein (broad lines) is shown aligned with its counterpart GIF sequence
contained within the complete GIF sequence of 254 amino acid residues.
B) A more detailed amino acid sequence alignment of the regions of identity
ofGIF (residues 57-144, underlined) and vaccinia virus (residues 64-140). (Identical
amino acids (italics) and conserved substitutions (+)between both sequences are
outlined).
116
3.2.3. Characterisation of a rabbit anti-GIF
In order to facilitate the further characterisation of the GIF, a rabbit anti-GIF
reagent was raised against the affinity-isolated GIF protein. The characterisation of
the rabbit anti-GIF is outlined in Fig. 3.10. Pre-treatment of GIF with an IgG fraction
of anti-GIF was effective in neutralising GIF-GM-CSF binding at dilutions of 1:200
when compared with GIF alone or GIF after treatment with a pre-immune rabbit
serum (Fig. 3.1 OA).
Western blot analysis of supernatant from the GIF-producing GM1-CHO cell line
with the anti-GIF revealed reactivity with the 28 kD peptide under reducing
conditions (Fig. 3.10B) and both 56 kD and 28 kD peptides under non-reducing
conditions (Fig. 3.10C). The anti-GIF also identified a 43 kD peptide expressed by
GM1-CHO cells and the two control cell lines GM2-CHO and CFIOUTF. Western
blot analysis with the pre-immune rabbit serum failed to identify any peptide from
the test samples.
3.2.4. Expression ofGIF during orf virus infection in vitro
From base sequence analysis (carried out by Colin Mclnnes), expression of the
GIF gene did not appear to be under the control of early transcriptional control
sequences that are A+T rich and appear to be conserved in poxviruses (Fleming et al,
1991, Prideaux et al, 1990). Instead it was thought that the GIF gene start and stop
control sequences were more analogous to those of vaccinia virus late genes. In order
to determine whether GIF was the product of an early or late orf virus gene, NZ2
virus-infected FTM cell cultures were analysed by ELISA and by Western blotting
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Fig. 3.10 Characterisation of a rabbit anti-GIF antibody.
A range of dilutions of a rabbit antiserum raised against the rovGM-CSF-affinity
purified GIF activity were tested for neutralisation ofGIF activity in the GM-CSF
ELISA (A). Neutralisation by anti-GIF was measured by an increase in O.D.
(x-axis, 492nm) as GIF was prevented from clearing rovGM-CSF. Maximum
neutralisation ofGIF activity was observed at an anti-GIF dilution of 1:200
however significant reactivity of anti-GIF for GIF was detected down to 1:1000
(p < 0.01) when compared with GIF activity tested in the presence ofpre-immune
rabbit serum at 1:500 dilution
The specificity of anti-GIF was tested by Western blot analysis of B) reduced
(28kD GIF) and C) non reduced (28 kD and 56 kD GIF) conditioned medium
from GM1-CHO cell cultures. Reactivity with the 43 kD protein that co-eluted
from the affinity column is also evident in cell-free supernatants from GM2-CHO











0 0.82 +/-0.04 0.74+/-0.05 0.77+/-0.004
1 0.81+/-0.03 0.75+/-0.06 0.85+/-0.01
2 0.80+/-0.05 0.76+/-0.05 0.86+/-0.07
4 0.82+/-0.02 0.76+/-0.03 0.81+/-0.04
6 0.83+/-0.05 0.77+/-0.05 0.84+/-0.02
8 0.78+/-0.03 0.67+/-0.03 0.82+/-0.04
10 0.77+/-0.03 0.29+/-0.001 0.79+/-0.05
12 0.63+/-0.02 0.11+/-0.01 0.69+/-0.01
18 0.21+/-0.01 0.05+/-0.002 0.71+/-0.02
20 0.17+/-0.005 0.05+/-0.001 0.5147-0.03
24 0.09+/-001 0.18+/-0.002 0.55+/-0.04
Table 3.1 Expression of GIF during orf virus infection.
Aliquots of cell-free supernatant (CFS), cell lysate and insoluble
cellular material (after cell lysis with NP40) from FFM cells
infected with orf virus (NZ2) were collected at various times after
infection and tested for the presence ofGIF by GM-CSF EFISA.
GIF activity in both supernatant and cell lysate material was
revealed by the lower O.D. (492nm) values which are underlined
and with p < 0.001 when compared with the value for GM2-CHO
GIF negative control (O.D. 0.78 +/- 0.04).
The value for the GM1-CHO GIF positive control for this
experiment was 0.048 +/- 0.004. Insoluble material was assayed
as a suspension for rovGM-CSF binding activity. No significant
GIF activity was detected.
All values represent the mean of 4 samples with +/- standard error
of the mean.
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Cells were infected at a m.o.i of 0.1 and >75% CPE was observed at 24 hours after
infection. Cytoplasmic GIF from cell lysate material was first detected at 10 hours
post infection (Table 3.1). Extracellular GIF was first detected 8 hours later. Low
levels ofGIF were detected in the later stages of infection (after 20 hours), associated
with insoluble cellular material.
Western blot analysis of supernatants from NZ2 virus-infected FLM cell cultures,
probed by the anti-GIF, identified proteins of 28 kD, 43 kD and 56 kD. (Fig. 3.11A
and B). Extracellular GIF was first detected by the anti-GIF 18 hours after virus
infection (Fig. 3.11 A). Treatment of the cultures with cytosine arabinoside (an
inhibitor of viral replication and the expression of late virus genes) was shown to
inhibit the production ofGIF as detected in the supernatant from untreated cultures
(Fig. 3.12B). In addition treatment of infected cultures with cytosine arabinoside
prevented the CPE that was observed in its absence.
Western blot analysis of cell lysate material (Fig. 3.11C). taken from cultures at
different times after infection, revealed that GIF was present within cells as early as
10 h after infection. Increased levels of GIF were found in lysates taken at 24 h but
GIF was not detected in lysates from infected cell cultures taken at 24 h after
treatment with cytosine arabinoside. In contrast to supernatants, cell lysate material
contained high levels of protein which, under non-reducing conditions, resulted in
gel distortion. Western blot analysis of cell lysate material was therefore carried out
under reducing conditions and as a consequence the 56 kD protein band observed
under non-reducing conditions was not detected in this material.
Northern blot analysis of orf virus infected FLM cells carried out by Colin
Mclnnes (using a DNA probe derived from the sequence within the GIF open
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Fig. 3.11 Viral GIF expression in FLM cells after infection with orf virus
NZ2.
A) Cell free supernatants collected from orf virus (NZ2) infected FLM cell
cultures at various times after infection (2h-24h) and tested for the presence
ofGIF (both 28 kD and 56 kD GIF where present are arrowed) by Western
blot analysis under non-reducing conditions using the rabbit anti-GIF.
B) A similar Western blot analysis of supernatants taken at 18h and 24h
after infection from infected cells maintained in the presence and absence
of cytosine arabinoside (CA: an inhibitor of viral replication and late viral
protein expression).
C) Cell lysate material collected at 1 Oh and 18h from infected FLM cells
was compared under reducing conditions with cell lysate collected at 24h
from infected cells maintained in the presence or absence of cytosine
arabinoside and cell lysate from uninfected cells (FLM).
As previously shown the 43 kD protein was present (dashed arrow) in all
samples tested including those from uninfected control cell cultures
(FLM).
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Fig. 3.12 Northern blot analysis ofGIF mRNA expression
(courtesy ofColin Mclnnes).
Viral RNA was isolated from FLM cell cultures 18 h after
infection with NZ2 at a MOI of 20 TCID50 in the presence
or absence of cytosine arabinoside (CA).
Using a DNA probe derived from the GIF open reading frame,
GIF mRNA was detected in infected FLM cultures
maintained in the absence of CA.
The positions ofRNA size markers (in bases) are indicated.
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reading frame) detected GIF mRNA at 18 h after infection. GIF mRNA was not
detected at 5 h after infection or at 18 h after cultures were treated with cytosine
arabinoside (Fig. 3.12). This result along with the results from the Western blot
analysis demonstrated that the GIF gene was expressed as an intermediate or late but
not early viral gene. The detection of multiple mRNA bands instead of a single
mRNA band (Fig. 3.12) supports this conclusion since the point at which
intermediate and late gene transcription stops can vary.
3.2.5. Expression of GIF by other parapoxviruses
FLM cells infected with different orf virus strains, orfl 1, NZ2, scabbymouth and
D1701, were all shown to express GIF when supernatants were analysed by GM-CSF
clearance ELISA 18-20 h after infection (Fig. 3.13). GIF activity was not detected in
supernatants taken (at > 90 % cytopathic effect) from FLM cells infected with the
parapox viruses bovine papular stomatitis virus (BPSV) and pseudocowpox
virus/milkers' nodule virus (MNV) and the control virus, Semliki forest virus (SFV).
Samples collected from FLM cell cultures that had been infected with different
parapox viruses were found to contain high levels of serum protein that prevented
protein separation by SDS-PAGE. Consequently Western blot analysis of these
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Fig. 3.13 GIF expression by parapoxviruses.
Different strains of orf virus, bovine papular stomatitis virus
(BPSV) and milkers nodule virus/pseudocowpox virus (MNV)
propagated in FLM cells were tested for expression of GIF by
GM-CSF ELISA.
All orf virus strains tested expressed GIF as demonstrated by
the low absorbance (x-axis, O.D. (492nm)).
Semliki forest virus (SFV), bovine papular stomatitis virus
and milkers nodule virus-infected cultures did not express GIF.
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3.3. Discussion
3.3.1. Mapping of the GIF gene
In this chapter the orf virus gene encoding the GIF protein mapped to a single
ORF located 20.1 kb from the right terminus of the orf virus genome. From earlier
studies, it was found that vaccinia virus did not express a protein that bound ovine
GM-CSF and consequently use was made of the VVOV recombinant library to map
the GIF gene to the orf virus genome. Without this library, the mapping of the GIF
gene by the isolation of single ORFs would have been extremely difficult. Due to the
high G+C content of the orf virus genome, it is difficult to identify individual stop
codons and so determine single ORFs. This problem ofORF identification was
highlighted in the orthopoxvirus, Molluscum contagiosum virus (MCV) which, like
orf virus, has a high G+C content (63%). Senkevich et al, (1996) demonstrated that
the genome ofMCV contains approximately 163 ORFs instead of the 588 ORFs
predicted by the analysis of apparent stop codons. This more realistic estimate was
derived from statistical predictions of coding regions, signal peptides and putative
promoters and correlates with the 187 and 198 ORFs for the orthopoxviruses, variola
virus and vaccinia virus respectively (Goebel et al, 1990).
The vaccinia virus-controlled expression of plasmids containing subclones of the
10 kb VVOV85 orf virus DNA fragment allowed further mapping of the GIF gene to
a 2.3 kb fragment (pVU13) at the right hand end ofVVOV85. Improved expression
ofGIF activity was achieved when this fragment was recloned in the 5'-3' orientation
into the pEE14 mammalian expression vector and transfected into CHO cells.
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3.3.2. GIF gene expression by parapoxviruses
Conservation ofGIF expression was found in all orf virus strains tested. These
included the tissue culture adapted strains; orfl 1, scabbymouth, D1701 and NZ2.
Comparison of the GM1 sequences of orf 11 and MRI scab viruses with that ofNZ2
revealed a high level of identity for the predicted protein product (>98%).
Binding to rovGM-CSF by samples from cultures infected with bovine papular
stomatitis virus or pseudocowpox virus was not detected. Interestingly, although
much of either genome has yet to be sequenced. Dr. Andy Mercer (University of
Otago) has found sequences homologous to orf virus GIF in both the genomes of
bovine papular stomatitis virus and pseudocowpox virus (personal communication).
This failure to bind ovine cytokine may reflect the fact that these viruses infect cattle
and through co-evolution with this host have selected viral receptors that are specific
for cytokines of bovine origin. Therefore any future study into GIF expression by the
bovine-specific parapoxviruses should be directed towards the analysis of GIF-
bovine GM-CSF binding.
3.3.3. Identification of the GIF gene product
Purification of recombinant GIF by GM-CSF-Sepharose affinity chromatography
resulted in the identification of 28 kD and 43 kD protein bands on SDS-PAGE under
reducing conditions. Subsequent N-terminal sequence analysis identified the 28kD
protein as the product of the GIF gene contained within the GM1 ORF. A BLAST
search of protein sequence databases failed to find any match with the N-terminal
amino acid sequence obtained for the co-eluting 43 kD protein. A less discriminatory
search using the FASTA search tool provided by the Daresbury Laboratories
126
(Daresbury, U.K.) for any match of the 20 terminal amino acids of the 43 kD protein
yielded no definitive match with any sequences held in the protein databases. There
was however some indication of a common sequence (40-50% identity in a 15 amino
acid overlap) with fungal/microbial chaperonins.
The GIF gene was predicted to encode a 265 amino acid (27.9 kD) protein (Colin
Mclnnes). From the alignment with 20 amino acid terminal sequence of the
recombinant GIF, the first 19 amino acids of the predicted sequence was thought to
constitute a putative signal that is cleaved as part of a post-translational modification.
There were similarities between the predicted sequence of the GIF protein and
the A41 protein precursor of variola virus and vaccinia virus strains Copenhagen and
Lister (32% similarity over an 88 amino acid overlap). The alignments of A41 and
GIF sequences based on identical amino acids and conserved amino acid
substitutions were shown in the same central region of the peptide chain. The
function of the A41 gene product is not known, the A41 protein sequence has been
reported to have homology with the 35 kD/Tl family of chemokine soluble receptors
(Lalani and McFadden, 1997; Lalani et al, 1998). These 35-40 kD secreted proteins
(35 kD for orthopoxviruses and T1 for leporipoxviruses) bind CC- chemokines with
high affinity. Whereas the 35kD/Tl proteins were shown to block CC-chemokines
binding to target receptors in vitro, they did not block IL-8 (a CXC-chemokine)
binding its receptor (Smith et al, 1997; Lalani et al, 1998; Alcami and Koszinowski,
2000). However no significant sequence homology was revealed when the sequences
ofGIF and Shope fibroma virus T1 protein (a representative of the 35 kD/Tl family,
Graham et al, 1997) were compared.
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3.3.4. Temporal expression of the GIF gene
From Western blot analysis and Northern blot analysis of samples collected from
virus infected cells at different times and maintained in the presence or absence of
cytosine arabinoside, it was shown that GIF was the product of an intermediate or
late expressed orf virus gene. GIF was first detected by GM-CSF clearance ELISA in
supernatant from FLM cell cultures approximately 18 hours after orf virus infection.
Nonetheless, cytoplasmic GIF can be detected eight hours earlier and this correlates
with the observation of Lear (1995) whereby constitutive GM-CSF production by
keratinocytes is effectively shut down 10 hours after orf virus infection. This
suggests that at least one role for GIF is to block GM-CSF in infected keratinocytes,
the target cell of orf virus in vivo. The significance of this is not yet clear.
Alternatively, the proper folding and secretion ofGIF may be dependent on
additional factors that include host gene products (possibly the 43 kD protein). The
roles of the 43 kD protein and the 56 kD protein (that was observed in the non-
reduced electrophoresis of affinity-purified material and is possibly a dimeric form of
the 28 kD GIF protein) in GIF-GM-CSF binding is investigated in Chapter 4.
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CHAPTER 4




In chapter 3, it was shown that the orf virus GIF gene encodes a secreted protein
of 28 kD and an additional 56 kD band in non-reduced gels. Like their cellular
counterparts, many poxvirus cytokine receptors are present in solution as higher
order oligomers (Lalani et al, 1997; Mossman et al, 1996; Loparev et al, 1998). The
aims of this chapter were therefore to determine firstly whether GM-CSF was bound
by GIF as a monomer and/or as an oligomer and secondly to investigate other
physico-chemical properties of GIF including; glycosylation, isoelectric point and
the stability ofGIF across a range of pH values, salt concentrations and temperatures.
The initial approach was to further purify the GIF protein by gel filtration
chromatography under physiological conditions (0.15M NaCl and pH 7.2). The
isolated GIF was then tested for GM-CSF binding in the ELISA. The calibration of
the gel filtration column with a range ofmarkers of known molecular mass enabled
the size of the GIF molecule to be determined.
In order to confirm that GIF bound GM-CSF directly, a ligand blot procedure was
developed. This approach entailed the blotting of rovGM-CSF by l2:T-GIF.
Analysis of chemically cross-linked cytokine-receptor complexes has revealed both
the molecular mass of the complex and the stoicheometry of the reaction. Upton et al
(1992) have characterised the binding of the M-T7 protein encoded by a myxoma
virus gene to rabbit IFN-y through SDS-PAGE analysis of the chemically cross-
linked M-T7/IFN-y complex. This approach was used to investigate the native
conformation of the GIF molecule when bound to GM-CSF and whether GIF bound
one or more GM-CSF molecules.
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Forces such as hydrogen bonds, disulfide bridges, attractions between positive
and negative charges, and hydrophobic and hydrophilic linkages cause a protein
molecule to coil or fold into a secondary structure, examples of which are the alpha
helix, the beta pleated sheet, turn and coil. The secondary structure of a protein can
be predicted from the amino acid sequence by proteomic computer programs that are
available on the world-wide web. These proteomics tools use a number of different
mathematical algorithms to calculate not only the probability of the various
secondary structures but also molecular mass, isoelectric point, regions of
hydrophophilicity/hydrophobicity, regions of antigenicity and potential glycosylation
sites. The tertiary and quaternary structures of some proteins have already been
determined by X-ray crystallography and nuclear magnetic resonance analysis.
These protein structures can be used as model templates for the mathematical
prediction of the higher order stuctures of other proteins with amino acid sequence
homology. Protein structure prediction tools provided the ExPASy proteomics server
were used to investigate the structure of GIF.
Gel mobility-shift analysis by SDS-PAGE of GIF before and after treatment with
endoglycosidases was used to investigate the level of glycosylation associated with
the GIF molecule. This approach was used previously to identify glycosylated and
non-glycosylated forms of secreted rovGM-CSF (Entrican et al, 1996)
Electrostatically-charged glycosidic residues such as neuraminic acid, N-acetyl
glucosamine and N-acetyl galactosamine can contribute, along with charged amino
acids, to the net charge of a protein molecule. Since the overall charge carried by a
protein molecule can influence what methods may be applied to its isolation and
characterisation (for example ion-exchange chromatography and isoelectric focusing)
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it was considered important to determine the isoelectric point (pi) of the GIF protein.
The pi is the pH at which a protein carries the same number of negative and positive
charges. The pi ofGIF was determined by the method outlined by Lampson and
Tytell (1965), whereby the binding ofGIF to an ion exchange resin, equilibrated with
buffers of different pH, was tested. At the isoelectric point, GIF, with no net charge,
would not bind to the resin. Unbound GIF was detected by the GM-CSF clearance
ELISA.
Previously, Andrea Lear (1995), in addition to demonstrating that the clearance
ofGM-CSF by GIF was not due to proteolytic activity, had shown that the process of
heating supernatants from infected cultures to 56°C affected the ability ofGIF to
clear GM-CSF detectable by ELISA. In this chapter, the physical and chemical
nature of the GIF-rovGM-CSF binding reaction was further investigated. The effects
of temperature, chemical reducing agents, high salt concentration and extremes of pH
on GIF-GM-CSF binding was tested by GM-CSF clearance ELISA. The kinetics of
GIF-GM-CSF reactivity over increasing time intervals was also investigated.
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4.2. Results
4.2.1. The identification of GIF oligomers
Sephacryl-200HR gel filtration of recombinant GIF activity isolated by rovGM-
CSF affinity chromatography (Section 2.3.1.) resulted in the identification of a
protein complex of approximately 110-120 kD with GIF activity as measured by the
GM-CSF clearance ELISA (Fig. 4.1A). Analysis by SDS-PAGE (Fig. 4.IB and C)
revealed that this complex consisted of 28 kD peptides when run under reducing
conditions. Under non-reducing conditions a 56 kD major protein band and a minor
28 kD band were observed.
GIF activity was not detected in the major absorbance peak (O.D. 280nm) from
gel filtration which had an estimated molecular mass of 55-60 kD (Fig. 4.1A). SDS-
PAGE analysis revealed that the major component of this peak was the 43kD peptide
that co-eluted with GIF from the rovGM-CSF affinity column.
The reduction of the GIF protein complex by boiling in the presence of 5 mM
dithiothreitol resulted in its dissociation to the 28 kD form as seen on SDS-PAGE
analysis ofGIF run under reducing conditions. The 28 kD GIF did not react with
rovGM-CSF as measured by GM-CSF clearance ELISA even after extensive dialysis
against PBS (Fig. 4. 2). GIF that had been boiled in the absence of dithiothreitol was
found to clear rovGM-CSF.
The 110-120 kD GIF protein complex was radio-iodinated and the product
evaluated by Sephacryl-200HR (Fig. 4.3). Since the protein load applied to the gel
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Fig.4.1 Purification of recombinant GIF.
A) The rovGM-CSF- affinity column eluate containing the 28 kD and 43 kD proteins
was further separated by gel filtration on Sephacryl 200F1R (solid line denoting retention
time vs O.D. 280 nm). Fractions were tested for GIF activity in the GM-CSF ELISA (O.D.
492nm denoted by the dashed line and showing a decrease in O.D. associated with GIF
activity). The molecular mass of each peak (110-120 kD and 55-60 kD) was estimated by
comparison with a range ofprotein standards (denoted by the light dotted line joining peaks
A-E) run previously under identical conditions.
Aliquots consisting of pooled peak fractions 22-24 and 30-34 were analysed by 12% SDS-
PAGE under B) reducing conditions and C) non-reducing conditions. The molecular
weights of the major protein bands isolated from the column fractions (arrowed, 28 kD,
43 kD and 56 kD) were calculated by comparison with a range ofmolecular mass protein
standards (dashed arrows 21.5 kD - 66 kD).
134
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
0.0 0.2 0.4 0.6 0.8 1.0
GM-CSF ELISA O.D.(492nm)
Fig. 4.2 The effect of dithiothreitol reduction on GIF activity.
To test the effect of reduction on GIF binding to GM-CSF, affinity
purified GIF was boiled in the presence of increasing concentration
of dithiothreitol (y axis, DTT (mM)). As shown by the increase in
absorbance (cross hatched bars), reduction by DTT resulted in loss
ofGIF binding activity which was not recovered even after removal
of the DTT by dialysis (diagonal hatched bars).
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Fig. 4.3 Gel filtration of 125I-GIF.
Purified GIF was radio-iodinated by the chloramine T method and
after removal of free 125Iodine was applied to Sephacryl 200HR.
Aliquots were taken from each fraction collected and radioactivity
(primary y-axis) measured by y-counter (solid line). The
approximate molecular mass of each peak of radio-labelled protein
was estimated (peak 1 = 115 kD; peak 2 = 55/60 kD) by comparison
with retention times of protein standards measured at O.D. at 280nm
secondary y-axis and peaks A-E joined by dotted line and run
previously under identical conditions.
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presence of 0.5 M NaCl and 0.1% CHAPS to minimise adsorption to the column
matrix. Two major peaks of radioactivity were measured with estimated molecular
masses of 115 kD and 55/60 kD respectively. Both peaks were found to comprise the
28 kD l2T- GIF subunit when analysed by SDS-PAGE under reducing conditions
(Fig. 4.4). There was no peak of radioactivity corresponding to the molecular mass
of the 28 kD subunit detected during the fractionation of 124-GIF by Sephacryl-
200HR.
The reactivity of l2H-GIF for rovGM-CSF was tested by GM-CSF clearance
ELISA (Fig. 4.5) and Western blot analysis (Fig. 4.6). Comparison of equal
concentrations of 12?I-GIF and unlabelled GIF for clearance of rovGM-CSF as
measured in the GM-CSF clearance ELISA showed that radioiodination did not
affect the ability of l2H-GIF to bind rovGM-CSF. Nitrocellulose strips containing
separated rovGM-CSF were incubated with 12?IGIF fractions collected during gel
filtration. Those fractions that corresponded to both l2l-GIF peaks were found to
react with rovGM-CSF (Fig. 4.6). The doublet bands bound by l2T-GIF represent
different glycosylated forms of the rovGM-CSF protein (see below Section 4.2.2.).
In an attempt to determine the molecular structure of the GM-CSF-binding
complex, the 115 kD l2:l-GIF was incubated with rovGM-CSF then crosslinked with
EDC (Fig.4.7). The effectiveness ofEDC in cross-linking the proteins in this study
was found to be low. As with untreated '""H-GIF (lane 2), cross-linked 12dI-GIF (lane
1), when analysed by SDS-PAGE under non-reducing conditions, comprised
predominantly 56 kD and 28 kD peptides, although some of the 115 kD complex
appears to be preserved (lane 2). A labelled complex can be seen in the presence of a
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Fig. 4.4 SDS-PAGE analysis of S200 peak fractions of 125I-GIF.
Aliquots from pooled fractions (12-13, 14-15, 16-18 ofpeak 1 and
33-35, 36-38 ofpeak 2) of S200-separated 1251-G1F were analysed
by 12% SDS-PAGE run under reducing conditions.
Radio-labelled protein (28 kD, solid lined arrow) was identified by
autoradiography of the fixed, stained and dried gel. The relative
positions ofprotein standards run at the same time and identified
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Fig. 4.5 Binding of 125I-GIF to rovGM-CSF.
The binding of equal concentrations of 124-GIF (solid circles)
and unlabelled GIF (solid triangles) to increasing amounts of
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Fig 4.6 Ligand blot analysis of 125I-GIF separated by gel filtration.
The reactivity of 125I-GIF separated by S200 gel filtration was tested
against purified rovGM-CSF by ligand blot analysis. SDS-PAGE-
separated rovGM-CSF (doublet bands of 20 kD and 24 kD) was
transferred to nitrocellulose membrane which was cut into strips.
Individual strips were incubated with column fractions (consecutive
fractions pooled as numbered) that were collected over the
duration of the run (63 min.) and tested for 125TGIF-rovGM-CSF
reactivity by autoradiography. (The positions ofmolecular mass





of 130 kD (lane 3). No complex (115 kD or 130+ kD) was observed when l2:iI-GIF
was crosslinked in the presence of an excess of rovIL-3 (lane 4). Due to low
mobility of the cross-linked l2:l- GIF-GM-CSF complex, an accurate estimate of its
molecular mass could not be made. Consequently the stoichiometry of the GIF-GM-
CSF interaction could not be ascertained.
4.2.2 The predicted protein structure of GIF
The amino acid sequence ofGIF was used as a template to predict the secondary
structure of the protein. The Predator and ProSite proteomics tools supplied by the
ExPASy proteomics server were used to predict the regions of the polypeptide chain
that were likely to form alpha helix, beta-pleated sheet, turn or coil secondary
structures. In addition, theoretical hydrophobic, hydrophilic and antigenic domains
were also calculated by the ProSite tool. Potential O-linked and N-linked
glycosylation sites were computed by the O-Glycbase tool and ProSite tool
respectively. The various structural domains and glycosylation sites are shown
aligned with the 246 amino acid sequence ofGIF in Fig. 4.8. Much of the
polypeptide chain ofGIF is predicted to be hydrophilic and comprised of a number
of extended alpha helical regions with smaller regions of beta-pleated sheet, turns
and coils. The regions of polypeptide calculated as being potentially antigenic
corresponded to the predicted turn secondary structures. Potential N-linked
glycosylation sites were mapped to asparagine residues at position 30, 36, 63 and 114
on the GIF polypeptide chain. Possible O-linked glycosylation sites were given at





Fig. 4.7 The effect ofEDC-crosslinking on 125I-GIF-GM-CSF
binding.
Samples of the 115 kD peak fraction of 125I-GIF were analysed by
SDS -PAGE (7.5% under non-reducing conditions) and
autoradiography after treatment with EDC peptide crosslinker (lane
1) and before treatment (lane 2). EDC crosslinking was also carried
out in the presence of a 50 fold molar excess of rovGM-CSF (lane
3) and a 50 fold molar excess of rovIL-3 as a non-specific control
(lane 4). The molecular masses ofGIF ( solid line arrows) present
as a monomer (28 kD), dimer (56 kD) and tetramer (115 kD) and
complexed with rovGM-CSF (>130 kD) were estimated by
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Fig. 4.8 Predicted secondary structure and glycosylation sites of GIF.
The secondary structure ofGIF was predicted from the amino acid sequence using
the Predator prediction tool.
Potential O-Iinked glycosylation sites were predicted by O-Glycbase tool that
searched for serine and threonine residues in the sequence. Potential N-linked
glycosylation sites were predicted by the ProSite tool based on the position of
tri-peptide asparagine-unspecified amino acid -serine/threonine residues.
The various structural domains are shown aligned with the GIF amino acid sequence.
The secondary structure predictions were calculated according to the algorithms of
'Kyte and Doolittle (1982), 2Beattie et al (1992) and 3Garnier et al (1978).
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The theoretical isoelectric point and molecular mass was calculated as pH 6.5 and
27,848 Daltons, respectively, using the Multildent tool.
The Swiss-Model automated protein-modelling server was used unsuccessfully to
predict tertiary and quaternary structures of GIF. This prediction tool calculates a
model of the three-dimensional and oligomer structure for a protein based on a
number of template structures derived by X-ray crystallography or nuclear magnetic
resonance analysis. For successful modelling, it is necessary that the template
proteins sequences closely match the sequence of the test protein. Template proteins
that matched GIF were not found.
4.2.3. Endoglycosidase-F treatment ofGIF
In spite of a number of potential glycosylation sites being present on the
polypeptide chain, the measured (from SDS-PAGE) 28 kD molecular mass ofGIF
corresponded to the predicted molecular mass, suggesting that GIF was not
significantly glycosylated. However, a mobility shift analysis (Fig. 4.9A) was
performed on GIF before (lane 1) and after treatment (lane 2) with the N-linked
specific endoglycosidase, PNGase-F. No change in molecular mass was observed on
Western blot analysis with anti-GIF. To ensure the efficacy of endoglycosidase
treatment, similar treatment was applied to rovGM-CSF (Fig. 4.9B). PNGase-F was
shown to remove N-linked glycosidic moieties from the upper doublet of rovGM-
CSF bands (lane 1) that are considered to represent N-glycosylated forms of the
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Fig. 4.9 The effect ofN-linked de-glycosylation on GIF mobility.
A) Purified rGIF was treated with endoglycosidase F to remove
N-linked glycosidic residues then analysed by Western blot analysis
using rabbit anti-GIF. Before treatment (lane 1) is compared with post
treatment (lane 2). No change in mobility of either 28 kD or 56 kD GIF
(solid line arrows) is observed.
B) The effectiveness of the de-glycosylation procedure is demonstrated
in a silver stained 12% SDS-PAGE gel, where glycosylated rovGM-CSF
(the upper set of bands in lane 1, 24 kD) is converted to the non/lower
glycosylated form (lane 2, 20 kD) by endoglycosidase F.
The relative positions ofmolecular mass standards on either gel is shown
(dashed arrows).
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4.2.4. The isoelectric point of GIF
GIF adsorption to the anion-exchange resin Q-Sepharose (that had been
equilibrated in buffers at different pH values) was measured by GM-CSF clearance
ELISA of the supernatants (Fig. 4.10). At pH less than 7, GIF did not bind to Q-
Sepharose as shown by the high level ofGIF activity in the supernatant. In contrast,
at pH 7-9 the majority ofGIF present bound to Q-Sepharose. For anion-exchange
separations, it is considered that proteins bind at 0.5 pff unit above their isoelectric
point (Flimmelhoch, 1971). From these data, the isoelectric point ofGIF was
estimated between pH 6.5 and 7. This value correlates with a value of 6.5 that was
computed by the Multildent proteomics tool from the amino acid sequence of the
GIF protein.
4.2.5. The effect of temperature, salt concentration and extremes of pH
i). Temperature
GIF bound rovGM-CSF maximally at 37°C (Fig. 4.11). There was some reduction
in this binding when the mixture was incubated at 20°C and 27°C. At lower
temperatures such as 4°C and 10°C and at the higher temperature of 56°C, binding
was significantly reduced (p < 0.01 when compared with GIF-rovGM-CSF binding
at 37°C).
ii). Salt concentration
Increasing the salt concentration of the GIF-rovGM-CSF mixture buffer to 1 M
NaCl, had little effect on GIF activity (p > 0.1 compared with GIF activity at
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Fig. 4.10 Determination of the isoelectric point (pi) ofGIF.
Affinity purified GIF was applied to 0.5 ml volumes of
Q-Sepharose, which had been equilibrated in buffer at different
pH (y-axis pH 4.5 -9). After mixing the gel was allowed to settle
and the supernatant was tested for GIF activity by ELISA. As
shown by the higher absorbances (x-axis, O.D. 492nm) observed
in supernatants taken from gel equilibrated in buffers at pH >
6.5, GIF has bound to the gel.
For anion exchangers, proteins bind at 0.5 pH unit above their
pi. The pi ofGIF is therefore between 6.5 and 7.
Values represent the mean of 4 samples and standard error of the
mean. The values for the GIF positive control and medium
negative control for this experiment were 0.104 +/- 0.003 and
0.91 +/- 0.01 respectively.
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Fig. 4.11 The effect of temperature on GIF-rovGM-CSF binding.
The binding ofGIF to increasing concentrations of rovGM-CSF
(x-axis, GM-CSF ng/ml) at different temperatures (4°C-56°C)
was measured by GM-CSF ELISA.
Maximum GIF-rovGM-CSF binding was observed at 37°C as shown
by the lowest O. D. (492nm) values.
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ELISA (Fig. 4.12). At this concentration, in the absence ofGIF, some interference
with GM-CSF detection by ELISA was observed.
iii). pH
GIF binding to rovGM-CSF was tested at pH 3.0, 4.0, 7.5, 10.0 and 11.0 (Fig. 4.
13). Lowering of the reaction mixture to pH 3.0 and pEI 4.0 resulted in little or no
rovGM-CSF binding to GIF. Incubation of the reaction mixture at pFl 10.0 was
shown to have less of an effect with 50-60% of the added GM-CSF binding GIF.
However at pH 11.0, little rovGM-CSF bound GIF. Exposure ofGIF to low pH prior
to neutralisation and addition of rovGM-CSF resulted in the loss of approximately
45% of total rovGM-CSF binding after treatment at pH 3.0 and 30-35% of total
binding at pH 4.0 when compared with control samples maintained at pH 7.5. A
similar but less marked effect on GIF binding to rovGM-CSF was observed when
GIF was exposed to pH 10.0 and pH 11.0. Acidic or basic pretreatment of rovGM-
CSF had little effect on its detection by ELISA.
4.2.6. GIF-rovGM-CSF binding with time
GIF was incubated with increasing amounts of rovGM-CSF for 1 h and 20 h (Fig.
4.14). For a range of saturating concentrations of rovGM-CSF, no difference in GIF-
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Fig. 4.12 The effect of increasing salt on GIF activity.
The binding ofGIF to rovGM-CSF in the presence of increasing
salt concentration (x axis, NaCl (M)) was assayed by ELISA
(y axis, O.D. (492nm)). Salt concentrations up to 1M NaCl had
little effect on GIF-rovGM-CSF binding but some interference
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Fig. 4.13 The effect of pH on GIF binding.
The binding of GIF to rovGM-CSF was tested after the reaction mix
had been exposed to different pH values for lh before neutralisation
to pH 7.5 (cross hatched bars) or after GIF had been exposed to the
same treatment prior to neutralisation and addition of rovGM-CSF
(solid bars).
The effect of pH on rovGM-CSF and its subsequent detection after
neutralisation was also investigated (cross hatched bars).
Maximum GIF-rovGM-CSF binding was observed at pH 7.5 as shown
by the lowest O.D. (492nm) values. Exposure of rovGM-CSF to high
and low pH values had little significant effect on rovGM-CSF detection
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Fig. 4.14 GIF reactivity with GM-CSF as a function of time.
The clearance of increasing concentrations of rovGM-CSF (x-axis,
ng/ml) by GIF was tested after incubations for 1 h and 20 h.
No significant increase or decrease ( p > 0.05 ) in GIF-rovGM-CSF
binding was observed after 20 h when compared with binding after 1 h.
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4.3. Discussion
4.3.1. Characterisation ofGIF multimer formation
In this chapter the monomer/multimer structure of the GIF molecule that bound
ovine GM-CSF in vitro was investigated. Under physiological conditions (0.15 M
NaCl and pH 7.2), GIF was present in solution predominantly as a homo-tetramer
comprising 4 x 28 kD GIF subunits. This was evidenced by the isolation of a 115 kD
GIF complex by Sephacryl-200FIR gel filtration run in the presence of PBS and the
dissociation of this complex into 28 kD subunits when exposed to reducing
conditions. Formation of a higher order GIF molecule was required for ovGM-CSF
binding since the 28 kD subunit did not bind ovGM-CSF. Both tetrameric and
dimeric forms ofGIF were shown to bind ovGM-CSF. In the presence of high salt
and non-ionic detergent (as observed with gel filtration of 12H-GIF), the tetrameric
conformation was less stable and dissociation to the dimer form was favoured. This
implied that tetrameric GIF comprised two dimers that were held together by non-
covalent bonds. In contrast, dimeric GIF was disrupted by boiling in the presence of
a reducing reagent and this suggests that intermolecular disulphide may be involved
in dimer formation. Furthermore, the 28 kD subunit did not self-associate under
physiological conditions in vitro, implying that oligomerisation may be part of post-
translational modification of the GIF protein in vivo. The degree of GIF
oligomerisation is clearly dependent on the ionic strength of the solution.
Ho and Shuman (1996) have shown that the dsRNA-binding protein encoded by the
E3L gene of vaccinia virus is a dimer at high ionic strength (>0.5M NaCl) but as the
ionic strength is reduced to 0.1M, self-associates to form higher order oligomers.
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In contrast to this evidence that supports dimeric GIF-rovGM-CSF interaction,
EDC-peptide cross-linking of both the '^I-GIF and GIF-rovGM-CSF complexes
suggested that rovGM-CSF was associated with tetrameric GIF whilst no mobility
shift concomitant with dimeric 125I-GIF binding rovGM-CSF was detected. Since the
efficiency of crosslinking in this study was low (a similar observation of low cross-
linking efficiency by EDC ofM-T7/IFN-y hetero-oligomers and IFN-y homodimers
was made by Upton et al, 1992), further analysis is needed to confirm this
observation. One explanation for the presence of tetrameric GIF rather than dimeric
GIF in the GIF-rovGM-CSF complex identified by cross-linking could be that the
binding of rovGM-CSF to dimeric GIF promoted further oligomerisation even in the
presence of high ionic strength. Stomski et al, (1996) and Guthridge et al (1998)
postulate a model for cellular receptors for IL-3, GM-CSF and IL-5 whereby the
cytokines bind their respective receptors and undergo oligomerisation which results
in the activation of the receptors.
Similarly ligand-induced receptor conversion from a dimer to a tetramer has been
reported for granulocyte colony-stimulating factor receptor (Hiraoka et al, 1994).
Horan et al (1997) report that soluble granulocyte-colony stimulating factor receptor
(G-CSFR) has a weak tendency to self-associate into a dimer in the absence of a
ligand but this receptor-receptor binding is enhanced by ligand binding and the most
stable complex occurs at 2:2 stoichiometry. Clearly the GIF-GM-CSF complex
observed in the cross-linking experiment could fit this model of ligand-induced
oligomerisation ifGIF homodimers bound single GM-CSF molecules then
oligomerised to form a more stable complex that comprised tetrameric GIF and two
GM-CSF molecules.
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The information obtained from protein structure prediction analysis was limited.
The predicted secondary structure ofGIF appeared typical of the structure ofmany
soluble globular proteins. Future experiments that involve such techniques as X-ray
crystallography are required to determine the structure of GIF and the GIF-GM-CSF
complex.
4.3.2. Analysis of glycosidic residues linked to GIF
In contrast to a number of soluble virus cytokine receptors that are glycoproteins
such as M-T7 (13% glycosylation, Talani et al, 1997) and M-Tl (12% glycosylation,
Lalani et al, 1999a) ofmyxoma virus, and cowpox virus CrmD (15% glycosylation,
Loparev et al, 1998), GIF does not appear to be glycosylated. Indeed it seems likely
that given that the observed and predicted molecular masses ofGIF are essentially
the same (28 kD), any contribution of carbohydrate (even O-linked) to GIF
molecular structure must be minimal. Unlike the human GM-CSFR a subunit that is
considered to modulate cellular responsiveness through differences in glycosylation
(Budel et al, 1993; Ding et al, 1995), GIF is a protein in which N-glycosylation is not
required for binding to GM-CSF in vitro. In addition, N-glycosylation of rovGM-
CSF is not associated with GIF-rovGM-CSF since, from ligand blotting analysis,
GIF was shown to bind both glycosylated and unglycosylated rovGM-CSF. In
contrast to the GM-CSFR a subunit, glycosylation ofGM-CSF is not required for its
biological activity (Kaushansky et al, 1989).
4.3.3 Factors affecting GIF-rovGM-CSF binding
Considerable rovGM-CSF-binding capacity was lost when GIF was exposed to
acidic pH. This was not recovered when the GIF solution was neutralised to pH 7.
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Acid-induced unfolding of proteins can result in loss of tertiary structure but with
retention of secondary structure. Narhi et al (1996) have shown that at acidic pH
(below pH 4) TNF-a not only disassociates from trimers to the monomeric form but
can convert from a native anti-parallel beta-sheet structure to an alpha-helix
structure. Such a loss of native tertiary structure may account for the loss ofGIF
activity observed during affinity chromatography where GIF is eluted at low pH
from the GM-CSF-Sepharose column.
Thermal disruption of the GIF complex by boiling appeared to be temporary with
much of the GM-CSF-binding activity recovered after the solution cooled. This
suggests that, in the absence of reducing agents or acidic conditions, the GIF
molecule can refold into the native conformation.
Formation of the GIF-rovGM-CSF complex appeared characteristic of ligand-
soluble receptor interactions, however a more detailed investigation into the binding
affinity ofGIF for its ligand(s) is described in the following chapter.
4.3.4. The role of the 43 kD protein in GIF-rovGM-CSF binding
The 43kD peptide that co-eluted with GIF from rovGM-CSF-Sepharose is not
required for GIF activity in vitro. It appears to be a ubiquitous protein present in
supernatant collected from a variety of cell types that include transfected and un-
transfected CHO cells and orf virus infected and uninfected FLM cells. From
Western blot analysis (carried out in the previous chapter) of samples collected from
virus infected cells at different times, the level of 43kD expression appears to mirror
that ofGIF. Whether the 43kD peptide has any definitive role in the expression and
secretion ofGIF remains unclear.
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CHAPTER 5




In the previous chapter, homo-tetrameric and homo-dimeric GIF complexes were
shown to bind rovGM-CSF. In this chapter, the binding specificity ofGIF was tested
against a range of cytokines and GM-CSF of different species.
Ovine recombinant cytokines and chemokines have been produced that are
biologically active (Entrican et al, 1989, 1996; Mclnnes et al, 1991, 1993, 1994;
Seow et al, 1993, 1994). This allows GIF reactivity with ligands other than GM-CSF
to be tested. The recombinant ovine cytokines and chemokines included in this study
were; IL-lp, IL-2, IL-3, IL-4, IL-5, IL-8, IFN-y, Stem cell factor (SCF), VEGF,
TNF-a, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory
protein la (MlP-la) and RANTES. These were expressed from CHO cells that had
been transfected with the pEE14 plasmid vector containing the respective cytokine
cDNAs. (see Section 2.4.1 and Mclnnes et al, 1991). These cytokines were tested for
their ability to compete with GM-CSF for binding with GIF as measured by the GM-
CSF clearance ELISA.
Since the heparin-binding domains of a number of chemokines are thought to be
involved in their binding by virus receptors, for example the M-T7 protein of
myxoma virus (Lalani et al, 1997), heparin was also tested for GIF-binding.
Alpha2-macroglobulin, a potent inhibitor of viral proteases (Menendez Aria et al,
1992; Kisselev et al, 1994; Ryan-Poirier and Kawaoka, 1993) was also included in
the competition ELISA to monitor for any proteolytic activity.
A second approach was based on the ligand blotting method described by
Schwabe et al (1988). In their report, the authors identified the human IFN-a
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Schwabe et al (1988). In their report, the authors identified the human IFN-a
receptor by probing nitrocellulose blots of SDS-PAGE-separated Burkitt lymphoma
cell extracts with 12:,I-IFN-a. In the present study, ligand blots of recombinant
cytokines separated by SDS-PAGE were probed with 12"I-GIF.
Orf virus is also capable of infecting humans (Groves et al, 1991; Yirrell et al,
1994b; Haig and Mercer, 1998) and it was important to determine whether GIF could
bind human GM-CSF. In order to test whether GIF reactivity was species-specific, a
number of commercially available recombinant cytokines of human and murine
origin were included in the analysis.
Finally, the binding affinity of 12~T-GM-CSF for GIF was measured in an assay
based on that described to measure IL-1 p-Il-1 P-receptor interactions in man (Dower
et al, 1985; Symons and Duff, 1990).
The specific aims of this study were;
1.) To investigate the ligand specificity ofGIF for cytokines and chemokines of
ovine origin.
2.) To determine whether this specificity is species restricted.
3.) To measure the binding affinity of the GIF-GM-CSF interaction.
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5.2. Results
5.2.1. Ligand specificity of GIF
A number of ovine cytokines, ovine chemokines. heparin and a2-macroglobulin
were tested for their ability to compete with GIF binding to rovGM-CSF as measured
by GM-CSF clearance ELISA (see Section 2.4.2.). Competitive ligand binding to
GIF was measured by a rise in GM-CSF levels detected by the ELISA as GIF-GM-
CSF binding was inhibited.
Only recombinant ovine IL-2 out of all potential ligands (tested at greater than
ten-fold molar excess to rovGM-CSF) demonstrated binding to GIF in the
competitive assay (p < 0.001 when compared with supernatant from CHO cell
culture (CHOUTF) that was included as a negative control sample, Fig. 5.1). In a
parallel control assay carried out in the absence ofGIF. the measurement of rovGM-
CSF by the ELISA was not affected by any other cytokine or chemokine.
5.2.2. Cross-species reactivity of GIF
The species range ofGIF reactivity was investigated (see Section 2.4.2.).
Recombinant murine, bovine and human GM-CSF and IL-2 samples were tested for
inhibition of GIF-ovGM-CSF reactivity (Fig. 5.2). GIF did not react with
recombinant IL-2 or GM-CSF from man or mouse but GIF did bind rbovGM-CSF (p
< 0.001 when compared with the GIF positive control). Binding to rbovIL-2 was
considerably lower (p < 0.05 ). The slight increase in O.D. (492nm) measured in
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GM-CSF ELISA (O.D. 492nm)
Fig. 5.1 GIF specificity by ligand competition assay.
The binding of ligands (labelled on the y-axis) to GIF (solid bar)
was measured by a rise in absorbance (O.D. 402nm, x-axis) as
rovGM-CSF clearance by GIF was inhibited. The cytokines and
chemokines tested in this assay were recombinant proteins
(100-200 ng/ml) and of ovine origin unless stated otherwise
(i.e. prefixes bo = bovine and hu = human).
Alpha2-macroglobulin, and heparin were used at between l-2pg/ml.
Recombinant ovine IL-2 was found to bind GIF ($ p < 0.001 when
compared with the GIF +ve control). Control samples included
supernatants from GM1-CHO. GM2-CF10 and untransfected
CHO (CHOUTF) cell cultures.
Cytokines were tested, in the absence of GIF (hatched bar), for any
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Fig. 5.2 Species specificity of GIF binding to various ligands.
Recombinant cytokines from sheep (ov), cattle (bov), mouse (mu)
and man (hu) were tested for inhibition ofGIF-rovGM-CSF
reactivity (solid bar) as measured by GM-CSF ELISA. Cytokines
were tested, in the absence ofGIF (hatched bar), for any
interference with rovGM-CSFdetection.
(Assay was carried out as described in Fig. 5.1)
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CSF was also seen in assays where GIF was absent and probably corresponds to low
level non-specific binding of the cytokines to the anti-ovine GM-CSF mAbs of the
ELISA. As already reported (Entrican et al, 1996), bovine GM-CSF was not detected
by the GM-CSF ELISA used in this study.
5.2.3. Ligand blot analysis
The recombinant ovine cytokines that bound GIF by competitive ovGM-CSF
clearance ELISA were identified and confirmed by ligand blot analysis (see Section
2.4.2.). This analysis was not performed on recombinant bovine GM-CSF and IL-2
due to lack of material.
Samples of human, murine and ovine cytokines were separated by 15% SDS-
PAGE under both reducing and non-reducing conditions and electro-transferred to
cellulose nitrate. I2;>I-GIF was used to probe the separated and immobilised proteins
(Fig. 5.3 A. and B.). 12~T-GIF bound only rovIL-2 and rovGM-CSF and was not
reactive with other ovine cytokines/chemokines or cytokines from mouse or man
tested in this study. No difference in l25I-GIF binding to rovIL-2 and rovGM-CSF
was observed when the cytokines were separated under reducing or non-reducing
conditions. In the presence of a 100-fold excess of unlabelled GIF as a specificity
control, 12:1-GIF binding to both rovIL-2 and rovGM-CSF was blocked (Fig. 5.3 C.
and D.)
5.2.4. The effect of rovIL-2 on GIF-rovGM-CSF reactivity
In order to investigate whether GIF bound both rovIL-2 and rovGM-CSF through
the same or proximal GIF binding site(s), increasing concentrations of rovIL-2 were
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Fig. 5.3 125I GIF-cytokine ligand blot analysis.
125I GIF was used to probe A) a range of ovine cytokines and
B) human, murine and ovine cytokines which were separated
by 15% SDS-PAGE and transferred to nitrocellulose membranes.
,25I GIF bound to rovGM-CSF (20kD + 24 kD) and rovIL-2 (27 kD).
As a specificity control, 10 nM of unlabelled GIF was used to
compete for 125I GIF binding to the cytokines (C and D).
The position of molecular weight markers (dashed arrows) are
indicated.
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Fig. 5.4 The effect of IL-2 on GIF-GM-CSF reactivity.
Increasing amounts of purified rovIL-2 (10-500 ng/ml, x-axis)
were tested for inhibition ofGIF clearance of an 8ng/ml spike of
rovGM-CSF in the GM-CSF ELISA (solid square). However,
the inhibition of GIF-GM-CSF binding (as shown by the rise in
O.D. (y-axis)) at saturating concentrations of rovIL-2
(200-500ng/ml) was shown to be incomplete (p < 0.001) when
compared with either the GIF - ve control for this experiment
(GM2-CHO supernatant O.D. (492nm) value of 1.42 +/- 0.02)
or with rovIL-2 and rovGM-CSF (8ng/ml) in the absence of GIF
(solid circle).
The value for the GIF positive control (GM1-CHO supernatant) in this
experiment was 0.098 +/- 0.002 (not shown).
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ELISA (Fig.5.4). Levels of purified rovIL-2 which were in 50-100 fold excess of the
rovGM-CSF spike failed to completely inhibit rovGM-CSF binding to GIF.
5.2.5. The affinity of binding of GIF to GM-CSF and IL-2
The affinity-binding ofGIF for rovGM-CSF and rovIL-2 was determined by a
soluble binding assay using i:bI-rovGM-CSF and 123I-rovIL-2 (Figs. 5.5 and 5.6).
Specific binding of either cytokine to GIF was determined by subtracting the counts
obtained by polyethylene glycol precipitation of each radio-labelled cytokine in the
absence ofGIF (see Section 2.4.3.). Scatchard analysis was applied to the mean
125values of the "I-ligand -GIF binding data that were collected from the soluble
binding assays. GIF bound to rovGM-CSF with a Kd of 369 +/- 52 pM (Fig. 5.7) and
to rovIL-2 with a Kd of 1040 +/- 79pM (Fig. 5.8). GIF bound to rovGM-CSF with a
higher affinity than it bound to rovIL-2.
Processing the same data by the Scatchard plot analysis tool provided with the
Equilibrate Ligand Binding Program (Version 1.2, G.J.C. Veenstra, Rockville, USA)
gave the binding affinity of rovGM-CSF to GIF as Kd = 374 +/- 175 pM. For rovIL-2
binding to GIF, the Kd was 1044 +/- 282 pM.
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Fig. 5.5 Equilibrium binding of 12:>I-rovGM-CSF to GIF in solution.
Purified GIF (100 ng) was incubated with increasing concentrations
of 12;>I-rovGM-CSF ( x-axis, pMoles). The PEG precipitated
GIF-123I-rovGM-CSF complex was collected onto fibre discs and
bound 12;,I-rovGM-CSF measured in a y-counter.
To determine the specific binding of 12?I-rovGM-CSF to GIF
(solid triangles and given as l23I-rovGM-CSF bound cpm on the
y axis), the binding of l25I-rovGM-CSF to the discs in the absence
ofGIF (solid squares) was subtracted from the total binding
(solid circles).
Data presented here represent the mean of quadruplicate samples.
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Fig. 5.6 Equilibrium binding of 123I-rovIL-2 to GIF in solution.
Purified GIF (100 ng) was incubated with increasing concentrations
of 125I-rovIL-2 ( x-axis, pMoles). The PEG precipitated GIF-12;T-rovIL-2
complex was collected onto fibre discs and bound 123I-rovIL-2 measured
in a y-counter.
To determine the specific binding of l23I-rovIL-2 to GIF (solid triangles),
the binding of 123I-rovIL-2 to the discs in the absence ofGIF
(solid squares) was subtracted from the total binding (solid circles).
Data presented here represent the mean of quadruplicate samples
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Fig. 5.7 GM-CSF-GIF binding: Scatchard plot analysis.
Scatchard analysis was applied to the mean of data collected
from three l2:,I-rovGM-CSF soluble binding assays and plotted
as the concentration of 123I-rovGM-CSF bound (x-axis, pM)
versus the ratio of 123I-rovGM-CSF bound/12;T-rovGM-CSF
free (y-axis, b/f). A linear best line fit was applied to the data
points in order to intercept both x-axis and y-axis (Origin,
Microcal).
The affinity of rovGM-CSF-GIF binding (Kd) was determined
from the modified Eadie-Scatchard equation (Segeh 1976):
[S]b/[S]f = - 1/Kd [S]b + n[E]/Kd
where [ S] = concentration of ligand, [S]b/[S]f = b/f and
n[E]t= the total concentration of ligand binding sites
(the intercept at the x-axis). The slope of any line plotted
through the points = -1/Kd and consequently the intercept
on the y-axis = n[E]t/Kd.
GIF bound rovGM-CSF with a Kd of 369 +/- 52 pM.
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Fig. 5.8 IL-2-GIF binding: Scatchard plot analysis.
Scatchard analysis was applied to the mean of data
collected from 123I-IL-2 soluble binding assays.
GIF bound ovIL-2 with a Kd of 1040 +/- 79 pM
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5.3. Discussion
5.3.1. Identification of the ligand specificity of GIF
A panel of recombinant ovine cytokines and chemokines from sheep were tested
for binding to GIF by a competition ELISA assay. GIF was shown to bind rovGM-
CSF with higher affinity than rovIL-2. Some poxvirus immunomodulatory proteins
such as the MT-7 (binds IFN-y and CXC, CC and C chemokines, Lalani et al, 1997)
and MT-2 (binds TNFa and inhibits virus-induced apoptosis, Sedger and McFadden,
1996) ofmyxoma virus and the 38 kD glycoprotein of tanapox virus (binds IL-2, IL-
5 and IFN- y, Essani et al, 1994) have the ability to bind and inactivate multiple,
sometimes apparently unrelated cytokines and this property represents an economical
way of controlling host immunity. Whilst no homology could be established between
GIF and any cytokine receptors identified to date, GIF appears to fit into this
category with its ability to bind both rovGM-CSF and rovIL-2.
The question arose whether rovGM-CSF and rovIL-2 shared the same binding
domain. The addition of a 100-fold excess of rovIL-2 to the reaction mixture was
shown to compete up to approximately 75% of the GM-CSF binding to GIF.
Kanakura et al, (1993) have reported that GM-CSF competed up to 75% with radio-
labelled IL-2 for binding to the (3 form of IL-2R that is expressed on the human
myeloid leukemia cell line, M07E, whereas no competition ofGM-CSF binding was
observed with IL-2 even at a 400-fold molar excess. This implied that whilst distinct
binding domains for either cytokine were present within the IL-2 receptor, the
binding of GM-CSF could sterically influence the binding of IL-2. Although this
evidence may suggest that the respective binding domains ofGIF for ovine GM-CSF
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and ovine IL-2 are not shared, in the absence of an assay system for ovine IL-2, the
reciprocal experiment whereby an excess of rovGM-CSF was tested for the effect on
GIF binding rovIL-2 was not carried out. Consequently the exclusivity or otherwise
of the GIF binding domains for ovGM-CSF and ovIL-2 remains uncertain.
Alternatively, the failure of an excess of rovIL-2 to completely inhibit GIF binding
rovGM-CSF may reflect the difference in binding affinities ofGIF for ovGM-CSF
and ovIL-2 or the effect of steric hindrance of one ligand by the other.
A structural comparison of human and ovine GM-CSF with human and ovine IL-2
(carried out by Colin Mclnnes) did not reveal any common features other than both
human GM-CSF and human IL-2 are members of the short chain, four a-helical-
bundle family of cytokines that also includes IL-4 (Von Feldt et al, 1994.). However
ovine IL-4 did not bind GIF.
5.3.2. Investigation into species specificity of GIF-Iigand binding
The binding ofGIF appears to be restricted to ovine and bovine GM-CSF and IL-
2. Although orf virus also infects humans, GIF did not bind human GM-CSF or
human IL-2. This suggests that the gene encoding GIF had been acquired through the
co-evolution of orf virus with sheep rather than with man. Whether the failure ofGIF
to bind human GM-CSF and human IL-2 could be associated with differences in the
pathologies of ovine and human infections described by Yirrell and Vestey (1994) is
unclear and warrants further investigation.
In spite of orf virus failing to infect cattle (Darbyshire and Huck, 1966), GIF did
bind bovine GM-CSF. (GIF also bound bovine IL-2 but at a lower level.) Further
investigation into GIF reactivity with bovine GM-CSF and IL-2 is clearly warranted.
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Whilst the amino acid sequence of ovine GM-CSF is highly homologous to the
published bovine sequence (80% identity, Leong et al, 1989) and human sequence
(80% identity, Cantrell et al, 1985), some conservation of sequence between ovine
and bovine GM-CSF is absent from the human sequence (Fig. 5.9). The sequences of
ovine GM-CSF and murine GM-CSF are less homologous with 57 % identity,
(Goughe/^/, 1985).
Ovine APTRQPSPVT RPWQHVDAIK EALSLLNDST TAAVMDETVE 40
Bovine P-NTA- H-S -D ND-*- 39
Human --A-S S- Q--E--N--Q --RR L-R E-N 40
Murine K--E MPVTLN-E- - 37
Ovine WSEMFDSQE PTCLQTRLEL YKQGLRGSLT SLTGSLTMMA 80
Bovine k K- --N--Q --M 79
Human -i l-- K-K-P 80
Murine NE-SFKK L--V KI FE NF- K-K-A-N-T- 77
Ovine SHYKKHCPPT QETSCETQII TFKSFKENLK DFLFIIPFDC 120
Bovine T--E P G--F- S--N D-- E 119
Human q p a --E LV 120





Fig. 5.9 Alignment of the amino acid sequences of GM-CSF from sheep, cattle, man
and mouse (adapted from Mclnnes and Haig, 1991).
The ovine sequence is given as the consensus with only those amino acids that are
different being shown for the other sequences. The dashes indicate complete identity
with the ovine sequence. Asterisks indicate amino acid deletions from the bovine and
murine sequences.
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Those regions of the human GM-CSF protein that are critical for species restricted
biological activity via its cellular receptor have been identified (Kaushansky et al,
1989). The regions encompassing amino acids 21-31 and 78-94 are considered
important (underlined, Fig. 5.9), with a single substitution ofArginine2' to glutamine
resulting in greatly reduced activity of the cytokine (Kaushansky et al, 1989). The
sequence of human GM-CSF differs from both ovine and bovine GM-CSF sequences
at amino acids 23 and 24 (bold type, Fig. 5.9) with neither change considered
conservative (Mclnnes and Haig, 1991). Whether this region of the ovine GM-CSF
protein contains the GIF binding domain would represent the basis for future study.
5.3.3. Analysis of binding affinities of GIF for rovGM-CSF and rovIL-2
In this study, the affinity ofGIF-rovGM-CSF binding was calculated as Kd = 369
pM. As yet there is no record of any GM-CSF- receptor proteins having been
characterised from ruminants. Consequently the activity ofGIF as a soluble cytokine
receptor cannot be directly compared with that of sheep GM-CSF receptors. A
soluble ovine IL-2-receptor alpha chain has been identified (Verhagen et al, 1992)
but with no structural similarity to the GIF protein. Nevertheless, human GM-CSF
and IL-2 receptors have been well characterised (Dipersio et al, 1990, 1991; Raines
et al, 1991; Brown et al, 1995 and Heaney et al, 1995) and for the purposes of this
study will be taken as representative of mammalian GM-CSF and IL-2 receptors.
The a subunit of human GM-CSFR (huGM-CSFRa) exists in both transmembrane
-anchored and soluble isoforms. The soluble isoform, a 55- to 60-kD glycosylated
protein, lacks the transmembrane and cytoplasmic domains of the intact receptor.
The soluble huGM-CSFRa binds to huGM-CSF in solution and has been shown to
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inhibit huGM-CSF biological activity in vitro (Brown et al, 1995; Monfardini et al,
1998). Soluble huGM-CSFRa has been reported to bind huGM-CSF in solution with
a dissociation constant range (Kd) of 500-3800 pM and when retained on the cell
surface with a Kd of 331 pM (Chiba et al, 1990; Khwaja et al, 1993.). If similar
soluble receptor-ligand interactions occur in sheep, then the antagonistic effect of
GIF on ovGM-CSF binding to its cellular receptor would be seen as significant,
particularly in the local environment of the responsive cell.
The receptor for IL-2 belongs to the same super-family of cytokine receptors as
GM-CSF. Like the GM-CSFRa, the alpha subunit of IL-2R is expressed as a soluble
or membrane-bound form. It has been proposed that soluble IL-2Ra (sIL-2Ra) could
negatively modulate local immune responses (Verhagen et al. 1994). Jacques et al,
(1987) have determined that the sIL-2Ra binds IL-2 with a dissociation constant (Kd
= 30 nM) identical to a low affinity cell-surface IL-2R (p55/ Tac antigen). This is in
contrast to the high affinity binding of IL-2 to the cell surface trimeric receptor
complex (Kd = 25 pM). From Scatchard analysis, the affinity ofGIF-rovIL-2 binding
was calculated as Kd = 1.04 nM. As with the GIF-rovGM-CSF interaction, the
binding ofGIF-rovIL-2 is again of higher affinity than that recorded for the soluble
IL-2Ra to IL-2 in man. Given that soluble forms of the cellular receptors for human
GM-CSF and human IL-2 are produced in general to downregulate normal GM-CSF
and IL-2 driven effector mechanisms, then clearly GIF has the potential to interfere
with similar immune response mechanisms in the sheep to the advantage of orf virus.




THE FUNCTION OF GM-CSF-INHIBITORY FACTOR
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6.1. Introduction
In Chapter 5, GIF was shown to bind both ovine GM-CSF and IL-2. However the
consequence of this binding on GM-CSF and IL-2 function was not determined. The
role ofGM-CSF and IL-2 in the anti-viral immune response to orf virus is unclear
but since they are both targeted by GIF, this suggests they may be important in sheep
cutaneous immunity to virus infection. The focus of this chapter was to investigate
whether GIF inhibited GM-CSF and IL-2 activity by binding to the cytokines and
preventing their interaction with their respective receptors.
Appropriate biological assays for ovine GM-CSF and ovine IL-2 were available
for this study. The effect ofGM-CSF on ovine bone marrow derived colony-forming
cells has been assessed in vitro. (Haig et al, 1990; Mclnnes et al, 1993; Haig et al,
1994). GM-CSF stimulated increased numbers of neutrophils, macrophages and
eosinophil colonies in soft agar haemopoietic clonogenic assays. In this study the
approach was to investigate firstly, whether GIF inhibited the binding of 12T-rovGM-
CSF to its receptor on the surface of neutrophils as measured by a cell binding assay
(based on Dower et al, 1985) and secondly, the effect ofGIF on the stimulation of
bone marrow haemopoietic cells by GM-CSF that is measured in a soft agar
clonogenic assay described by Haig et al (1994).
Ovine IL-2 stimulates T cell blast proliferation (Bujdoso et al, 1990). The assay
exploits the ability of IL-2 to stimulate the proliferation of sheep T cell blasts
(generated by antigen or mitogen (Con A) stimulation of lymphocytes) as measured
by a H-thymidine uptake assay. In the present study, the approach was to determine
firstly, the effect of GIF on 12:>I-rovIL-2 binding to IL-2 receptors on an enriched
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CD4+ T cell subset isolated from ovine lymph node and measured by the 125I-
cytokine-cell binding assay, and secondly, the effect ofGIF on IL-2 -induced
proliferation ofCD4+ T cell blasts transformed with Con A and measured by cellular
uptake of H-thymidine.
The aims of this study were;
1.) To determine whether GIF can block the binding ofGM-CSF and IL-2 to their
respective cellular receptors.
2.) To show that in binding both GM-CSF and IL-2, GIF can also block the
biological activities of the cytokines.
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6.2. Results
6.2.1. The effect ofGIF on cytokine-cell surface receptor interactions
In order to determine the effect ofGIF on the binding of rovGM-CSF and rovIL-2
to their respective cell surface receptors, two separate cell-binding assays were
developed (see Section 2.5.).
In the first analysis, the binding of increasing concentrations of 12:,I-rovGM-CSF
to GM-CSF receptors on neutrophils isolated from peripheral blood was measured.
In the second, l2'T- rovIL-2 binding to a predominantly CD4+ T cell population
(90%), isolated from mesenteric lymph node, was measured.
l2T-rovGM-CSF was found to bind to neutrophils in a dose-dependent fashion
(Fig. 6.1). This binding was inhibited across a range of l2"I-rovGM-CSF
concentrations (100-1000 pM) by the addition of 10 nM purified GIF. The addition
of 100 nM of unlabelled rovGM-CSF to the cell suspension served to demonstrate
the specificity of 12"I-rovGM-CSF binding. Neutralisation of GIF inhibition of 123I-
rovGM-CSF binding to its receptor on neutrophils was achieved by pre-treatment of
GIF with the rabbit anti-GIF (ralOl).
A similar level of inhibition by GIF on 12T-rovIL-2 binding to CD4+ T cells was
observed (Fig. 6.2). The specificity of both 12:>I-rovIL-2 — T cell binding and l25I-
rovIL-2-GIF binding was demonstrated by inclusion of 100 nM unlabelled rovIL-2
and 2 pg/ml ralOl respectively.
In order to compare the binding affinities of both cytokines for their respective
surface receptors with the affinities ofGIF for rovGM-CSF and rovIL-2 that were




























Fig. 6.1 Effect ofGIF on 12:>I-rovGM-CSF binding to neutrophils.
12:>I-rovGM-CSF was found to bind to neutrophils in a dose-
dependent fashion (solid circles). This binding (y-axis, cpm x 103^
was inhibited across a range of l25I-rovGM-CSF concentrations
(x-axis, pM) by the addition of 10 nM GIF (inverted solid triangles).
The addition of 100 nM of unlabelled rovGM-CSF (solid squares) to
the cell suspension served to demonstrate the specificity of
12:,I-rovGM-CSF binding. Specificity ofGIF-12:>I-rovGM-CSF binding
was shown by the neutralisation of GIF-125I-rovGM-CSF binding by
pre-treatment with the rabbit anti-GIF ralOl (solid upright triangles).
Data represent the mean of triplicate samples.
A further two independent experiments showed similar results.
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Fig. 6.2 Effect ofGIF on 12:>I-rovIL-2 binding to CD4+ T cells.
CD4+ T cells were isolated from mesenteric lymph nodes.
123I-rovIL-2 binding to CD4+T cells was measured (solid circles).
GIF (10 nM) was found to inhibit 125I-rovIL-2 binding across
the range of l2r,I-rovIL-2 concentrations tested (inverted triangles).
Unlabelled rovIL-2 (100 nM) and anti-GIF were included as
specificity controls for 12>I-rovIL-2 binding (squares) and GIF
binding (upright triangles) respectively.
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Fig. 6.3 Scatchard analysis of 123I-rovGM-CSF binding to
neutrophils.
Data from the mean of three assays of !2?I-rovGM-CSF binding to
neutrophils (Fig. 6.1) were converted to the Scatchard coordinate
system (as described for Fig.5.7).
Binding shown represents specific binding, with binding in the
presence of excess unlabelled rovGM-CSF subtracted from total
125I-rovGM-CSF binding.
The binding affinity of rovGM-CSF for GM-CSF cell surface
receptor on neutrophils was computed as Kd = 784 pM
Scatchard plot analyses applied to the individual data sets
showed a Kd range 718 to 850 pM.
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Fig. 6.4 Scatchard analysis of 12;,I-rovIL-2 binding to CD4+ T cells.
The data from the mean of three assays measuring specific
123I-rovIL-2 binding to CD4+ T cell blasts were converted to the
Scatchard coordinate system and the binding affinity of rovIL-2 for
its cell surface receptor calculated as Kd = 3.084 nM.
Scatchard plot analyses applied to the individual data sets showed
a Kd range 1.88 to 4.24 nM.
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performed on the data from both radio-labelled cytokine-cell binding assays (Figs 6.3
and 6.4). The binding affinity of rovGM-CSF for GM-CSFR on neutrophils was
calculated as Kd = 784 +/- 66 pM. From the equilibrium binding data, as outlined by
Porteu and Nathan (1990), the number of GM-CSF receptors present on sheep
polymorphonuclear cells was estimated at 4000 +/- 960 per cell. For IL-2 binding to
its receptor on CD4+ T cells the binding affinity was estimated as Kd = 3040 +/-
1200 pM. The number of IL-2 R molecules bound per cell was calculated as 5250 +/-
807 per cell.
6.2.2. The effect of GIF on GM-CSF and IL-2 function
i). RovGM-CSF
The effect ofGIF on rovGM-CSF activity was measured in a soft agar bone
marrow haemopoietic clonogenic assay (Fig. 6.5). The results of a dose response
experiment (typical of three repeat experiments) which measured the effect of
increased rovGM-CSF concentrations on the development of cell-colonies from 10"^
bone marrow cells cultured for 14 days in soft agar are outlined in Fig. 6.5a.
Maximum colony counts (73 +/- 2 colonies/10" cells) were obtained from cultures
treated with 460 pg/ml rovGM-CSF. No further increase in colony formation was
obtained with a 10-fold increase in rovGM-CSF concentration. The addition ofGIF
at 52 ng/ml and 520 ng/ml to the cultures inhibited the development of colonies from
cultures responding to rovGM-CSF to different degrees but was most noticeable for
both GIF concentrations when 460 pg/ml rovGM-CSF was used. The specificity of
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Fig.6.5 The effect of GIF on rovGM-CSF activity in the soft-agar bone marrow
clonogenic assay.
A) Dose response experiment measuring the effect of increasing rovGM-CSF
concentration alone (x-axis, solid squares) and in the presence of 50 ng/ml
(solid circles) and 520 ng/ml (solid triangles) of GIF on the development of cell
colonies (y-axis) from 105 bone marrow cells cultured for 14 days in soft agar.
The inhibitory action ofGIF was neutralised by pre-treatment ofGIF with
anti-GIF (solid inverted triangles), which had no effect on its own on colony
development (open triangles).
B) Direct comparison of day 14 colony counts (x-axis) from cultures that were
treated with rovGM-CSF (460 pg/ml), GIF (520 ng/ml) and rovIL-3 (50 ng/ml).
GIF is shown inhibiting the stimulation of rovGM-CSF ( § p < 0.005 when
compared with rovGM-CSF alone). Controls included cultures that were set up
in the presence of medium, GIF or anti-GIF alone.
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GIF specificity was further examined in the comparative analyses of colony counts
from a number of repeat bone marrow cultures set up in either rovGM-CSF (460
pg/ml) or rovIL-3 (50 ng/ml) (Fig. 6.5B). Whilst GIF was shown to inhibit colony
development stimulated by rovGM-CSF (p < 0.005 when compared with colony
numbers from cultures set up in rovGM-CSF alone), it had no significant effect on
rovIL-3-induced colony development (p >0.1). Both GIF and anti-GIF were tested
for any direct effect on colony formation. None was found.
ii). RovIL-2
The effect of increasing rovIL-2 concentrations (20-320 ng/ml) on CD4+ T cell
■j
proliferation was measured by the incorporation of H-thymidine into dividing cells
(Fig. 6.6A). T cell proliferation in response to rovIL-2 was dose-dependent. GIF
inhibition of JH-thymidine uptake by T cells was particularly significant at 40 and
160 ng/ml rovIL-2 concentrations (p < 0.005 when compared with cultures treated
with rovIL-2 alone) but less so at 320 ng/ml (p < 0.05). The presence of anti-GIF
neutralised the inhibitory effect ofGIF.
Further analysis of CD4+ T cell proliferation was carried out to compare cultures
grown in the presence of rovIL-2 (40ng/ml) and GIF (520ng/ml) with control
cultures maintained in the presence of either GIF, anti-GIF or medium alone (Fig.
6.6B). GIF inhibited rovIL-2 stimulation of T cells (p < 0.001 when compared with
cultures treated with rovIL-2 alone). H-thymidine uptake by control T cell cultures
maintained in the presence ofGIF or anti-GIF did not exceed the uptake by those
cells grown in medium alone. Anti-GIF had no significant effect on H-thymidine
uptake by T cell cultures. The counts observed from cultures maintained in GIF
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Fig. 6.6 GIF inhibition of rovIL-2 stimulation of CD4+ T cells.
A) The effect of increasing rovIL-2 concentration (x-axis, nM) on CD4+ T cell
proliferation (y-axis, cpm 3H-thymidine uptake) was measured 48 hours later
(solid squares). Activation ofCD4tT cells by rovIL-2 was compared in the
presence ofGIF +/- anti-GIF. GIF (520 ng/ml solid circles) was shown to inhibit
rovIL-2 driven CD4+ T cell proliferation across the range of rovIL-2 concentrations
used. Values given represent the mean cpm of 3H-thymidine incorporated into
dividing cells in quadruplicate wells and standard error of the mean.
B) Comparison of CD4+ T cell proliferation (x-axis) in the presence of rovlL-2
(40ng/ml) and GIF (lOOng/ml). GIF is shown inhibiting the stimulation of rovIL-2
(§ p < 0.001 when compared with rovlL-2 alone). Cultures maintained in the
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GIF reacting with traces of endogenous IL-2 present in the cultures (bovine IL-2




6.3.1. GIF inhibition of cytokine binding to cell surface receptors
In this chapter GIF was shown to inhibit the binding of rovGM-CSF and rovIL-2
to their respective cellular receptors on neutrophils and CD4+ T cells. The binding
affinities (Kd) of rovGM-CSF for cell surface GM-CSF receptor (784 +/- 66 pM) and
rov IL-2 for IL-2R (3064 +/- 1176 pM) were compared with the binding affinities
calculated for GIF binding rovGM-CSF (369 +/- 52 pM) and rovIL-2 (1040 +/- 79
pM) in solution and described in Chapter 5. Given the apparent higher affinities of
both cytokines for GIF, it is evident that if these values that were obtained in vitro
reflect ligand-receptor binding in vivo, then GIF reactivity towards either cytokine in
solution would be favoured over the interaction of the cytokine with its natural
receptor.
Little is known concerning cytokine-receptor interactions in sheep but the range
of Kd values that were obtained for rovGM-CSF- GM-CSF cell surface receptor and
rovIL-2- IL-2 cell surface receptor interactions correspond to those values reported
for GM-CSF and IL-2 binding to low affinity sites on human and murine neutrophils
and T cells. For example, Khwaja et al, (1993) have identified low affinity receptors
on human neutrophils that bound GM-CSF with a Kd = 1800 +/- 300 pM and at a
density of 8600 +/- 1150 receptors per cell. This is in contrast to the high affinity
'y
GM-CSF transmembrane receptor that has been reported at lower density (2-5 xlO )
on cells of the granulocyte and monocyte lineages and that binds human GM-CSF
with a Kd in the range 5-100 pM (Griffin et al, 1990, Brown et al, 1995, Murray et
al, 1998). In spite of a two-site model of high and low affinity GM-CSF receptors
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expressed by human monocytes (Elliot et al, 1989), the experimental data showed
only one class of receptor for ovGM-CSF present on ovine neutrophils. This is
consistent with the work of Onetto-Pothier et al, (1990) who identified a single class
of GM-CSF receptors on human neutrophils (albeit of intermediate affinity, Kd =
100-160 pM).
Similarly, the rovIL-2-cellular receptor interaction appeared to follow the one
site-low affinity model with little indication of higher order rovIL-2-receptor
binding. As with GM-CSF-receptor interactions, little is known regarding IL-2-
receptor dynamics in the sheep. From human studies, three distinct IL-2 receptor
subunits with different binding affinities have been identified (Taniguchi and
Minami, 1993, Caligiuri et al, 1990; Vanham et al, 1994). In the cell-binding assay,
unlike the proliferation assay, the CD4+ T cells had not been activated with ConA,
and it is possible that those cells expressed only low affinity ovIL-2 receptors. This is
in contrast to more activated/blast transformed CD4" T cells that may express
receptors of high, low and intermediate binding affinities (Vanham et al, 1994). The
IL-2 -receptor status of ovine CD4^ T cell blasts warrants future investigation.
Whatever the nature of the cytokine receptors present on the effector cells
targeted by orf virus in vivo, it is probable that GIF in solution can compete
successfully with cell surface receptors exhibiting higher binding affinities like the
soluble forms of both GM-CSF and IL-2 low affinity receptors (Brown et al, 1995
and Jacques et al, 1987 respectively).
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6.3.2. GIF inhibition of cytokine biological function
i). GM-CSFfunction
GIF was shown to inhibit GM-CSF-driven myelopoiesis from bone marrow
precursor cells in the soft agar clonogenic assay. Beside its haematopoietic action,
GM-CSF also has a stimulatory effect on mature neutrophil, eosinophil and
macrophage function particularly those related to recruitment and activation at the
sites of inflammation (Rapoport et al, 1992; Gagnadoux et al, 1997; Bernasconi et al,
1995). The data from this study suggests that GIF expressed by infected cells could
also block GM-CSF and IL-2 stimulation of responder cells recruited to the site of
infection. GM-CSF alone and in concert with IL-lp and TNF-a has also been shown
to mediate in the accessory cell function of epidermal Langerhans cell (immature
DC) (Steinman, 1988; Heufler et al, 1988a and b). This accessory function of
Langerhans cells involves the uptake and processing of antigens, followed by
migration to lymph nodes where they interact with T cells (King and Katz, 1990).
Thus, GIF blocking ofGM-CSF function might also result in the failure of DC to
activate the T cell mediated immune response.
ii). IL-2function
In this study GIF was shown to inhibit IL-2-driven T cell proliferation. Apart
from promoting T cell proliferation at sites of inflammation and within lymph nodes
in vitro (Egan et al, 1996; Haig et al, 1996e), IL-2 has been shown to be responsible
for human T cell and natural killer cell chemotaxis (Robbins et al, 1986; Cao et al,
1998). In vivo, IL-2 was shown to mediate the infiltration of neutrophils into sites of
inflammation in mice (Tang et al, 1997). In each study, chemotaxis could be
neutralised by anti-IL-2 antibodies.
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6.3.3. Summary
By targeting both GM-CSF and IL-2, orf virus, through the action ofGIF, has the
potential to block their biological activities that may either directly or indirectly
regulate cell mediated anti-viral immunity.
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CHAPTER 7
TISSUE DISTRIBUTION OF GM-CSF-INHIBITORY FACTOR
DURING ORF VIRUS REINFECTION
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7.1. Introduction
In this study, the in vivo localisation of GIF in the skin of orf virus infected sheep
and in lymph either entering (afferent lymph) or exiting a local draining lymph node
was mapped. The immunohistological analysis ofGIF in fixed and paraffin-
embedded orf skin biopsy material is described. This investigation follows the same
methodology employed by Jenkinson et al (1992) to define the changes in cutaneous
T and B lymphocyte populations which follow experimental infection with orf virus.
In the present study, sections were tested for the presence of orf virus antigen and
GIF protein, using respectively, an anti-orf virus antigen mouse monoclonal antibody
(Housawi et al, 1998) and mouse and rabbit polyclonal antibodies raised against
purified recombinant GIF (described in Section 2.6.1.). In addition afferent and
efferent lymph samples collected at various times from orf virus reinfected and
control scarified sheep (as part of an earlier study) were analysed for the presence of
GM-CSF and GIF by ELISA.
The aims of this study were;
1.) To determine whether GIF could be detected in orf virus-infected skin and lymph,
and if so where in the skin and in which lymph compartment.
2.) To investigate whether the expression ofGIF by orf virus-infected cells in vivo is




Serial sections of sheep skin were taken from biopsies taken at various times
before and during an orf virus reinfection and analysed for the presence of orf virus
antigen (39kD envelope protein) and GIF (see Section 2.6.1.). Neither orf virus
antigen nor GIF was detected in skin sections taken from experimental animals prior
to orf virus reinfection (Fig. 7.1) nor control animals where PBS instead of live orf
virus was applied to the scarification lines. Attempts to stain sections for GM-CSF
with the anti-rovGM-CSF mAbs 3C2 and 8D8 proved unsuccessful.
In the experimental animals, staining for orf virus antigen was most intense on
day 3 (Fig. 7.2A) and on day 5 (Fig. 7.3A) after reinfection but declined in intensity
thereafter. Staining was observed in the region of epidermis close to the area of
scarification and also in underlying hair follicles. In sections taken early in the course
of reinfection, orf virus antigen was localised to the ballooning/vacuolated and
degenerating epidermis seen in the outer stratum spinosum beneath the corneum and
lining the hair follicle at the edge of the expanding lesion. A heavy infiltration of
leucocytes (with intensely stained nuclei) was observed in the dermis beneath the
lesion. By day 7 (Fig7.4A), staining for orf virus antigen was less intense and
localised to the periphery of the original lesion where the epidermis had disintegrated
into a large pustule heavily infiltrated with neutrophils. Sections taken on day 9,
showed orf virus antigen present in a scab that had formed from the remnants of
pustules above a highly proliferative layer of epidermal cells. By day 14, the scab
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A)
Fig. 7.1 Immunohistological staining of sheep skin for orf
virus antigen and GIF prior to reinfection with orf virus.
Serial sections from a skin biopsy specimen taken from
the inner thigh prior to challenge with orf virus and tested
for A) orf virus antigen using mAb 10E6 (reactive against
the 39kD envelope protein, Housawi et al, 1998) and
B) GIF using an IgG fraction ofmouse anti-GIF serum,
muLTl.
Staining for either orf virus antigen or GIF was not observed.





Fig. 7.2 Immunohistological staining of orf virus-infected skin at day 3
after reinfection.
A) A section from a skin biopsy specimen stained for orf virus antigen.
Orfvirus ( intense dark brown staining) is shown present in the
degenerating epidermis lining the hair follicle (F). The virus has spread
laterally along the outer layers of the stratum spinosum (E) on both sides
of the lesion.
B) A serial section to (A) stained for GIF and showing GIF present in the
infected epidermis with less intense staining observed throughout the
underlying dermis (D).
C) Section incubated with IgG fraction from pre-immune mouse serum
as a negative control. (Immunoperoxidase; haematoxylin and eosin, x 112)
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A)
Fig. 7.3 Immunohistological staining of orf virus-infected skin at day 5 after
reinfection.
A) A section from a skin biopsy specimen taken around the area of
abraded skin (S) and stained for orfvirus antigen. The localisation of orf
virus (dark brown staining) is evident in the ballooning degenerating
epidermis in the outer stratum spinosum (E), and lining the hair follicle (F).
B) A serial section of (A) stained for GIF using muLTl. This section shows
weak staining for GIF distributed throughout the tissue but with more
intense staining (G) localised to the infected epidermis. C) A further serial
section was incubated with an IgG fraction from pre-immune mouse serum
as a negative control. (Immunoperoxidase; haematoxylin and eosin, x 112)
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Fig. 7.4 Immunohistological staining of orfvirus-infected skin at day 7 after
reinfection.
A) A section taken and stained for orf virus antigen. Staining for orfvirus
antigen is still strong but not so extensive as in the section taken on day 5.
B) A serial section of (A) stained for GIF and showing reduced levels ofGIF
present in the epidermis of the lesion.
C) Section incubated with an IgG fraction from pre-immune mouse serum as
a negative control. (Immunoperoxidase; haematoxylin and eosin, x 112)
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A)
Fig 7.5 Immunohistological staining of orf virus-infected skin at day 9 after
reinfection.
(A) Orf virus antigen was detected only within the newly formed scab (S).
The remnant ofpustules form a scab above a highly proliferative layer of
epidermal cells (E).
(B) Trace amounts ofGIF (G) were only detected in those areas of scab
staining for orfvirus antigen. Note the columns of epidermal cells (E)
growing out of the stratum basale into the dermis and towards each other.
(C) Section treated with pre-immune mouse IgG fraction as control.






Fig. 7.6 Immunohistological staining of sheep skin at day 14 after orfvirus
reinfection.
Serial sections taken at day 14 after orfvirus reinfection and stained for
A) orf virus antigen and B) GIF. A further section C) was included as
a negative control (IgG fraction ofpre-immune mouse serum).
Orf virus antigen and GIF were not detected in sections taken at this time.
The new epidermis is still hypertrophied but not yet fully cornified
particularly around the site of the old lesion (P). Inflammatory cells can
still be seen in the dermis underlying the site of the lesion.
(Immunoperoxidase; haematoxylin and eosin, x 112)
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had sloughed off and with it the newly replicated orf virus. Orf virus antigen was not
detected in these sections.
Staining for GIF was carried out initially with ralOl, ral61 and muLTl. Non¬
specific staining was observed with ral01-treated control sections and consequently
its use was discontinued. GIF was detected in sections taken on day 3 through to day
9 by both ral61 and muLTl. Sections presented are stained with muLTl. On day 3
after reinfection (Fig. 7.2B), heavy staining for GIF was observed in those areas of
infected epidermis in the outer stratum spinosum and lining the hair follicles. There
was also some staining present in the dermis immediately adjacent to the infected
epidermis. By day 5 (Fig 7.3B), staining for GIF appeared less intense than on day 3
but with the most intense staining for GIF again coincident with that for orf virus
antigen. GIF was also detected in the dermis underlying and adjacent to infected
cells. GIF staining was much reduced by day 7 (Fig. 7.4B). It was most noticeable in
the area of the resolving lesion coincident with orf virus antigen and also in and
around the periphery of the newly formed pustules/scab. By day 9 (Figs 7.5B), with
the resolution of the lesion in progress, only trace amounts ofGIF were detected in
those areas of scab containing orf virus (as antigen) and in the process of sloughing
off. Neither GIF nor orf virus antigen was detected in sections taken on day 14 after
infection.
7.2.2. Analysis of lymph for GIF activity
GIF activity was measured in afferent and efferent lymph plasma taken at various
times after orf virus reinfection (see Section 2.6.2.). Supernatants from cultured
afferent and efferent lymph cells were also tested for the presence ofGIF.
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GIF was detected in afferent lymph plasma samples (Fig. 7.7A) but not in efferent
lymph plasma samples (Fig. 7.7B) from reinfected animals. GIF was not present in
either afferent or efferent lymph plasma samples from control scarified animals or
those that were injected intradermally with UV-inactivated virus (Fig. 7.7B).
Moreover, GIF was not detected in supernatants from cultured afferent or efferent
lymph cells. In afferent lymph, maximum GIF activity was measured in samples
taken at days 5 and 6 from all three animals tested. Note that the lower O.D. [450nm]
seen with sheep no. 1215 reflected a lower GM-CSF spike of 4ng/ml. As observed in
the assays carried out on recombinant GIF, anti-GIF (ralOl) was shown to neutralise
the GM-CSF-binding capability of viral "natural" GIF.
The levels ofGM-CSF in lymph plasma were measured by ELISA at various
times after orf virus reinfection (Fig. 7.8). GM-CSF content of afferent lymph plasma
was seen to vary between animals. Reduced levels in all 3 sheep were detected in
samples taken between days 4 and 7 after reinfection. The biphasic GM-CSF
response as described previously (Haig et al, 1996e, 1999) was clearly seen in
samples collected from sheep no. 1215 (p < 0.005 value for reduction in GM-CSF
levels when compared with pre-challenge levels). Such a GM-CSF response was not
seen in efferent lymph collected from two orf virus infected sheep (sheep nos. 1118
and 1126). After an early rise, GM-CSF levels were observed to decline gradually as
the infection was resolved.
Control sheep (358 and 567) challenged with UV-inactivated orf virus displayed
considerable variation in afferent lymph GM-CSF content. Whereas the GM-CSF
response in afferent lymph of sheep no. 358 showed some similarity to the biphasic
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Fig. 7.7 GIF activity measured in lymph plasma from samples taken before
and after orf virus re-infection.
Lymph plasma samples were spiked with rovGM-CSF at 8ng/ml
(sheep nos. 1134, 1225, 1118, 358 and 567) or 4ng/ml (sample nos. 1215
and 1126) and tested for GIF activity by ELISA.
A) GIF activity (open symbols) measured in afferent lymph samples
(sheep nos. 1134,1215 and 1225). Addition of anti-GIF (solid symbols) was
found to neutralise lymph plasma GIF activity.
B) Analysis of efferent lymph plasma (open symbols) from reinfected sheep
(1134 and 1126) and afferent lymph plasma (crossed symbols) from control
sheep ( 358 and 567; challenged with UV-inactivated orf virus) for GIF activity.
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Fig. 7.8 Detection ofGM-CSF in lymph plasma from samples taken
before and after orf virus re-infection.
GM-CSF concentrations (y-axis, pg/ml) were measured by ELISA at
various times after orf virus re-infection in A) afferent lymph plasma
samples (sheep nos. 1134, 1225 andl215) and B) efferent lymph
plasma samples (sheep nos. 1118 and 1126). Afferent lymph samples
from control sheep (358 and 567) which were challenged with UV-
inactivated orf virus were also assayed.
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observed in lymph plasma from the other control animal (sheep no. 567) did not.
Efferent lymph from control animals was not tested. In addition, due to the loss of
material, GM-CSF was not measured in supernatant from cultured afferent and
efferent lymph cells for this experiment.
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7.3. Discussion
7.3.1. GIF in orf virus-infected skin
GIF was detected by specific antibody in sections taken from skin during an orf
virus reinfection. Staining for GIF observed on day 3 through to day 7 coincided with
the period ofmaximum virus replication as observed by the presence of virus
antigen. Not only was GIF present in the area of regenerating epidermis that was the
site of viral replication as shown by the staining for orf virus envelope antigen, but
during this period GIF was also detected in the dermis adjacent to and underlying
this site of infection. This indicates that it is secreted from infected cells.
Counterstaining with hematoxylin revealed that the area of dermis, underlying
infected cells, was infiltrated with leucocytes. Phenotypic analysis of orf virus-
infected cells in sheep skin has shown that CD4+ T cells in particular of the
lymphocyte subsets, accumulate in large numbers adjacent to and underlying the site
of the lesion (Haig et al, 1996d. 1997). Since these cells are the principal source of
GM-CSF and IL-2 in afferent and efferent lymph after orf virus infection, it is likely
that both cytokines are produced in sheep skin as part of the host immune response to
orf virus reinfection. Indeed, mRNA encoding both GM-CSF and IL-2 has been
detected in sheep skin biopsy specimens obtained during orf virus infection (Haig et
al, 1996c). Thus, it is highly probable that the release ofGIF during the period of
viral replication (days 3-7 of an orf virus reinfection), would counteract at least part
of the host cellular response due to the production ofGM-CSF and IL-2 in the
vicinity of the lesion site.
Whilst IL-2 has been implicated in the immune response to orf virus (Haig et al,
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1996c and e, 1997; Lear, 1995; Lear et al, 1996) the role of GM-CSF is less clear.
GM-CSF stimulates the recruitment and activation of neutrophils and macrophages
either directly or indirectly. Both of these cell-types are present in orf lesions.
Another possible point ofGIF intervention would be GM-CSF regulation of antigen
presentation by dendritic cells. Haig et al (1995a) have shown that GM-CSF and
TNF-a are involved in the recruitment of Langerhans cells and other DC to the ovine
dermis. Interestingly, a feature of orf virus infection is the dense network of DC that
surrounds the lesion (Jenkinson et al, 1991). The inhibition ofGM-CSF in the
vicinity of orf virus infected epidermal keratinocytes could affect DC function,
especially their role in antigen presentation to effector T cells and the induction of
the cell -mediated immune response. Whatever the origin of the GM-CSF circulating
through orf virus infected tissue, GIF has the capacity to inhibit GM-CSF function.
7.3.2. GIF in afferent lymph draining orf virus infected skin
After orf virus reinfection of sheep, GIF was detected in afferent lymph plasma
samples that had low levels ofGM-CSF and which corresponded to the period of
maximum viral replication in the epidermis (Haig et al, 1996c). Orf virus has not
been detected in lymph cells and GIF was not detected in supernatants taken from
lymph cells in culture. This confirms that GIF is produced locally at the site of
infection as a soluble mediator and appears in the afferent lymph plasma.
GIF was not detected in efferent lymph and this indicates that GIF either does not
pass through the lymph node into efferent lymph or is diluted out by the large
volume of efferent lymph that passes out of the node and is mainly derived from
blood. As in infected skin, the inhibitory action ofGIF on circulating IL-2 and GM-
208
CSF in afferent lymph or those cytokines in the lymph node remains undefined. Orf
virus-specific CD8T cytotoxic T cells that are directly cytotoxic (effector rather than
precursor CTL) for virus infected autologous epidermal cells are also enriched in
afferent lymph (Haig et al, 1996b). Any mediation of CTL function by IL-2 would
therefore constitute a target for GIF activity. Another possible target for GIF
inhibition is a migrating population of dermal dendritic cells that transport antigen
from the skin to the paracortical areas of the draining lymph node and are potent
antigen-presenting cells for T cells in both primary and secondary immune responses
(Bujdoso et al, 1989; McKeever et al, 1991). These afferent lymph dendritic or
veiled cells (ALDC) have been shown to be stimulated to grow in culture in response
to GM-CSF and TNF-a but not GM-CSF on its own (Haig et al, 1995a). It is
suggested however that GM-CSF is required for the acquisition of accessory function
by ALDC as measured by an increase in CD4+ T cell autologous proliferation (Haig
et al, 1995a).
7.3.3. GIF and the host immune response
By targeting GM-CSF function, GIF has the capability of regulating the
migration, differentiation and the accessory function of dendritic cells in the skin and
afferent lymph. In addition, GIF may also affect neutrophil and macrophage
function. Similarly the clearance of IL-2 by GIF may also serve to down-regulate or





In this study, the characterisation of the novel orf virus immunomodulatory
protein, GM-CSF-inhibitory factor (GIF) has been described. GIF is the product of a
gene located within the right terminal region of the viral genome, in an area
associated with non-essential genes in poxvirus genomes. GIF has been expressed as
a recombinant protein of 28 kD that associates with itself to form dimers and
tetramers under physiological conditions. The dimer and tetramer forms ofGIF are
biologically functional, binding and inhibiting the activities of the ovine cytokines
GM-CSF and IL-2. GIF is of in vivo relevance as it is produced by virus-infected
cells in orf lesions and is detected in afferent lymph plasma draining the infection
site. GIF is therefore a novel member of a growing family of immunomodulatory
proteins produced by DNA viruses (Alcami and Koszinowski, 2000; McFadden et al,
1998). In orf virus it is one of several immuno-modulatory proteins that include a
viral homologue of IL-10 (vIL-10, Fleming et al, 1997), and a interferon resistance
protein (vIFNR, Mclnnes et al, 1998) and proteins active in inflammation such as
vascular endothelial growth factor (vVEGF, Lyttle et al, 1994). It is probable that the
GIF gene has been acquired during the co-evolution of orf virus and its host to
function in a co-ordinated fashion with other immuno-modulatory genes and their
products to interfere with host immunity and gain enough time for the virus to
complete its life cycle in infected epidermal cells and produce infective progeny
virions.
Studies carried out previously at Moredun Research Institute examined the
immune response to orf virus in the skin and lymph of infected sheep. It was
demonstrated that in both primary and secondary infections, there was an influx of
immune and inflammatory cells into the dermis underlying the infected epidermis,
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that were activated and produced cytokines and effector molecules typical of an anti¬
viral response (Jenkinson et al, 1990, 1991; Lear et al, 1996; Haig and Mercer,
1998). In spite of this vigorous immune and inflammatory response, orf virus is
capable of reinfecting its host and replicating. Immunomodulatory proteins encoded
by orf virus genes that target host defence mechanisms are probably a major factor in
virus survival.
Binding ofGM-CSF and IL-2 by GIF could interfere with immune and
inflammatory responses at several levels. GM-CSF is produced by a wide variety of
tissue types, including fibroblasts, endothelial cells, T cells, macrophages,
mesothelial cells, epithelial cells and many types of tumor cells, in response to
inflammatory mediators, such as IL-1, IL-6, TNF or endotoxin, (Griffin et al, 1990;
Baldwin, 1992; Groves et al, 1996). GM-CSF stimulates the proliferation and
maturation ofmyeloid progenitor cells in haemopoiesis (Clark, 1988), as well as
functionally activating mature neutrophils, eosinophils, and monocytes (Ruef and
Coleman, 1990; Burdach et al, 1991; Smith et al, 1995; Dale et al, 1998; Yagisawa
et al, 1999). Haig et al (1995b) reported that the intradermal injection of recombinant
ovine GM-CSF resulted in the accumulation over five days ofMHC Class II+
dendritic cells at the injection site, as well as increased numbers of neutrophils,
eosinophils and lymphocytes. In vitro, Hu and Yasui (1997) found that GM-CSF
suppressed anti-Fas antibody-induced apoptosis in mature human neutrophils and
maintained their function of superoxide production and enzyme release in response
to the invasion ofmicro-organisms.
GM-CSF is involved in the early stages of immune responses in the tissues
particularly in regulating the differentiation and activation of antigen-presenting
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dendritic cells, the most important cell type for the induction of primary T cell
responses (Tarr, 1996; Stewart-Akers et al, 1993). In sheep, Haig et al (1995a)
reported that together with TNF-a, GM-CSF supports the survival and growth in
culture of afferent lymph DC which were found to retain MF1C class II and ovine
CD1 antigen expression and accessory function for antigen presentation to T cells.
Vaccination ofmice with irradiated tumour cells producing GM-CSF led to a ten¬
fold increase in DC infiltrating the vaccination site when compared with control sites
vaccinated with p-galactosidase-producing cells (Kielian et al, 1999).
Immunohistochemical analysis of the vaccination sites suggested that GM-CSF,
through the local production of the chemokine MlP-la, was responsible for the
recruitment of DC (Kielian et al, 1999).
IL-2, a T-cell derived lymphokine that induces proliferation of antigen- or
mitogen-stimulated T cells, was first described as "T-cell growth factor" by Morgan
et al. in 1976. Inaba et al (1983) reported that in culture, DC induced T cells to
produce and become responsive to IL-2. CD4+ T helper cells and CD8+ CTL both
produce IL-2 (Farrar et al, 1982). CD4+ T cells are thought to "help" CTL by
producing IL-2 (Swain et al, 1991). In addition, IL-2 induces the production of IFN-y
(Kasahara et al, 1983). The stimulation ofCTL and IFN-y production, along with the
activation ofNK cells by IL-2 (Baume et al, 1992) are features of an anti-viral
response.
In addition to the stimulation of T cell and NK cell activation and proliferation,
IL-2 directly triggers the responsive T cells to release B cell helper factors (Inaba et
al, 1983; Glassman, 1989; Farner et al, 1997). Purified natural or recombinant
human IL-2 in the absence of exogenous antigen or mitogen has been shown to
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induce the differentiation and activation of lymphokine-activated killer (LAK) cells
from peripheral blood lymphocytes. LAK cells show an extensive target cell range
and are capable of killing NK-resistant human tumour cells (Grimm et al, 1991).
However the immunological consequences of IL-2 stimulation may be more complex
than the mediation of T cell growth.
Both GM-CSF and IL-2 are members of the short chain, 4-a-helical-bundle
family of cytokines that also includes IL-4 (Von Feldt et al, 1994). However GIF did
not bind rovIL-4. A comparison of the ovGM-CSF and ovIL-2 sequences did not
reveal any obvious feature other than some similarity (29% in a 38 amino acid
overlap) towards the N-terminus of each of the proteins. Interestingly, this region of
ovGM-CSF sequence encompasses the domain (amino acids 21-31 of the mature
peptide) which is considered important in GM-CSF binding to its receptor in humans
2.3
(Kaushansky et al, 1989). In addition, the conservation of amino acids Leucine" and
Serine24 in GM-CSF of sheep and cattle that is not present in human GM-CSF may
reflect the failure ofGIF to bind human GM-CSF. Construction ofmutant human
and ovine recombinant GM-CSF with appropriate substitutions at amino acids 23 and
24 would allow this to be tested experimentally.
The binding ofGIF to both ovine GM-CSF and ovIL-2 and the blocking ofGIF-
rovGM-CSF interaction by rovIL-2, whilst reflecting the different binding affinities
ofGIF for each cytokine, suggests that the binding domain(s) for each cytokine is
shared or overlapping and can be sterically inhibited. GM-CSF has been shown to
compete with IL-2 for binding to IL-2 receptors on the myeloid leukemia cell line,
M07E, suggesting that human GM-CSF and human IL-2 may share a common
receptor (Kanakura et al, 1993). Human keratinocytes have been shown to express a
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cell surface IL-2 like molecule which binds the soluble IL-2 receptor a and may be
involved in the activation of Langerhans cells and infiltrating T cells both of which
carry surface IL-2 receptors (Dreno et al, 1989a and b). Interestingly, the authors
describe the blocking of this IL-2 receptor-IL-2 binding by anti-IL-2 monoclonal
antibodies that recognise epitopes that may be shared by both IL-2 and GM-CSF.
Although the receptor proteins for ovine GM-CSF have yet to be characterised,
there is no evidence of any structural similarity between GIF and any known
mammalian cytokine receptor. Apart from GIF, the only other natural inhibitor of
GM-CSF identified to date is a secreted form of the human GM-CSF receptor a-
chain (Brown et al, 1995; Raines et al, 1991). This is a post-translationally modified
form of the low-affinity a subunit that is specific for GM-CSF but when crosslinked
with a P subunit gives rise to a high affinity trans-membranous binding site for GM-
CSF (Park et al, 1992). The soluble GM-CSFRa form has been shown to
successfully compete with the high affinity oligomeric cell surface receptor for GM-
CSF binding in spite of exhibiting a much lower affinity (Brown et al, 1997). Like
GIF, the soluble GM-CSFRa forms oligomers in solution (Brown et al, 1997) but
GIF bound ovGM-CSF with a ten-fold higher affinity than soluble GM-CSFRa
bound huGM-CSF (Kd 369 pM and 3.9 nM respectively). In addition the soluble
GM-CSFRa monomer exhibited the highest affinity of binding to human GM-CSF
whereas the monomeric form ofGIF did not bind either ovGM-CSF or ovIL-2.
The receptor for IL-2 belongs to the same super-family as the GM-CSF receptor.
As yet the IL-2 receptor(s) of sheep have not been characterised (except the IL-2Ra
chain, Bujdoso et al, 1992), but in man and mouse a high affinity IL-2R has been
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identified that is expressed on the cell surface of lymphocytes as a trimeric protein
complex consisting of an a, P and y subunit (Nelson and Willerford 1998, Herrmann
and Diamantstein 1987). Like the GM-CSFRa, the a subunit of IL-2R can be
expressed in a soluble form. Following T cell activation with antigen or mitogens in
vitro, there is an up-regulation of IL-2Ra chain expression, a high proportion of
which is shed from the surface of the T cell in a soluble form (Verhagen et al 1994).
It has been proposed that as with soluble GM-CSFRa, soluble IL-2Ra could
negatively modulate local immune response. High levels of soluble IL-2Ra have
been found in the serum and ascites of ovarian cancer patients (Elg et al 1997).
Jacques et al (1987) have determined that the soluble IL-2Ra binds human IL-2 with
a dissociation constant (kd = 30nM) identical to a low affinity cell-surface IL-2R
(p55/ Tac antigen), this is in contrast to the high affinity binding of IL-2 to the cell
surface trimeric complex (kd = 25pM). In this study GIF bound ovIL-2 with a 30-
fold higher affinity than soluble human IL-2Ra bound huIL-2 and a 3-fold higher
affinity than ovine IL-2 bound to T cells (Kd 1.04 nM, 30 nM and 3.084 nM
respectively).
Clearly, if the binding affinities of the ovine receptors for GM-CSF and IL-2 reflect
the binding affinities reported for human receptor-ligand binding then, from our
studies, GIF has the potential to block either ovine GM-CSF or ovine IL-2 binding its
cellular receptor.
GIF represents the first example of a microbial inhibitory protein for GM-CSF
and for both GM-CSF and IL-2. A 38 kD protein encoded by tanapox virus, a
pathogen of primates, binds human IL-2 but also human IL-5 and human IFN-y
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(Essani et al, 1994). Like GIF, the tanapox virus protein represents a group of
poxvirus proteins that have the ability to bind and inactivate multiple cytokines and
chemokines, some of which appear unrelated. Within the Poxvirus family, genome
size appears to be controlled (Wittek, 1982). Consequently one gene product with the
ability to bind and inhibit several important immune effector molecules confers a
clear advantage to virus survival and efficiency. Another example of this genetic
economy practised by the poxviruses, is the M-T7 protein encoded by the myxoma
virus B8R gene that was not only shown to inhibit rabbit IFN-y and human IL-8 but
bound promiscuously through a conserved heparin-binding domain to all CXC, CC
and C chemokines tested (Lalani et al, 1997).
GIF at present appears to have no direct homologue in any organism in the
databases. Some sequence similarities have been identified between the genes
encoding GIF and A41 of vaccinia virus, variola virus and Shope fibroma virus and
the 35 KD/T1 family ofCC chemokine binding proteins of rabbit pox (35 kD) and
myxoma virus (Tl). Like GIF, these genes may have evolved independently from
their respective hosts (Graham et al, 1997; Lalani and McFadden 1997 and Lalani et
al, 1998). It is conceivable that GIF has evolved from an ancestral poxvirus gene that
has ultimately given rise to a number of cytokine receptors with different
specificities. Alternatively the GIF gene could represent an acquired host gene that
has undergone radical modification such that the host and viral protein no longer
resemble one another except for short peptide sequences that are essential for ligand
binding. However until the genes encoding ovGM-CSF receptors have been
identified, the origin of the GIF gene remains speculative.
Common to these viral proteins which have been shown to bind a number of
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different cytokines is their possession of 8 cysteine residues, some of which are in
similar positions in their respective polypeptide chains (Graham et al, 1997). It is
postulated that the cysteines, through intramolecular disulphide bridges, influence
molecular conformation and ultimately ligand specificity of the proteins. From the
present study, the involvement of disulphide bridges would appear to be crucial to
the activity ofGIF particularly in the formation of active homo-dimers that associate
under physiological conditions to active homo-tetramers. The construction of single
point GIF gene mutations whereby each of the eight cysteines is substituted in turn is
proposed as part of a future study. The recombinant GIF proteins expressed from
these mutated genes would be analysed for GIF activity in the GM-CSF clearance
ELISA to determine which of the eight cysteines are crucial to the formation of an
active GIF molecular complex. In addition to providing valuable structural
information regarding the conformation of active GIF, this study would provide the
basis whereby an orf virus mutant strain could be developed. This orf virus, carrying
a defective GIF gene could then be used to infect sheep and by comparing the
pathology of the infection with that resulting from a wild type orf virus infection, the
contribution of GIF to orf virus infectivity/virulence could be more fully assessed.
The ability to form higher order oligomers is a feature of certain poxvirus
receptors with multiple specificities (Lalani et al, 1997, 1999a; Loparev et al, 1998).
These receptors are capable of binding multiple structurally-unrelated cytokines
through different binding domains of the oligomeric complex. GIF appears to fall
into this category, since even in the presence ofmolar excess of rovIL-2, GM-CSF
binding is not completely inhibited. Whilst this might reflect the differences in
binding affinities of GIF for GM-CSF and IL-2, it is possible that GIF possesses 2
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separate binding domains for IL-2 and GM-CSF which are in close proximity to one
another and consequently the binding of one ligand may partially block the binding
of the other.
An investigation into the crystallographic structure ofGIF and GIF-GM-CSF and
GIF-IL-2 complexes would hopefully identify the natural structure ofGIF and the
complexes GIF forms with GM-CSF and IL-2. The molecular structures of a number
of cytokines, cytokine receptors and the complexes they form have already been
determined by X-ray crystallography. For example, the crystal structure of the
ligand-binding domain of the common GM-CSF/IL-3/IL-5 receptor [I chain has been
determined and key amino acid residues identified (Rossjohn et al, 2000). In addition
the crystal structures of ligand-receptor complexes that include; IFN-y and IFN-y
receptor (Walter et al, 1995), IL-1 and IL-1 receptor (Schreuder et al, 1997), IL-10
and IL-10 receptor (Hoover et al, 1999) and G-CSF and G-CSF receptor (Aritomi et
al, 1999) have been examined by X-ray crystallography and their molecular structure
resolved. These studies have identified not only the binding domains of the ligands
and their respective receptors but have revealed how the molecules are folded, their
oligomeric structure and the stoichiometry of the ligand-receptor complexes.
GIF is essentially species-specific. Some reactivity towards bovine GM-CSF and
IL-2 may reflect structural similarities between the ovine and bovine cytokines. Orf
virus does not infect cattle and so the consequence of this binding is not known. GIF
does not react with either human GM-CSF or IL-2 in spite of orf virus being capable
of infecting humans. An obvious conclusion is that since GIF cannot bind human
GM-CSF, those functions already outlined for GM-CSF in an anti-viral response
may not be affected in man unless by some other viral agent acting independently.
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Clearly the reservoir of orf virus in the environment is maintained through infection
of sheep rather than man and the majority of viral immuno-modulatory proteins, such
as viral VEGF and viral IL-10 which closely resemble their sheep homologues, could
be considered to be the consequence of the co-evolution of virus and sheep. However
it is possible that the virus has evolved additional virulence factors that counteract
specific components of the human immune system. There may be differences in the
pathology of the disease in man when compared with orf in sheep. A further
investigation into differences/similarities in skin pathology of orf infections in sheep
and man is therefore warranted.
GIF activity has not been reported in the other genera of the poxviruses.
The expression of a GIF-like activity appears restricted to orf virus and possibly the
other parapoxviruses bovine papular stomatitus virus and pseudocowpox virus,
since GIF- like sequences in both genomes have recently been identified (Dr. A.
Mercer, personal communication). Testing for exogenous ovGM-CSF clearance in
supernatants from bovine fibroblasts infected with either BPSV or MNV failed to
detect a GIF that bound ovGM-CSF. Although orf virus GIF was shown to bind
bovGM-CSF and bovIL-2, it is possible that any GIF encoded by genes expressed by
either BPSV- or MNV- infected cells binds only bovine cytokines. An ELISA that
measures bovine GM-CSF is now available and a future study, similar to the
investigation described here, would enable any BPSV and MNV gene products that
bind bovGM-CSF to be identified.
GIF is detected at several local sites during orf virus reinfection: in the infected
cell, in the vicinity of the infected cell and in the lymph draining the site of infection.
This is likely to be a consequence ofGIF being a soluble (secreted) mediator.
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However, GIF must act primarily in and around the infected cell since this is where
GIF is produced. By binding GM-CSF, GIF could down-regulate macrophage and
neutrophil activation and the antigen-presenting function of DC. By binding IL-2,
GIF could down-regulate CD4+ T cell and CD8+ CTL effector function, IFN-y
production and (through blocking helper T cell function) down-regulate the antibody
response to orf virus.
Within the infected epidermal cell GIF may bind GM-CSF constitutively
produced by keratinocytes (Lear, 1995), the host cell targeted by orf virus (Fig. 8.1).
This is a selective action by orf virus since the expression of the chemokine IL-8 and
the inflammatory cytokine TNF-a was not inhibited. Instead, expression of IL-8 has
been reported to be increased in infected keratinocytes (Lear, 1995). The production
of the orf virus immunomodulatory proteins, vIL-10 and vIFNR protein, along with
GIF and vVEGF by infected keratinocytes may be part of a concerted strategy that is
not only directed against certain key areas of the anti-viral immune response but also
promotes conditions favourable to orf virus replication. IL-8 is thought to promote
the proliferation of keratinocytes (Tuschil et al, 1992) and so expand the number of
possible targets for further infection. At the same time the release of vVEGF will
increase the vascularisation in and around the site of the lesion and may in so doing,
provide the nutrients and growth factors required by the regenerating epidermis
which orf virus targets (Savory et al, 2000). Although human IL-10 has been shown
to inhibit antigen-specific T cell proliferation by down regulating MHC class 11+
molecules on antigen-presenting cells (e.g. DC and macrophages, Allavena et al,
1998), this property has not been demonstrated for orf virus IL-10. The orf virus



























Fig. 8.1 GIF expression by orf virus infected keratinocytes (day 3 after
infection).
Schematic representation of the proposed role ofGIF in clearing
GM-CSF constitutively produced by keratinocytes. (Insert showing
skin section stained with anti-orf virus antigen-specific mAb 10E6).
1.) Orf virus targets the regenerating epidermis (keratinocytes) at the
site of the orf lesion.
2.) Viral VEGF, IL-10, IFNR and GIF are expressed and secreted by
the infected keratinocyte. GM-CSF, IL-8 and TNF-a are constitutively
produced but whilst IL-8 and TNF- a are secreted, GM-CSF is bound
by GIF. (Insert showing proposed assembly of active GIF within the
infected keratinocyte).
3.) Virus-induced cell lysis results in the release ofprogeny virions
and residual virus immunomodulatory proteins.
The vacuolated areas of the lesion as seen in the stained section are
indicative of this cytopathic effect.
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synthesis shutdown that is part of the anti-viral state within infected cells. This
inteferon resistance property of vIFNR has been demonstrated by its ability to protect
Semliki Forest virus from the anti-viral effects of both type 1 and type 2 interferons
when the vIFNR gene was transfected into ovine fibroblasts prior to SFV infection
(Flaig et al, 1998).
Whilst the role ofGM-CSF and IL-2 on keratinocyte function remains to be
defined, GIF, by clearing GM-CSF produced by keratinocytes, would be capable of
preventing the activation of local (to the epidermis) DC such as Langerhans cells.
These cells are responsible for capturing and processing viral antigen prior to
presentation to effector T cells. Futhermore, human keratinocytes have been shown
to express a surface IL-2-like molecule that may also be implicated in Langerhans
cell-directed T cell activation (Dreno et al, 1989a and b). Similarly, GIF has the
potential to suppress this mechanism through binding ovIL-2.
Within several days of orf virus reinfection, GIF is present at detectable levels
throughout the dermis underlying the site of infection. Whether this is as a result of
active secretion ofGIF by the infected keratinocytes or the release of accumulated
GIF through virus-induced cell lysis is not yet clear but since recombinant GIF can
be secreted by transfected CHO cells, both appear likely.
Except for GIF, the parapox immodulatory proteins identified so far are all
products of early viral genes. GIF was expressed as an intermediate-late gene. This
suggests that GIF activity is co-ordinated with those later stages of the viral life cycle
within the infected cell, in particular the replication ofDNA and the generation of
new virus particles. The release ofGIF prior to, and coincident with release of
progeny virions could be seen as a mechanism by which orf virus encourages the
223
survival of the newly released virions which are vulnerable to phagocytosis and
antibody clearance (Fig. 8.2). Through its reactivity with GM-CSF, GIF could
neutralise the phagocytic response mounted by neutrophils and macrophages and
inhibit the maturation of DC and ultimately the induction of cytotoxic T cells.
Neutralisation of IL-2 function would have a similar effect on the activation on CTL
and on NK cells. The accumulation of neutrophils and MHC class II+ DC in the
dermis surrounding the lesion site may be seen as a consequence of recruitment
brought about by chemokines produced in response to orf virus infection. However
the further signal(s) that these cells require to become functional in the anti-viral
response, namely GM-CSF, is cleared by GIF circulating within the dermis and
consequently their activation is delayed to the benefit of the virus.
In the skin, immuno-staining for GIF antigen increased in intensity from day 3
after orf virus reinfection, to reach a peak by day 5 and then declined over the next 2-
3 days until by day 9 no GIF antigen could be detected. A similar pattern was seen
when afferent lymph samples taken during the course of reinfection were tested for
the presence ofGIF. The presence ofGIF, as measured by GM-CSF clearance
ELISA, in afferent lymph plasma samples from days 5 and 7 after infection
coincided with the period ofmaximum virus replication and the period of 2-3 days
when afferent lymph cell output falls. This followed an initial rise in predominantly
CD4+ T cells (considered to be a transient anamnestic response to orf virus).
Around day 7-8, CD4+ T cell output rose again but to considerably higher levels that
reflect the predicted cell mediated anti-viral response (Fig. 8.3, Haig et al, 1999).
This increase in CD4+ T cell output in afferent lymph was shortly followed by an




Fig. 8.2 Schematic representation of the proposed role ofGIF in
preventing GM-CSF and IL-2 mediated activation of effector
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Fig. 8.3 Differential lymphocyte output analysis of afferent lymph
draining the site of orf virus reinfection (Haig et al, 1996e).
Samples of afferent lymph collected daily ( x-axis) prior to and after
orf virus reinfection were analysed by flow cytometry (FACSCAN)
for the output ( cells per hour, y-axis) of CD4+ -T cells (open circles),
CD8+ T cells (upright triangles), T-19+ T cells (inverted triangles) and
B cells (open diamonds) using specific mouse monoclonal antibodies.
Data set presented is a representative example from a single animal.
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that peak GIF levels preceded this later rise in afferent lymph cell output and that the
role ofGIF is to delay any local cell mediated response. Subsequently, as GIF
percolates into the afferent lymph, it may contribute to the inhibition of further T and
B cell mobilisation that is centred on the draining lymph node. Whether the influence
ofGIF extends to within the draining lymph node and those cell-cell interactions that
include antigen presentation and lymphocyte clonal proliferation is not known.
Unfortunately the draining lymph nodes were not available in this study but a future
study may benefit from an immunohistological analysis ofGIF within the draining
lymph node. This analysis carried out in parallel with an assay (still to be developed)
for ovIL-2 might clarify whether the targeting of IL-2 and GM-CSF by GIF is
mutually exclusively or not. Furthermore, whether this specificity is influenced by
local environment such as in and around the lesion site or within the afferent
lymphatics and draining node. Of particular interest is whether IL-2 levels in afferent
lymph draining the site of orf virus reinfection follow the same biphasic response
whereby the fall ofGM-CSF levels in the lymph, observed in samples taken at days
5-7, is coincident with the detection ofGIF.
In conclusion, there is still much work to be done before the mode of action of
GIF and its role in orf virus infection of sheep is fully elucidated. A future X-ray
crystallographic study will hopefully determine the nature of the GIF and GIF-ligand
molecular structures while the generation of a "knockout" orf virus, where the GIF
gene is made dysfunctional, will enable the contribution ofGIF activity to orf virus
virulence to be tested.
The results presented in this thesis indicate that GIF represents a co-ordinated
interference with host inflammatory and cell-mediated immune responses to orf virus
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infection. These results also suggest that GM-CSF and IL-2 are important in host
immunity to orf virus. GIF is a protein with unusual properties and part of a growing
number of pathogen immunomodulators that will be useful not only in determining
mechanisms of viral pathogenesis and the nature of host anti-viral immunity but also
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The parapoxvirus orf virus encodes a novel soluble protein inhibitor of ovine granulocyte-macrophage
colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2). The GM-CSF- and IL-2-inhibitory factor (GIF)
gene was expressed as an intermediate-late viral gene in orf virus-infected cells. GIF formed homodimers and
tetramers in solution, and it bound ovine GM-CSF with a Kd of 369 pM and ovine IL-2 with a Kd of 1.04 nM.
GIF did not bind human GM-CSF or IL-2 in spite of the fact that orf virus is a human pathogen. GIF was
detected in afferent lymph plasma draining the skin site of orf virus reinfection and was associated with
reduced levels of lymph GM-CSF. GIF expression by orf virus indicates that GM-CSF and IL-2 are important
in host antiviral immunity.
Poxviruses stimulate a vigorous immune response in their
hosts. In spite of this, these viruses can replicate and induce
lesions. A possible explanation for this is that poxviruses, along
with other large DNA viruses, express immunomodulatory vir¬
ulence proteins that inhibit or mimic key effector molecules of
the host immune and inflammatory response to infection (35,
56, 57). A common general mechanism is the production of
viral proteins inhibiting early events in the host response to
infection, including inflammatory cytokine, interferon, chemo-
kine, and complement function and apoptosis. Many of the
immunomodulatory genes are orthologues of host cellular
genes that have been acquired and modified by the viruses. For
example, the orthopoxviruses vaccinia virus and cowpox virus
encode soluble receptor proteins that bind to and inactivate
the host cytokines interleukin-ip (IL-1J3), tumor necrosis fac¬
tor alpha (TNF-a), and interferons (IFNs) as well as comple¬
ment components (1, 2, 8, 31, 50, 58, 62). Viral proteins that do
not bind directly to IFNs but instead interfere with down¬
stream signalling molecules following ligand-receptor coupling
also inhibit the antiviral activity of interferons (10, 27, 44). By
studying these viral immunomodulator proteins, insight into
the mechanisms of not only virus virulence but also host pro¬
tective immunity to virus infection is gained.
We have been studying the mechanisms of immune system
evasion by the prototype parapoxvirus orf virus (contagious
ecthyma virus). Orf virus is a ~140-kb double-stranded DNA
(dsDNA) parapoxvirus that has a worldwide distribution and
infects sheep, goats, and man (reviewed in references 26 and
49). Infections are acute, giving rise to pustular lesions that
turn to scabs. Virus is contained locally and shed with the scab.
The virus infects via broken or scarified skin and replicates in
regenerating epidermal keratinocytes. The immune response
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to orf virus is characterized by a local accumulation of CD4+
and CD8+ T cells, B cells, neutrophils, and a dense network of
dermal dendritic cells (32, 33, 38). Immune system evasion by
orf virus is implicated because the virus can repeatedly infect
previously exposed lambs in spite of an apparently normal host
antivirus immune and inflammatory response (21-24, 64, 65).
Host immunity has some effect, since the size of the lesions and
the time to resolution in reinfections are diminished compared
to those of the initial infection.
Most of the orf virus genome of 140 kbp has been se¬
quenced. However, only 31 gene sequences (or partial gene
sequences) spanning the genome are presently in the data¬
bases. Several putative immunomodulating genes have been
discovered: a viral orthologue of mammalian vascular endo¬
thelial growth factor (VEGF) (40), a viral orthologue of IL-10
(16), and an orf virus orthologue of the vaccinia virus E3L
gene, which codes for an interferon resistance protein (27, 44).
In a study of cytokine production in orf virus-infected keratin¬
ocytes, IL-8, TNF-a, and granulocyte-macrophage colony-
stimulating factor (GM-CSF) mRNAs and IL-8 and TNF-a
protein, but not GM-CSF protein, were detected (37). In this
article, we describe the isolation and characterization of a
novel protein, GM-CSF-inhibitory factor (GIF), derived from
a gene within the right terminal quarter of the orf virus ge¬
nome, that binds to and inhibits the ovine cytokines GM-CSF
and IL-2.
MATERIALS AND METHODS /
Viruses. The orf virus strains NZ-2 (47), orf 11 (generated at the Moredun
Research Institute [unpublished]), and scabbymouth (52) were tissue culture
adapted from field isolates and were maintained by passage in primary bovine
testis or fetal lamb muscle (FLM) cells. Semliki Forest virus was used as an
unrelated virus control; it was maintained by passage in ST-6 ovine fibroblasts
(12). MRI scab virus (45) was obtained by infection of sheep and harvesting of
virus from the resultant scabs; it has not been adapted to grow in cell culture.
Ovine primary keratinocytes were obtained, cultured, and characterized as de¬
scribed previously (37). Vaccinia virus-orf virus recombinants (VVOVs) contain¬
ing approximately 95% of the orf virus genome in overlapping DNA fragments
have been described previously (48) and were propagated in CV-1 cells in
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal
bovine serum (FBS).
Lymph samples were from previous experiments (21, 23). In these experi¬
ments, scabbymouth virus was used to infect Sulfolk cross sheep in the hind flank
(i.e., the prefemoral lymph node drainage region) by scarification with a needle
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and topical application of orf virus (106 50% tissue culture infective doses
[TCID50]). For controls, the virus was inactivated by UV irradiation (21) and the
equivalent of ~106 TCID50 of virus was injected intradermally into the hind
flank. Cannulated pseudo-afferent lymph (herein referred to as afferent lymph)
and efferent lymph samples were obtained from reinfected sheep as described
previously (21, 23).
DNA and RNA techniques. dsDNA templates were sequenced by using a
LI-COR 4200 automated DNA sequencing system and manufacturer-recom¬
mended procedures. Single-stranded DNA (ssDNA) templates were sequenced
by using a T7 DNA Sequencing Kit (Amersham Pharmacia Biotechnology
[APB], St. Albans, United Kingdom). Viral RNA was prepared from FLM cells,
infected for 5 or 18 h with NZ2 orf virus at a multiplicity of infection (MOI) of
20 TCID50, by an acid phenol-guanidine hydrochloride method (6). Cells were
grown in the presence and absence of cytosine arabinoside (CA) (40 |xg/ml),
which inhibits viral DNA replication but not the expression of early viral genes
(27). Preparation of dsDNA and ssRNA probes and Northern analysis were
performed as described previously (44).
Expression and purification of recombinant GIF. A 908-bp DNA fragment
containing the entire open reading frame (ORF) of the GIF gene was amplified
by PCR with oligonucleotides 5'-GGAAAGCTTGCGCCGGCTCTAGGAAA
GAT-3' and 5' -GGGGAATTCAAGGATAAGGTCCACGGCGT-3'. The PCR
product was ligated into the pEE14 expression vector (Celltech, Slough, United
Kingdom) (7, 13) in tandem with a glutamine synthetase selectable marker gene
and verified by sequencing prior to transfection into CHO cells by the use of
Superfect transfection reagent (Qiagen, Crawley, United Kingdom) in accor¬
dance with the manufacturer's recommended procedures. The stable transfected
CHO cells were maintained in glutamine-free Glasgow's modified Eagle's me¬
dium (Gibco BRL. Paisley, United Kingdom) supplemented with 7.5% heat-
inactivated dialyzed FBS (PAA Laboratories, Kingston upon Thames, United
Kingdom) and methionine sulfoxamine (an inhibitor of glutamine synthetase)
(Sigma, Poole, United Kingdom) to select cells with high levels of production of
GIF. GIF was purified from CHO cell-free supernatants (CFSs) (serum-free
medium) by affinity chromatography with purified recombinant ovine GM-CSF
(rovGM-CSF) bound to CNBr-Sepharose (APB) followed by gel filtration on a
Sephacryl S-200 column (APB). The rabbit anti-GIF immunoglobulin G (IgG)
was prepared by injecting affinity-purified GIF (10 p.g) and 20 jxg of Quil-A
saponin adjuvant intramuscularly followed by two booster injections. An IgG
fraction was prepared by protein A-Sepharose affinity chromatography. Western
blot analysis of proteins was performed with phosphate-buffered saline (PBS)
plus 4% nonfat milk (blocking buffer) and PBS (0.5 M NaCl) plus 0.5% Tween
80 (antibody dilution and blot wash buffer) by the enhanced chemiluminescence
technique (ECL; APB). Proteins were electrotransferred (Schleicher & Schuell)
to BA 83 nitrocellulose membranes (Anderman, Kingston upon Thames, United
Kingdom).
N-terminal amino acid sequencing of the soluble recombinant protein was
achieved by liquid-phase Edman degradation chemistry on a model 492 Procise
Protein Sequencer (Perkin-Elmer Applied Biosystems, Warrington, Cheshire,
United Kingdom). The purified protein was applied to a Polybrene-treated glass
fiber filter prior to sequencing. The N-terminal 20 amino acids of two separate
samples were analyzed.
Cytokines and GIF-binding assays. The recombinant ovine cytokines IL-ip,
IL-2, IL-3, IL-4, IL-5, IL-8, GM-CSF, MCP-1, macrophage inflammatory protein
la, RANTES. TNF-a, and IFN-y were prepared by transfection of the cytokine
cDNAs (from Ian Colditz, T. Yoshimura, Heng-Fong Seow, Paul Wood, J.-P.
Scheerlink, and Paul Chaplin, CSIRO, Melbourne, Australia, and Gary Entrican,
Moredun Research Institute) into CHO cells and purification of the recombinant
proteins by fast protein liquid chromatography, anion-exchange chromatogra¬
phy, and/or gel filtration chromatography. Purified human (hu) and murine (mu)
GM-CSF, huIL-2, and huIL-4 recombinant proteins produced in Escherichia coli
were purchased from R&D Systems (Abington, United Kingdom). Heparin was
purchased from Sigma.
For GIF-cytokine ligand blots, purified GIF was radioiodinated (125I labelled)
by the chloramine T method (42) and further purified on Sephadex G-25 and
Sephacryl 200 HR (APB) columns in PBS with 0.15% (vol/vol) 3-[(3-cholami-
dopropyl)-dimethylammonio]-l-propanesulfonate (CHAPS) buffer, pH 7.2. Two
hundred to 350 ng of each cytokine was separated by sodium dodecyl sulfate
(SDS)-15% polyacrylamide gel electrophoresis (PAGE) under reducing and
nonreducing conditions and then transferred to nitrocellulose membranes. The
membranes were blocked in blocking buffer, washed in PBS plus 0.05% Tween
20 (wash buffer), and then incubated with 125I-GIF (20 pM) for 2 h at room
temperature. After the membranes were washed three times in wash buffer,
cytokine-GIF binding was detected by autoradiography, using Hyperfilm MP
X-ray film (APB). A 100 nM concentration of unlabeled ("cold") GIF was used
for competitive inhibition of binding of 125I-GIF to the cytokines.
GIF activity was assayed by inhibition of ovine (ov) GM-CSF detection in an
ovGM-CSF capture enzyme-linked immunosorbent assay (ELISA) using two
monoclonal murine antibodies: 8D8 as the capture antibody and horseradish
peroxidase-conjugated 3C2 as the detection antibody (13). 1,2 Diaminobenzene
and tetramethylbenzidine peroxidase substrates were used (determined by opti¬
cal densities at 450 and 492 nm [OD450 and OD492], respectively). Samples
containing GIF and control samples were incubated (spiked) with either 4 or 8
ng of ovGM-CSF/ml (in 20-pl volumes) for 1 h at 37°C. These samples were then
assayed by ovGM-CSF ELISA. Binding of GIF to ovGM-CSF results in the loss
of antibody binding to ovGM-CSF and a reduction in ELISA optical density
(OD). The specificity of the ovGM-CSF inhibition ELISA was demonstrated by
preincubation of samples for 1 h at room temperature with the rabbit anti-GIF
IgG prior to spiking of the mixture with ovGM-CSF and proceeding as described
above. The antibody-GIF complex inhibits the binding of GIF to exogenously
added ovGM-CSF, which is detected in the ELISA. This is not a quantitative
assay for GIF. Cytokines were assayed for GIF binding by competition with
ovGM-CSF in the ovGM-CSF ELISA. Cytokines (10 to 20 ng/ml) were added to
GIF prior to the addition of 4 ng of ovGM-CSF/ml and subsequent ELISA.
Scatchard analysis of GIF reactivity. Purified cytokines were radioiodinated
by the chloramine T method. A soluble-ligand-binding assay was performed for
each cytokine as described by Symons et al. (61) with some modifications. Briefly,
50-p.l volumes of a range of 125I-GM-CSF and 125I-IL-2 concentrations (2 to 20
nmol) were incubated with 100 p.1 of GIF (100 ng) containing 5% FBS for 2 h at
room temperature. Bound proteins were precipitated by the addition of 300 jxl of
20% polyethylene glycol (PEG 6000; Sigma) in PBS and incubation on ice for 30
min. The material precipitated from each sample was collected by filtering
through GF/C filter discs (Whatman, Maidstone, United Kingdom) under a
vacuum and washing with four 10-ml volumes of ice-cold 10% PEG 6000 in PBS.
Radiolabeled complex was detected and quantified in a gamma scintillation
counter (Cobra II Auto-Gamma Counter; Packard, Pangbourne, United King¬
dom). The levels of nonspecific binding of 125I-cytokines to the filters were
obtained in the absence of GIF, and the data were adjusted accordingly. Scat¬
chard analysis was performed on best-fit plots (bound counts per minute/free
counts per minute [y axis] versus bound counts per minute [x axis]) generated by
using Origin software (Microcal, Northampton, Mass.).
GIF bioassays. The soft-agar hematopoietic cell clonogenic assay has been
described in detail elsewhere (25, 43). Briefly, sternal bone marrow cells (5 X
104/ml of culture) in Iscove's modification of DMEM (Gibco BRL) containing
20% FCS and 3% (vol/vol) Bacto Agar (Difco) were set up in 35-mm-diameter
petri dishes. Dilutions of rovGM-CSF and rovIL-3 with and without dilutions of
GIF were added, and the cultures were incubated in a highly humidified atmo¬
sphere of 5% C02 in air. Cell colonies (>40 cells) were analyzed on day 14 of
culture.
GIF inhibition of ovIL-2 activity was measured in a T-cell proliferation assay.
Briefly, mesenteric lymph node cells were enriched (>85%) for CD4+ T cells by
magnetic activated cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany)
depletion of CD8+, y8 T-cell receptor-positive, and B lymphocytes, using 7C2,
86D, and VPM8 (anti-light chain) antibodies, respectively (22). Lymphoblasts
that developed after stimulation with 5 peg of concanavalin A (Sigma)/ml for 3
days were expanded in ovIL-2 or huIL-2 for 3 days. After the lymphoblasts were
thoroughly washed with medium containing 2% FBS to remove IL-2, 100 p.1 of
T-cell blasts at a density of 5 X 105/ml were added to each well of a 96-well plate
(Costar). Additional 100-jjlI volumes containing a range of ovIL-2 dilutions (final
concentration range, 10 pg/ml to 100 ng/ml) in Iscove's modification of DMEM
with and without GIF were added to quadruplicate wells. After 24 h, the cells
were pulsed with [3H]thymidine (18.5 MBq/well) for a further 24 h before being
harvested onto glass fiber sheets in a Micromate 196 cell harvester (Packard).
Incorporated [3H]thymidine in each sample was measured with a Matrix 96
direct beta counter (Packard).
Statistical analysis. Where appropriate, Student's t test was applied to data
normalized by log10 transformation.
Nucleotide sequence accession number. The nucleotide sequence of the GIF
cDNA has been deposited in the GenBank database under accession no. AF
192803.
RESULTS
Identification and isolation of the GIF gene. In preliminary
studies, orf virus infection of ovine skin keratinocytes prior to
a cytopathic effect occurring at around 20 to 24 h after infec¬
tion stimulated ovGM-CSF mRNA expression. However,
ovGM-CSF was at a low or undetectable level in cell lysates or
CFSs as measured by ovGM-CSF ELISA. In contrast, the
ovIL-8 and ovTNF-a cytokine concentrations increased in the
same cultures. The ovGM-CSF inhibition was not due to pro¬
teolytic activity, since the addition of proteinase inhibitors to
the CFSs did not result in ovGM-CSF detection (37).
To determine whether the ovGM-CSF inhibition was due to
the product of a viral gene(s), FLM cells were infected with 18
VVOVs containing among them >95% of the NZ2 orf virus
genome in overlapping fragments. CFSs were analyzed for
ovGM-CSF inhibition by adding 4 ng of ovGM-CSF/ml and
then testing for ovGM-CSF clearance by ELISA. WOV 85,
containing a ~10-kb DNA fragment from within the right
terminal quarter of the orf virus genome, expressed ovGM-
CSF-inhibitory activity. Subclones of this fragment in the
VOL. 74, 2000 POXVIRUS INHIBITOR OF GM-CSF AND IL-2 1315
TCGGGTAAAAACGTACACCGTCGCCTTGTCGCGGCGGTGTACGCTTTTTTCACGCCCTTT












TABLE 1. GIF activity in ovine keratinocytes infected with tissue
culture-adapted orf virus strains"
Sample OD492 (SEM)
NZ2 virus 0.032 (0.008)
Orf 11 virus 0.05 (0.002)
Scabbymouth virus 0.012 (0.004)
SFV control 0.62 (0.02)
Mock infection 0.86 (0.004)
ovGM-CSF, 4 ng/mF 0.71 (0.03)
a Ovine primary keratinocytes were infected with each of the viruses at an
MOI of 2 TCID50/cell or were mock infected (control). Twenty-four hours later,
CFSs were harvested. GIF activity was detected by adding 4 ng of ovGM-CSF/ml
to the CFS samples and analyzing them by ovGM-CSF ELISA. Results are
expressed as ELISA OD492 units. Semliki forest virus (SFV) was used as a
control.



















FIG. 1. DNA sequence of, and predicted amino acid sequence encoded by,
the NZ2 orf virus GIF cDNA. The entire GIF ORF together with 100 bases of
flanking sequence on either side of the ORF is shown. The initiator methionine
is 20.1 kb from the right terminus of the orf virus genome. The gene is tran¬
scribed toward this terminus. The mature secreted protein starts with Ala20. The
region containing potential transcription promoter and/or initiator sequences is
underlined.
gene sequences from orf 11 and MRI scab viruses were also
obtained. These were predicted to encode proteins that were
98% identical to the NZ2 sequence. The GIFs of orf 11 and
MRI scab viruses, expressed in CV-1 cells transfected with the
GIF cDNAs, inhibited ovGM-CSF as detected by ELISA. Fur¬
thermore, NZ2, orf 11, and scabbymouth virus GIF activities
were demonstrated in CFSs of virus-infected ovine keratino¬
cyte cultures (Table 1).
The NZ2 GIF cDNA was expressed as a secreted protein in
CHO cells. Recombinant GIF was purified by ovGM-CSF af¬
finity chromatography and Sephacryl S-200 gel filtration (Fig.
2A). Sequence analysis of the 20 N-terminal amino acids of the
secreted recombinant GIF revealed that the mature protein















pEE14 mammalian expression vector were assayed as de¬
scribed above. A single ORF, located 20.1 kb from the right
terminus of the viral genome that encoded GIF was identified.
The sequence of the ORF plus 100 bases of flanking sequence
on either side, as well as the predicted amino acid sequence of
GIF, is shown in Fig. 1. The GIF gene is predicted to encode
a 265-amino-acid (27.9-kDa) protein, the first 19 amino acids
of which constitute a putative signal peptide. A comparison of
the predicted GIF protein sequence with that of the vaccinia
virus A41L gene product by the use of the Swiss-Prot (release
37.0) and TREMBL (release 10.0) databases revealed 32%
amino acid similarity (over the entire protein) (17, 18, 55).
Although the vaccinia virus A41L protein has sequence simi¬
larity to the T1 secreted chemokine-binding proteins of lepo-
ripoxviruses, its function is not known. Furthermore, a com¬
parison of the GIF amino acid sequence with that of the Shope
fibroma virus T1 protein did not reveal any similarity. The GIF
C. Virus-infected CFS
-28 kDa
2 4 8 10 18 24
w Cr hours after infection
FIG. 2. Expression of recombinant and nonrecombinant GIF in virus-in¬
fected FLM cells. (A) Silver stain of recombinant GIF produced in CHO cells
and purified by GM-CSF affinity chromatography followed by Sephacryl S-200
gel filtration. The positions ofmolecular mass markers are shown on the left. (B)
Northern analysis of GIF mRNA expression in FLM cells at 18 h after infection
with NZ2 virus at an MOI of 20 TCID50 in the presence (lane 2) or absence (lane
1) of CA. Positions of RNA size markers (in bases) are indicated. (C) GIF
expression in FLM CFSs at various times after infection with NZ2 (MOI = 2
TCID50) in the absence of CA. Shown is a Western blot, prepared with rabbit
anti-GIF. of samples subjected to SDS-15% PAGE. Recombinant GIF and
GM2 (the product of an uncharacterized ORF adjacent to the GIF gene) were
included as a positive and negative control, respectively. Both the recombinant
and native GIFs are 28-kDa proteins.
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GIF is an intermediate-late viral gene. In orf virus-infected
cells in culture, progeny virions are detected at approximately
12 h after infection. Maximum titers are obtained between 24
and 72 h, concomitant with the virus-induced cytopathic effect
(37). Using a DNA probe derived from sequence entirely
within the GIF ORF, GIF mRNA was detected at 18 h after
infection of FLM cells with orf virus in the absence of CA, an
inhibitor of late viral gene expression and viral DNA replica¬
tion (Fig. 2B). GIF mRNA was not detected at 5 h after
infection of FLM cells in either the presence or the absence of
CA. This demonstrated that the GIF gene was expressed as an
intermediate or late, but not early, viral gene. The detection of
multiple bands rather than a single mRNA also supports this
conclusion, since the point at which intermediate and late
poxvirus gene transcription stops can be heterogeneous (9, 41,
63). An equivalent ssRNA probe gave the same result as the
DNA probe. Confirmation that the GIF gene was expressed as
an intermediate or late viral gene was obtained by Western
blot analysis of GIF protein production in FLM cells after virus
infection, using the rabbit anti-GIF IgG. GIF was detected at
18 and 24 h after infection in CFSs (Fig. 2C).
GIF forms functional dimers and tetramers. During GIF
purification it was observed that two peaks of GIF activity were
separated by Sephacryl S-200 gel filtration. To determine
whether GIF forms dimers and/or oligomers, purified recom¬
binant 125I-GIF was separated by S-200 gel filtration. Two
125I-GIF peaks eluted from the column, at approximately 56-
and 112-kDa-equivalent volumes (Fig. 3A). Both of these 125I-
GIF peaks contained ovGM-CSF-binding activity, as deter¬
mined by ligand blot analysis (Fig. 3B). The 56- and 112-kDa
GIF moieties correspond in mass to homodimers and tetram¬
ers, respectively, of 28-kDa GIF. There was no S-200 125I-GIF
(or protein) peak at the elution point predicted for a GIF
monomer mass of 28 kDa. Furthermore, each of the 56- and
112-kDa GIF moieties dissociated to the 28-kDa monomer
form in the presence of SDS in PAGE performed under non-
reducing conditions (Fig. 3C).
GIF binds ovGM-CSF and ovIL-2. Currently available ovine
cytokines expressed in CHO cells, a selection of human and
murine cytokines, and heparin were screened for the ability to
bind GIF by the competitive ovGM-CSF inhibition ELISA.
Only ovIL-2 inhibited the binding of GIF to ovGM-CSF (data
not shown). Binding of GIF to ovGM-CSF and ovIL-2 was
confirmed by a direct cytokine-GIF ligand blot assay (Fig. 4).
Unlabelled (cold) GIF inhibited the binding of 125I-GIF to
ovGM-CSF and ovIL-2 (data not shown). The affinity binding
of GIF to ovGM-CSF and ovIL-2 was determined by Scatchard
analysis. GIF bound to ovGM-CSF with a Kd of 369 pM (range,
317 to 421 pM) and to ovIL-2 with a Kd of 1.04 nM (range,
0.961 to 1.124 nM). GIF therefore binds to ovGM-CSF with a
higher affinity than it binds to ovIL-2. GIF did not bind to
human or murine GM-CSF (Fig. 4a) or to human IL-2 (Fig.
4b). In the presence of SDS, GIF dimers and tetramers disso¬
ciated to the monomer form, which did not bind 125I-ovGM-
CSF or 125I-ovIL-2 in SDS-PAGE ligand blot assays (data not
shown).
GIF inhibits GM-CSF and IL-2 biological activities. Figure
5 shows that GIF inhibited the hematopoietic activity of
ovGM-CSF, but not that of the control, IL-3, in the soft-agar
bone marrow cell colony assay and that GIF inhibited the
activity of ovIL-2 in the T-cell proliferation assay. Neutraliza¬
tion of GIF by rabbit anti-GIF prevented the inhibition of each
of the cytokines in the assays.
GIF is produced in vivo during orf virus reinfection. To
determine whether orf virus produces GIF in vivo, samples of
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FIG. 3. GIF forms dimers and tetramers under physiological conditions. (A)
Separation of 125I-GIF on a Sephacryl S-200 column in 0.15% (vol/vol) CHAPS
buffer at pH 7.4. Each fraction contained 1 ml of eluate. Two peaks of GIF
eluted, with apparent molecular masses of —112 and —56 kDa. The arrows
indicate the elution positions of protein standards (fi-galactosidase, phosphory-
lase B, bovine serum albumin, ovalbumin, and chymotrypsinogen A) used to
construct the molecular mass-versus-elution volume standard curve. (B) ovGM-
CSF-GIF ligand blot showing the pooled and concentrated (10-fold) Sephacryl
S-200 fractions of 125I-GIF that bound to ovGM-CSF (19-21-kDa dimer), sub¬
jected to SDS-15% PAGE under nonreducing conditions and electrotransferred
onto nitrocellulose strips. (C) Pooled and concentrated 125I-GIF fractions from
the S-200 column, subjected to SDS-15% PAGE under nonreducing conditions
and revealed by autoradiography. Fractions 12 to 18 contained the 112-kDa GIF
peak from the S-200 column, and fractions 33 to 38 were from the 56-kDa peak.
All fractions showed a 28-kDa protein band. To the left of panels B and C are
shown the positions of molecular mass markers.
(prefemoral lymph node drainage area) of orf virus reinfection
from previous studies (21, 23) were analyzed for GIF activity
by GM-CSF inhibition ELISA. Afferent lymph plasma from
virus-infected sheep contained GIF (Fig. 6b). The presence of
GIF was associated with reduced levels of GM-CSF in the
lymph plasma (Fig. 6a). GIF was detected only in afferent
lymph plasma samples from infected animals, not in those
from control animals injected intradermally with UV-inacti-
vated virus (data not shown). GIF was not detected in efferent
lymph plasma or in CFSs from cultured afferent or efferent
lymph cells. IL-2 was not tested for clearance by GIF because
an IL-2-specific antibody was not available.
DISCUSSION
Poxviruses as a group encode a large number of immuno¬
modulatory proteins that interfere with host immune and in¬
flammatory responses to infection and, consequently, aid virus
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FIG. 4. GIF binding of ovGM-CSF and ovIL-2: 125I-GIF-cytokine ligand
blot analysis. 125I-GIF was used to probe a range of ovine cytokines (A) and
ovine, human, and murine cytokines (B) which were separated by SDS-15%
PAGE and transferred to nitrocellulose membranes. 125I-GIF bound to ovGM-
CSF and ovIL-2. As a specificity control, 100 nM of unlabelled GIF was used to
compete for 125I-GIF binding to the cytokines. This inhibited 125I-GIF binding to
ovGM-CSF and ovIL-2. The positions of molecular mass markers are indicated.
replication. A proportion of these proteins bind to and inhibit
cytokines that regulate the host response to infection. In this
study, we isolated and characterized GIF, a novel cytokine-
inhibitory protein encoded by several strains of the parapox-
virus orf virus.
GIF bound to and inhibited the biological function of
ovGM-CSF and ovIL-2. GM-CSF is produced by a variety of
cell types, including T cells. It stimulates neutrophil, monocyte,
and eosinophil myelopoiesis and the recruitment and/or acti¬
vation of these cell types in the tissues (46). GM-CSF is also
involved in early events in immune responses, regulating the
differentiation and function of antigen-presenting dendritic
cells. IL-2 is a T-cell-derived lymphokine that stimulates T-cell
and NK cell activation and proliferation and activated-B-cell
proliferation (15). This is the first description, to our knowl¬
edge, of a microbial inhibitory protein for GM-CSF or for both
GM-CSF and IL-2. huIL-2 was bound by a 38-kDa protein,
encoded by tanapox virus, a poxvirus pathogen of primates,
which was secreted from infected cells and bound huIL-5 and
huIFN-y (14). The ability to bind and inactivate multiple,
sometimes apparently unrelated cytokines is a property of
some poxvirus proteins and represents an economical way of
controlling host immunity. Another example of such a protein
is the M-T7 gene product of myxoma virus, which inhibited
rabbit IFN-y and CXC, CC, and C family chemokines (36).
The chemokine binding was via a conserved chemokine hepa-
rin-binding domain. The binding of GIF to both GM-CSF and
IL-2 indicates the existence of a binding domain(s) shared by
both cytokines. A comparison of the ovGM-CSF and ovIL-2
sequences did not reveal any obvious common feature other
than the fact that both GM-CSF and IL-2 are members of the
short-chain, four-a-helical-bundle family of cytokines that also
includes IL-4. However, ovIL-4 did not bind to GIF. Interest¬
ingly, GM-CSF has been shown to compete with IL-2 for
binding to IL-2 receptors on the myeloid leukemia cell line
M07E (34), indicating that there may be a common receptor-
binding domain in huGM-CSF and huIL-2.
Many of the viral cytokine-binding proteins are orthologues
of host cytokine receptor molecules. GIF has no counterpart in
the amino acid sequence databases. This may be because the
ovGM-CSF receptor proteins have not been characterized.
The human and murine cellular GM-CSF receptors consist of
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FIG. 5. GIF inhibits ovGM-CSF and ovIL-2 activities, (a) GIF inhibition of
ovGM-CSF activity in the soft-agar bone marrow cell clonogenic assay. Colonies
in triplicate cultures were counted on day 14 of culture, and the numbers were
adjusted to represent the mean number of colonies, ± the standard error of the
mean, that developed from 105 bone marrow cells plated on day zero. ovGM-
CSF was used at 460 pg/ml; ovIL-3 and GIF were used at 520 and 50 ng/ml,
respectively, based on dose-response experiments, (b) GIF inhibition of ovIL-2
activity in the 48-h T-cell proliferation assay. C.P.M., mean counts per minute of
[3H]thymidine incorporated into dividing cells in quadruplicate wells ± standard
error of the mean. ovIL-2 and GIF were used at 40 and 100 ng/ml, respectively,
based on dose-response experiments. *, P < 0.002 versus ovGM-CSF-stimulated
colonies, (a) or IL-2-stimulated T-cell proliferation counts per minute (b).
a low-affinity-binding a subunit that is specific for GM-CSF
and a 3 subunit that is common to GM-CSF, IL-3, and IL-5
receptors (51). Cross-linking of the a and 3 subunits gives rise
to a high-affinity binding site for GM-CSF. The IL-2 receptor
(IL2R) consists of a, (3, and y chains. The a subunit (p55) has
a low affinity for IL-2 but forms a high-affinity IL-2-binding site
when cross-linked with the (3 and y subunits (60). The ovIL-2R
a chain has been cloned and sequenced (5), but there are no
regions of homology between this sequence and GIF. There is
a natural secreted form of the IL-2R a subunit and evidence of
secreted forms of the IL-2R p and y subunits (11, 30). All of
these subunits have a low affinity for IL-2.
The only other natural inhibitor of GM-CSF described to
date is a posttranslationally modified secreted form of the
GM-CSF receptor alpha chain (GMRa) (3, 29, 53). The se¬
creted form of GMRa was produced by myeloid but not lym¬
phoid cell lines, and it bound ligand with a Kd of 3.8 nM (3, 29).
Both GIF and GMRa form oligomers in solution in the ab¬
sence of ligand (this study and reference 4). However, GIF
bound ovGM-CSF with a 10-fold-higher affinity than GMRa
bound huGM-CSF (Kd, 369 and 3.8 nM, respectively). In ad¬
dition, GIF dimers and tetramers bound ovGM-CSF, whereas
the monomer of the multimeric forms of GMRa exhibited the
1318 DEANE ET AL. J. Virol.





b) Reinfection lymph plasma
34+anti-GIF
25+anti-GiF
FIG. 6. GIF and ovGM-CSF in virus reinfection and control afferent lymph
plasma, (a) GM-CSF concentrations in afFerent lymph plasma samples from
reinfected and control sheep. Control sheep (no. 18 and 26) received UV-
inactivated virus intradermally. (b) Detection of GIF, by ovGM-CSF inhibition
ELISA, in afferent lymph plasma samples obtained at various times after orf
virus reinfection of sheep 15, 25, and 34 on day zero. Lymph plasma samples
were spiked with 8 ng of GM-CSF/ml (4 ng/ml for sheep 15 samples, hence the
lower OD) and analyzed for GM-CSF by ELISA. Rabbit anti-GIF was used as a
specificity control to neutralize GIF in the assay.
highest-affinity binding of huGM-CSF (4). We did not observe
binding of 12;T-ovGM-CSF or 125I-ovIL-2 to the 28-kDa GIF
monomer in SDS-PAGE ligand blot assays.
However, the lack of homology to host cytokine receptors by
viral cytokine-binding proteins is not without precedent. The
35-kDa virulence proteins of variola and cowpox viruses inhibit
P-chemokines but have no sequence homology to known pro¬
teins (54). The B18R gene product of vaccinia virus binds
IFN-a/p but is in a protein superfamily different from that of
known host IFN-a/p receptor proteins (62). It is possible that
in the coevolution of virus and host, radical modification of the
acquired host gene occurred such that the host and virus pro¬
teins no longer resemble each other except for short stretches
of sequence that are important for ligand binding. Viral ge¬
nome sizes for different families of viruses tend to be critically
controlled. The ability to acquire host genes and modify them
to produce minimally sized immunomodulatory proteins that
inhibit one, or preferably several, important immune effector
molecules has a clear advantage with regard to survival of the
virus.
After orf virus reinfection of sheep, GIF was detected in
afferent lymph plasma samples that had low levels of ovGM-
CSF. Coupled with the fact that GIF was detected only in the
afferent lymph plasma and not in cultured afferent lymph CFS,
this demonstrated that GIF is produced from virus-infected
epidermal cells and has in vivo relevance. The inability to
detect GIF in efferent lymph plasma indicates that GIF either
does not pass through the lymph node into efferent lymph or is
diluted out by the large volume of efferent lymph plasma car¬
rying lymphocytes derived from the blood via high endothelial
venules (for a review of lymph, refer to reference 28). The time
at which GIF was detected in afferent lymph corresponded to
the period of maximum viral replication in the epidermis of the
cannulated sheep, which occurred between 5 and 7 days after
reinfection (21).
We can only speculate the function of GIF in orf virus
infection. ovGM-CSF and ovIL-2 mRNAs have been detected
in skin biopsy specimens obtained during orf virus reinfection
(24). ovGM-CSF and ovIL-2 have been detected in afferent
and efferent lymph after orf virus reinfection (21, 22). The
principal source of these cytokines in both lymph compart¬
ments is the CD4+ T cell. CD4+ T cells, in particular of the
lymphocyte subsets, accumulate in large numbers adjacent to
and underlying orf virus-infected cells in sheep skin. IL-2 and
IFN-y have been implicated in protective immunity to orf virus
reinfection (21, 24, 37, 39). The role of GM-CSF is less clear.
GM-CSF is involved in the activation of neutrophils and mac¬
rophages, both of which are present in orf lesions. Macrophage
colony-stimulating factor (M-CSF; CSF-1), granulocyte colo¬
ny-stimulating factor, and IL-3 are also hematopoietic growth
factors that support the development and activation of neutro¬
phils and macrophages. Recently, an M-CSF-inhibitory protein
encoded by the Epstein-Barr virus BARF1 gene was identified
(59). The BARF1 product has sequence homology to the M-
CSF receptor protein (c-fms). The function of macrophages in
orf or Epstein-Barr virus infection is not clear. However, GM-
CSF also regulates antigen presentation by dendritic cells, and
this would be a usefuf point of intervention for viral immuno-
modulator proteins. We have previously shown that ovGM-
CSF and ovTNF-a are involved in the recruitment of dendritic
cells to the ovine dermis (19) and in supporting the survival
and proliferation of afferent lymph veiled dendritic cells in
culture (20). The inhibition of GM-CSF in the vicinity of orf
virus-infected epidermal keratinocytes could affect dendritic
cell function. Ovine keratinocytes in culture produce ovGM-
CSF both constitutively and after stimulation with phorbol
ester and calcium ionophore (37). A role for GIF in aiding
virus replication in infected keratinocytes must also be consid¬
ered.
ovGM-CSF and ovIL-2 were bound by GIF, whereas huGM-
CSF. muGM-CSF, and huIL-2 were not. In the broader con¬
text, the orf virus IL-10 and VEGF protein sequences are most
homologous to those of ovIL-10 and ovVEGF, respectively
(16, 40). Taken together, these data demonstrate that orf virus
has adapted to sheep, rather than man, as its principal host.
Orf virus lesions in man are grossly similar to those in sheep,
but they have not been studied in the same detail. The conse¬
quences (if any) of orf virus immunomodulatory proteins that
are active in sheep but not active in man are of interest but are
not known.
Except for GIF, the parapoxvirus immunomodulatory pro¬
teins discovered so far are all the products of early viral genes.
GIF was expressed as an intermediate-late viral gene, orf virus
expression of vIL-10 (16), the orf virus interferon resistance
protein (27, 44), and GIF represents a coordinated interfer¬
ence with host inflammatory and type 1 immune responses to
virus infection. This suggests that GM-CSF, along with IFN-y,
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IFN-a/(3, and IL-2, are important in host immunity to orf virus
(24).
GIF, a protein with unusual properties, is part of a growing
number of pathogen immunomodulators that will be useful not
only in determining mechanisms of viral pathogenesis and the
nature of host antipathogen immunity but also as templates for
potentially therapeutic proteins or peptides.
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